

## Mitochondrial Function, Biology, and Role in Disease A Scientific Statement From the American Heart Association

Elizabeth Murphy, PhD, Chair\*; Hossein Ardehali, MD, PhD; Robert S. Balaban, PhD\*; Fabio DiLisa, MD; Gerald W. Dorn II, MD; Richard N. Kitsis, MD; Kinya Otsu, MD, PhD; Peipei Ping, PhD; Rosario Rizzuto, MD; Michael N. Sack, MD, PhD\*; Douglas Wallace, PhD; Richard J. Youle, PhD†; on behalf of the American Heart Association Council on Basic Cardiovascular Sciences, Council on Clinical Cardiology, and Council on Functional Genomics and Translational Biology

**Abstract**—Cardiovascular disease is a major leading cause of morbidity and mortality in the United States and elsewhere. Alterations in mitochondrial function are increasingly being recognized as a contributing factor in myocardial infarction and in patients presenting with cardiomyopathy. Recent understanding of the complex interaction of the mitochondria in regulating metabolism and cell death can provide novel insight and therapeutic targets. The purpose of this statement is to better define the potential role of mitochondria in the genesis of cardiovascular disease such as ischemia and heart failure. To accomplish this, we will define the key mitochondrial processes that play a role in cardiovascular disease that are potential targets for novel therapeutic interventions. This is an exciting time in mitochondrial research. The past decade has provided novel insight into the role of mitochondria function and their importance in complex diseases. This statement will define the key roles that mitochondria play in cardiovascular physiology and disease and provide insight into how mitochondrial defects can contribute to cardiovascular disease; it will also discuss potential biomarkers of mitochondrial disease and suggest potential novel therapeutic approaches. (*Circ Res.* 2016;118:1960-1991. DOI: 10.1161/RES.000000000000104.)

**Key Words:** AHA Scientific Statements ■ calcium ■ cardiovascular disease ■ cell death ■ energetics  
■ metabolism ■ mitochondria ■ reactive oxygen species

The mitochondria are recognized as a key player in cardiomyocyte cell death after myocardial infarction and cardiomyopathies. Alterations in mitochondrial function are increasingly recognized in cardiovascular disease. Although it has been suggested that the failing heart is energy starved,<sup>1</sup> the recent understanding of the complex interaction of the mitochondria in regulating metabolism and cell death provides novel insight and therapeutic targets. This bioenergetics perspective of cardiomyopathy can be understood as one manifestation of an array of different common clinical phenotypes, including myopathies, neuropathies, nephropathies, endocrine

disorders and metabolic diseases, aging, and cancer. This is because the organs that are affected in the common “complex” diseases are the same organs that have the highest reliance on mitochondrial function.<sup>2</sup>

The purpose of this statement is to better define the potential role of mitochondria in the genesis of cardiovascular disease such as ischemia and heart failure (Figure 1). To accomplish this, we will define the key mitochondrial processes that play a role in cardiovascular disease, which are potential targets for novel therapeutic interventions. This is an exciting time in mitochondrial research. The past decade

\*The findings and conclusions of this report are those of the authors and do not necessarily represent the views of the National Heart, Lung, and Blood Institute.

†The findings and conclusions of this report are those of the authors and do not necessarily represent the views of the National Institute of Neurological Disorders and Stroke.

The American Heart Association makes every effort to avoid any actual or potential conflicts of interest that may arise as a result of an outside relationship or a personal, professional, or business interest of a member of the writing panel. Specifically, all members of the writing group are required to complete and submit a Disclosure Questionnaire showing all such relationships that might be perceived as real or potential conflicts of interest.


This statement was approved by the American Heart Association Science Advisory and Coordinating Committee on September 28, 2015, and the American Heart Association Executive Committee on October 27, 2015. A copy of the document is available at <http://professional.heart.org/statements> by using either “Search for Guidelines & Statements” or the “Browse By Topic” area. To purchase additional reprints, call 843-216-2533 or e-mail [kelle.ramsay@wolterskluwer.com](mailto:kelle.ramsay@wolterskluwer.com).

The American Heart Association requests that this document be cited as follows: Murphy E, Ardehali H, Balaban RS, DiLisa F, Dorn GW 2nd, Kitsis RN, Otsu K, Ping P, Rizzuto R, Sack MN, Wallace D, Youle RJ; on behalf of the American Heart Association Council on Basic Cardiovascular Sciences, Council on Clinical Cardiology, and Council on Functional Genomics and Translational Biology. Mitochondrial function, biology, and role in disease: a scientific statement from the American Heart Association. *Circ Res.* 2016;118:1960–1991. doi: 10.1161/RES.000000000000104.

Expert peer review of AHA Scientific Statements is conducted by the AHA Office of Science Operations. For more on AHA statements and guidelines development, visit <http://professional.heart.org/statements>. Select the “Guidelines & Statements” drop-down menu, then click “Publication Development.”

Permissions: Multiple copies, modification, alteration, enhancement, and/or distribution of this document are not permitted without the express permission of the American Heart Association. Instructions for obtaining permission are located at [http://www.heart.org/HEARTORG/General/Copyright-Permission-Guidelines\\_UCM\\_300404\\_Article.jsp](http://www.heart.org/HEARTORG/General/Copyright-Permission-Guidelines_UCM_300404_Article.jsp). A link to the “Copyright Permissions Request Form” appears on the right side of the page.

© 2016 American Heart Association, Inc.



**Figure 1.** Mutations in mitochondrial proteins (either from mutation in mitochondrial DNA [mtDNA] or nuclear DNA [nDNA]) or acquired defects can lead to defects in mitochondrial quality control, which leads to a vicious cycle of more acquired mitochondrial defects and defects in metabolic signaling, bioenergetics, calcium transport, reactive oxygen species (ROS) generation, and activation of cell death pathways. This leads to a vicious feed-forward cycle that leads to cardiomyocyte cell death.

has provided novel insight into the role of mitochondria function and their importance in complex diseases. In the section on Mitochondrial Function, this statement will define the key roles that mitochondria play in cardiovascular physiology and disease. The section on Mitochondria and Cardiovascular Disease will provide insight into how mitochondrial defects can contribute to cardiovascular disease and will also discuss potential biomarkers of mitochondrial disease and suggest potential novel therapeutic approaches.

Mitochondria are well known as the powerhouse of the cell, and as discussed in the section on Generation of ATP: Bioenergetics and Metabolism, in an active tissue such as heart, they are responsible for generating most of the ATP in the cell. The role of posttranslational modifications (PTMs) in the regulation of metabolism is also discussed (Regulation of Function and Metabolism—The Role of PTMs). It has long been known that in addition to generating ATP, the mitochondrial electron transport chain (ETC) is also important in regulation of mitochondrial calcium. The recent identification of the proteins involved in regulation of mitochondrial matrix calcium is providing new insights into the regulation and role of mitochondrial calcium (Calcium Transport). As discussed in the section on Mitochondria and Cell Death, mitochondria are also key regulators of cell death. In the process of electron transport to generate ATP, mitochondria can be a major source of reactive oxygen species (ROS) that can both contribute to cell death and serve as a signaling molecule (Generation of ROS). Because the generation of ROS can lead to damage to mitochondrial DNA (mtDNA) and proteins, it is important for the mitochondria to have mechanisms to ensure quality control (Mitochondrial Quality Control). Quality control can occur by fission/fusion to allow segregation of damaged mitochondria (Fission/Fusion/Mitochondrial Dynamics), mitophagy to remove damaged mitochondria (Mitophagy and Mitochondrial Autophagy: Mechanisms, Overlap, and Distinctions), and ultimately cell death if the damage is too severe (Mitochondria and Cell Death). Although mitophagy is important for quality control and for removal of damaged

mitochondria, based on measurement of mitochondrial protein turnover (Protein Turnover Independent of Mitophagy) it appears that mitochondrial proteins turn over at different rates, which suggests that under normal circumstances, mitophagy is not the main driver of mitochondrial protein turnover. In fact, it is suggested that the dynamics of protein turnover can provide an assessment of the physiological state. Alterations in these mitochondrial functions are important in many cardiac diseases, as discussed in the section on Mitochondria and Cardiovascular Disease. The section on Mitochondrial Myopathies: Mitochondrial Pathogenesis of Cardiomyopathy examines the mitochondrial pathogenesis of cardiomyopathy, and the section on Cardiotoxicity discusses the role of mitochondria in cardiotoxicity. The section on Biomarkers discusses potential biomarkers for mitochondrial diseases. Taken together, this American Heart Association scientific statement provides a state-of-the-art assessment of the current status of basic mitochondrial biology and how alterations in mitochondria can be major contributors to complex cardiovascular diseases.

## Mitochondrial Function

### Generation of ATP: Bioenergetics and Metabolism

#### *Energy Demands of the Heart*

The incessant energy requirements of the heart are sustained by the consumption of a mass of ATP daily that surpasses cardiac weight itself by approximately 5 to 10 fold.<sup>3</sup> This perpetual demand for energy reflects the continuous contractile functioning of the heart to sustain systemic circulation and nutrient supply. This high-energy flux translates into the cardiomyocyte having a mitochondrial volume between 23% and 32% of myocellular volume.<sup>4</sup> Interestingly, cardiac mitochondrial density increases from human to mouse in parallel with increasing heart rate and oxygen consumption.<sup>4</sup> On the basis of the role of mitochondria in energy transduction, it is not surprising that any perturbations in mitochondrial energy balance, production, or propagation would result in the

development of cardiac pathology or susceptibility to injury (Mitochondrial Myopathies: Mitochondrial Pathogenesis of Cardiomyopathy; Cardiotoxicity); however, a linear or direct correlation between mitochondrial energy metabolism and heart pathology is not clear cut. In this section, we give a brief overview of metabolism and perturbations and their consequences on myocardial function.

### ***ETC Biology: Energetics and ROS***

The final common pathway for oxidative metabolism, which generates the bulk of cardiac ATP, is the sequential passage of electrons from high (NADH or FADH<sub>2</sub>) to low (molecular oxygen) redox potentials down the ETC (complexes I through IV). This stepwise electron transfer results in the active pumping of hydrogen ions out of the mitochondrial matrix into the intermembranous space. The ensuing electrochemical gradient generated across the inner mitochondrial membrane (IMM) facilitates the translocation of protons from the intermembranous space through the F<sub>0</sub>/F<sub>1</sub> ATPase (ATP synthase) back into the mitochondrial matrix. This proton translocation is coupled to the phosphorylation of ADP to generate ATP. Collectively, these reactions constitute oxidative phosphorylation, and the direct synthesis of ATP from electron transfer encapsulates coupled respiration.<sup>5</sup> Being cognizant of the high-energy demands of the heart, it is not surprising that mutations in genes that encode for ETC proteins are linked to the development of cardiomyopathy (Mitochondrial Myopathies: Mitochondrial Pathogenesis of Cardiomyopathy).<sup>6–8</sup> However, it should also be recognized that dysfunction in the ETC not only affects ATP production but can concordantly impair intracellular Ca<sup>2+</sup> flux (Calcium Transport), increase the generation of ROS (Generation of ROS), and alter redox balance by altering the NAD<sup>+</sup>/NADH ratio.<sup>9,10</sup>

### ***Fuel Substrates and Cardiac Energetics in Health and Disease***

Mitochondrial fatty acid  $\beta$ -oxidation (FAO) is the most efficient and predominant substrate for energy production in the normal adult human heart, with glucose oxidation, glycolysis, lactate, and ketones additionally contributing to myocardial ATP production.<sup>11</sup> Regulation of cardiac energy metabolism is complex and determined by the summation of intracellular substrate concentrations, transcriptional rates and activity of metabolic enzymes, and metabolic demands of the myocardium.<sup>12,13</sup> However, as the heart remodels in response to hypertrophy and ischemia, marked changes in cardiomyocyte substrate metabolism can occur, with an ultimate effect on ATP levels in the decompensating heart.<sup>14–16</sup> The relative contribution of fatty acids diminishes with enhanced reliance on glucose utilization during the development of cardiac hypertrophy. The regulatory programs that attenuate fat utilization have been investigated extensively and include regulation at the transcriptional and posttranscriptional levels.<sup>17–20</sup> Moreover, this reduction involves coordinate downregulation of proteins that control fatty acid uptake by the heart and mitochondria, as well as of the enzymes that control mitochondrial FAO (Protein Turnover Independent of Mitophagy).<sup>17,21–24</sup> Enzymes involved in glycolytic pathways are upregulated even during early stages of cardiac dysfunction in response to increased adrenergic signaling, upregulation of fetal gene

programs, and hypoxia.<sup>25,26</sup> The shift toward glucose metabolism improves myocardial contractile efficiency by increasing the stoichiometric ratio of ATP production to oxygen consumption in addition to minimizing oxidative losses through the mitochondrial respiratory chain uncoupling associated with free fatty acid metabolism.<sup>27,28</sup> Abnormally high myocardial dependence on fatty acid metabolism, as seen during ischemia or high adrenergic states, increases cardiac oxygen consumption by 30% to 50%, adjusted for equivalent stroke work indexes.<sup>29,30</sup> Strategies to increase glucose oxidation and decrease fatty acid metabolism can improve myocardial energy efficiency by up to 30%.<sup>31</sup> Although the initial shift toward glucose metabolism at progressively more advanced stages of cardiac dysfunction is physiologically adaptive, the magnitude and impact of this adaption can be significantly limited by extracardiac factors, specifically the development of insulin resistance. Whole-body insulin resistance can affect cardiac energy metabolism, even in structurally normal hearts. Patients with type 2 diabetes mellitus who have otherwise normal cardiac function regenerate phosphocreatine at a significantly lower rate after exercise than control subjects without diabetes mellitus.<sup>32</sup> In patients with cardiomyopathy, the development of insulin resistance is linked to increased sympathetic signaling, which leads to liberation of free fatty acids from adipose tissue into the bloodstream.<sup>33</sup> Thus, in the failing myocardium, decreases in insulin sensitivity can lead to further reductions in glucose oxidation and deteriorations in cardiac function by depriving the heart of access to a more metabolically efficient substrate.

### ***Tricarboxylic Acid Biology and Anaplerosis***

The capacity to use multiple substrates and the plasticity to switch substrate utilization enables continuous cardiac work under a wide variety of biological and pathological circumstances. Interestingly, under some pathological conditions such as severe hypertrophy, the coupling of glycolysis and pyruvate oxidation becomes disrupted, with an increase in glucose oxidation that is insufficient to completely compensate for the reduced fat oxidation.<sup>24,34</sup> These perturbations in substrate partitioning and selection can become associated with reduced contractile reserve and increased susceptibility to ischemia-reperfusion injury.<sup>34–36</sup> Partial compensation for this energy-substrate oxidation deficit has recently been identified to occur via recruitment of alternative intermediary pathways (anaplerosis) to enhance flux through the tricarboxylic acid cycle.<sup>23</sup> The need for anaplerosis in the heart is well established, in that the mechanical performance of isolated rat hearts when exclusive precursors of acetyl coenzyme A (CoA) are used as substrate shows progressive deterioration with rapid restoration after introduction of anaplerotic substrates.<sup>37</sup> Whether the disruption of anaplerosis plays a significant role in cardiac maladaptation and whether it could be a therapeutic target for therapy are currently unknown.<sup>27</sup>

### ***Metabolic Modulation as a Strategy for Cardiac Muscle Pathology***

Despite the findings of altered metabolism and energetic capacity in experimental models and in patients with cardiac muscle injury and remodeling, the myriad of agents that have been directly assessed as metabolic modulators have not been

found to have significant clinical benefit in the management of heart disease. The use of these agents has recently been reviewed,<sup>16</sup> and only some of the studies are discussed here to illustrate the overall lack of efficacy, inadequate sample size, and potential adverse effects associated with the administration of these metabolic modulators. Etomoxir is an irreversible inhibitor of mitochondrial carnitine palmitoyltransferase-1 (CPT-1) and thus results in a reduction in long-chain FAO. An initial pilot study suggested that etomoxir might improve myocardial function in patients with heart failure<sup>38</sup>; however, a subsequent controlled study was stopped prematurely because the drug was associated with hepatic transaminitis.<sup>39</sup> Another inhibitor of CPT-1 and CPT-2 is perhexiline, and one study showed improvement in maximum oxygen consumption and ejection fraction<sup>40</sup>; however, larger studies are needed before a conclusion can be made regarding the use of this drug in heart disease. Trimetazidine is a partial inhibitor of the  $\beta$ -oxidation enzyme 3-ketoacyl CoA thiolase and has been shown in small studies to improve symptoms and cardiac function in patients with heart failure.<sup>41</sup> Ranolazine has a similar structure to trimetazidine and is currently approved by the US Food and Drug Administration for treatment of stable angina. Although it can affect free fatty acid metabolism, its main mechanism of action might be related to inhibition of the late inward  $\text{Na}^+$  channel. In the MERLIN-TIMI 36 trial (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Elevation Acute Coronary Syndromes–Thrombolysis in Myocardial Infarction 36), ranolazine did not reduce hospitalization rates for heart failure among patients with acute coronary syndrome.<sup>42</sup> Finally, dichloroacetate increases myocardial glucose utilization by inhibiting pyruvate dehydrogenase kinase, which leads to increased activity of the mitochondrial pyruvate dehydrogenase. In a small study of patients with heart disease, dichloroacetate increased stroke volume and myocardial efficiency<sup>43</sup>; however, more substantial studies are needed to characterize the role of dichloroacetate in patients with heart disease.

#### ***Creatine Kinase and High-Energy Transfer***

The creatine kinase (CK) reaction is the prime energy reserve that provides a rapid source of ATP and facilitates its delivery from the mitochondrial site of production to sites of use, including the myofibrils in the heart.<sup>44</sup> Although the heart is a high-energy-consuming organ, human genetic mutations linked to creatine deficiency usually result in neurological deficits.<sup>45</sup> In parallel, the genetic disruption of whole-body creatine synthesis in the mouse had no detrimental effects on exercise capacity, cardiac workload, or adaptation to ischemia-reperfusion injury,<sup>46</sup> and overexpression of the creatine transporter, or exogenous creatine supplementation in mice, showed no cardiac benefit.<sup>47</sup> Nevertheless, in a large-animal model, reduced CK ATP delivery was associated with impaired myocardial contractile function,<sup>48</sup> and in human heart failure, morbidity and mortality are linked to impaired CK metabolism and flux.<sup>49,50</sup>

#### **Regulation of Function and Metabolism: The Role of PTMs**

It has been increasingly clear that there is cross talk and signaling between the mitochondria, the cytosol, and the nucleus.

Posttranslational modifications are a primary mechanism by which the mitochondria communicate with the rest of the cell.

#### ***Acetylation***

Nutrient overload is linked to mitochondrial dysfunction and to the cardiovascular risk factors of obesity and diabetes mellitus.<sup>27,51</sup> Conceptually, perturbations in mitochondrial metabolic intermediates, such as acetyl-CoA, which itself can function as a direct posttranslational substrate to modify mitochondrial proteins through acetylation, could link these pathophysiological effects.<sup>52,53</sup> Additional short-chain carbon metabolic intermediates, including succinyl groups and malonyl groups, can also bind to and modify protein lysine residues.<sup>45,54</sup> Our knowledge of the regulation of these latter modifications is too preliminary to expand on,<sup>45,54,55</sup> and this section will focus on the role of acetylation, as a nutrient-dependent mechanism, in the regulation of mitochondrial function.

#### ***Enzymatic and Nonenzymatic Control of Protein Acetylation***

There are 3 major acetyltransferase families, and member proteins from each group have been implicated in the control of cellular homeostasis.<sup>56</sup> Deacetylase proteins are similarly grouped into distinct classes.<sup>57</sup> Class III deacetylases are  $\text{NAD}^+$  dependent and function as sensors of the energetic status of the cell in response to the subcellular compartment levels of  $\text{NAD}^+$  and nicotinamide or to the ratio of  $\text{NAD}^+$  to  $\text{NADH}$ .<sup>35,58,59</sup> Recent findings have highlighted novel mechanisms that regulate levels of  $\text{NAD}$ .<sup>60–62</sup> The class III enzymes are termed sirtuins, and 7 family members (Sirt1 through Sirt7) are evident in mammalia.<sup>63</sup> Sirt1, 2, and 3 have the most robust deacetylase activity and predominantly function in the nuclear (Sirt1), cytoplasmic (Sirt1 and 2), and mitochondrial (Sirt3) compartments, respectively. Because the focus of this section is on mitochondrial PTMs, it will focus on Sirt3.

The counterregulatory acetyltransferase enzyme system is less well characterized, although nuclear Gcn5 and p300 counter the actions of Sirt1.<sup>64</sup> The process of protein acetylation in the mitochondria is even less well understood, although GCN5L1 has been identified as a critical molecular component of this program, and its functional role is beginning to be explored.<sup>53,65</sup> Recently, the mitochondrial protein acetyltransferase, acetyl-CoA acetyltransferase 1 (ACAT1), which functions in ketogenesis to combine 2 acetyl-CoA molecules,<sup>66</sup> has been found to regulate the pyruvate dehydrogenase complex as a canonical acetyltransferase.<sup>67</sup> This finding could open the door to expanding our understanding of acetyltransferase functioning within mitochondria.

Concurrently, the recognition of nonenzymatic acetylation of proteins in the presence of acetyl-CoA is evident,<sup>68</sup> and denatured mitochondrial proteins undergo acetylation in the presence of acetyl-CoA.<sup>65</sup> Furthermore, elevated levels of acetyl-CoA, coupled to the alkaline mitochondrial pH, have been shown to promote nonenzymatic protein acetylation.<sup>69</sup> This concept of nonenzymatic protein acetylation might be operational in diabetes mellitus, in which metabolic inflexibility, which is defined as the inability to switch from fatty acid to glucose oxidation during the transition from the fasted to the fed state, results in part from the allosteric inhibition of pyruvate dehydrogenase by increased mitochondrial acetyl-CoA

levels.<sup>70,71</sup> The role of nonenzymatic protein acetylation has not been investigated extensively, although its potentially important regulatory role has been reviewed.<sup>72</sup> Interestingly, analysis of the mitochondrial acetylome, under various nutrient conditions and in the presence or absence of Sirt3, shows evidence compatible with nonenzymatic and enzymatic control of the mitochondrial acetylome.<sup>73</sup>

### **Mitochondrial Sirt3 and the Heart**

Although Sirt3 functions predominantly in mitochondria,<sup>74</sup> data do support extramitochondrial deacetylase activity.<sup>75–77</sup> The depletion of Sirt3 has a subtle phenotype<sup>78</sup> that is unmasked in response to prolonged fasting,<sup>79</sup> after chronic perturbations in caloric intake,<sup>80–82</sup> and in response to redox stress.<sup>83</sup> Numerous proteomic approaches have been used to identify substrates of Sirt3 deacetylation, and the vast majority of proteins with alternations in acetylation are found within mitochondria.<sup>73,84,85</sup> The functional characterization of these proteins shows that Sirt3-mediated deacetylation regulates numerous aspects of mitochondrial function, including the regulation of enzymes that control  $\beta$ -oxidation, branch-chain amino acid metabolism, ketone biology, the ETC, ATP production, the urea cycle,<sup>73,79,85,86</sup> and ROS catabolism.<sup>74,87</sup>

In light of the high energy demand of the heart and based on the Sirt3 targets characterized to date, the disruption of Sirt3 would be expected to have cardiac consequences. Despite this, young Sirt3 knockout mice do not have any obvious phenotype<sup>88</sup> and furthermore display normal exercise performance.<sup>89</sup> However, consistent with a “fine-tuning” function, aging Sirt3 knockout mice develop cardiac dilatation,<sup>88</sup> and pressure overload results in maladaptive cardiac hypertrophy.<sup>88,90</sup> The mechanisms underpinning these pathologies align with established functions attributable to Sirt3, including increased generation of ROS.<sup>88,90</sup> Conversely, Sirt3 overexpression promotes antiapoptotic programs in cardiomyocytes,<sup>76</sup> and cardiac-restricted Sirt3 transgenic mice exhibit enhanced ROS scavenging.<sup>90</sup> An interesting additional mechanism whereby Sirt3 deficiency could potentially contribute to the pathophysiology of cardiac hypertrophy is its regulatory role in controlling fatty acid metabolism.<sup>79</sup> Because the loss of metabolic plasticity with the downregulation of FAO is synonymous with cardiac pressure overload–mediated decompensation,<sup>12,17</sup> it is conceptually possible that the downregulation of FAO in Sirt3 knockout mice could play a role in the pressure-overload and aging maladaptive phenotype in the heart. However, this needs to be delineated further, because high-fat feeding has been shown to increase cardiac FAO in parallel with downregulation of Sirt3.<sup>91</sup>

Because regulatory control of mitochondrial protein acetylation is nutrient-level and redox-potential dependent, it is conceivable that primary perturbations within mitochondria that can modulate metabolic intermediates or redox potential could initiate changes in the acetylome. This concept has been explored in the heart in response to genetic perturbations associated with cardiovascular pathology in which disruption of frataxin, cyclophilin D, and components of the ETC result in either basal or excessive pressure-overload–induced cardiac dysfunction and are associated with reduced NAD<sup>+</sup>-NADH ratio and increased mitochondrial protein acetylation.<sup>13,92,93</sup> In

primary cardiomyocytes, frataxin and complex I disruption of the acetylome are corrected in parallel with improvement in mitochondrial function after Sirt3 induction.<sup>13,92</sup> Although incompletely characterized, these data support the concept that control of acetylation by intrinsic mitochondrial functioning could, via a feedback loop, affect global mitochondrial functioning via mitochondrial acetylome regulation.

### **Future Directions in Understanding the Mitochondrial Acetylome**

Advances in proteomics have enhanced our understanding of both the static and dynamic alteration of the mitochondrial acetylome.<sup>73,94</sup> Additionally, these studies have identified site-specific changes in lysine residue acetylation that modulate protein function, stability, localization, and allosteric interactions or control synergistic PTMs.<sup>79,84,95,96</sup> Moreover, the stoichiometry of proteins and the domains that surround substrate protein lysine residues could play important regulatory roles in the interaction of acetylase and deacetylase enzymes,<sup>73</sup> and the further characterization of the acetylome-modifying enzymes themselves might expand our understanding of the role of acetylation in controlling mitochondrial function.<sup>53,74,94</sup>

An area of some functional discrepancy has also arisen with respect to the acetylation of specific targets within a pathway compared with the global functioning of the canonical pathway in response to acetylation. This is most vividly illustrated where FAO is increased in the presence of excess fat and mitochondrial protein acetylation,<sup>52,97</sup> in contrast to studies that have shown direct deacetylation of lysine residues on FAO enzymes resulting in activation of enzyme activity.<sup>79,98</sup> The mechanisms underpinning these effects and whether this might be a result of tissue-distinct regulatory cues need to be explored.

Finally, although the role of acetylation in modifying individual proteins is the main focus of this section, data are emerging to show that the overall function of mitochondrial quality control and integrity, which are also modulated by nutrient levels and redox stress, including mitochondrial turnover (mitochondrial dynamics, mitophagy, and biogenesis)<sup>53,64,99,100</sup> and redox- and proteotoxic-stress amelioration effects,<sup>101,102</sup> might be regulated by the mitochondrial acetylome.<sup>53</sup> The complexity of this regulation is further underscored where cross talk between different PTMs functions in concert to regulate protein function, as has been shown by concomitant modifications in acetylation and phosphorylation.<sup>103</sup>

### **Phosphorylation**

As recently reviewed, there is extensive phosphorylation of proteins in the mitochondrial matrix, as well as in the mitochondrial electron transport complexes.<sup>104,105</sup> A number of recent studies have reported that there are several hundred phosphorylated proteins in cardiac mitochondria.<sup>106,107</sup> There are also sex differences in phosphorylation of mitochondrial proteins.<sup>108</sup> Many of the phosphorylated mitochondria proteins are outer mitochondrial proteins, which are likely phosphorylated by cytosolic kinases and have been shown to regulate mitochondrial dynamics and cell death pathways. As discussed previously,<sup>104</sup> the occupancy or fraction of the protein that is phosphorylated might be low for many of these proteins, and it is possible that these many of these low-level

modifications are of little or no functional consequence. It is also unclear to what extent phosphorylation of mitochondrial matrix proteins occurs in the matrix as opposed to before import into the matrix. Furthermore, with the exception of the PDH (pyruvate dehydrogenase) and BCKDH (branched-chain  $\alpha$ -keto acid dehydrogenase) kinase and phosphatase, little is known about the kinases and phosphatases responsible for mitochondrial phosphorylation. O'Rourke et al<sup>105</sup> recently reviewed the evidence for mitochondrial localization of other kinases. Furthermore, although a large number of phosphorylated mitochondrial proteins have been identified, very few phosphorylation sites have been demonstrated to alter enzyme or protein activity. It has been proposed that cAMP generated in the mitochondria activates mitochondrial protein kinase A to regulate ATP production.<sup>109</sup> However, recent studies have found that alterations in mitochondrial cAMP and protein kinase A do not contribute significantly to acute calcium stimulation of oxidative phosphorylation.<sup>110</sup>

Given that extensive phosphorylation has been identified in the mitochondria, it is tempting to speculate that changes in mitochondrial phosphorylation regulate mitochondrial function. However, it will be important for future studies to better define the function consequences of these sites of phosphorylation and to define the kinases and phosphatases that regulate their phosphorylation.

### **S-Nitrosylation**

S-nitrosylation (SNO) is the covalent attachment of nitric oxide (NO) moiety to a protein thiol group. As recently reviewed,<sup>111–113</sup> SNO is a redox-dependent modification that is suggested to alter cell function by altering protein or enzyme activity, altering protein localization, shielding critical cysteine residues from oxidation, altering protein stability, altering binding partners, and competing with other PTMs. An increase in oxidative stress leads to a decrease in protein SNO, which thereby alters the SNO/ROS balance. ROS leads to the consumption of NO, and thus, cardiac-specific overexpression of SOD leads to an increase in NO bioavailability.<sup>114</sup> Another mechanism by which an increase in oxidative stress reduces NO/SNO signaling is by uncoupling of NOS. Alterations in NOS signaling have been proposed to predispose one to cardiovascular disease.<sup>115</sup> Cardioprotection is associated with a modest increase in SNO, and the majority of the proteins that exhibit an increase in SNO are mitochondrial.<sup>116</sup> This might be related to the redox environment of the mitochondria. Changes in cell redox can alter the generation of NO, the lifetime or bioavailability of NO, and the reactions that lead to protein SNO and denitrosylation. A key cysteine in the mitochondrial ATP synthase was shown to undergo multiple redox modification, and the extent of different modifications differed in dyssynchronous heart failure compared with cardiac resynchronization therapy.<sup>117</sup>

### **Calcium Transport**

The electrochemical gradient across the IMM is the driving force for calcium transported across the mitochondria inner membrane by the recently identified<sup>118,119</sup> mitochondrial calcium uniporter (MCU). Uptake into the mitochondria of small physiological levels of calcium is thought to regulate

mitochondrial metabolism and ATP production.<sup>120–123</sup> In the heart, an increase in contractility is mediated by an increase in the cytosolic calcium transient. The increase in cytosolic calcium is transmitted to the mitochondria via Ca uptake into mitochondria, which leads to activation of the calcium-sensitive mitochondrial dehydrogenases<sup>124</sup> and several complexes of electron transport, thereby increasing ATP production as needed for the increase in work.<sup>120</sup> Under pathological conditions of high cytosolic calcium (calcium overload), mitochondria are capable of taking up large amounts of calcium, which leads to the opening of the mitochondrial permeability transition pore (mPTP), a large conductance channel in the IMM<sup>125,126</sup> (Mitochondria and Cell Death). The sustained opening of this transition pore is a trigger for cell death.<sup>126</sup>

As reviewed recently, the MCU exists in a multiprotein complex with several proteins that regulate its activity.<sup>127–132</sup> Calcium efflux from cardiac mitochondria occurs via the Na-Ca exchanger (NCXL) (see Boyman et al<sup>133</sup> for a recent review). Calcium transits the outer mitochondrial membrane (OMM) via the voltage-dependent anion channel. Mitochondrial Na-Ca exchange has been shown to regulate mitochondrial calcium levels and to connect mitochondrial calcium to intracellular sodium, such that the rise in sodium that occurs during hypertrophy and heart failure is reported to lead to alterations in mitochondrial calcium that lead to altered redox and metabolism.<sup>134,135</sup> There are recent data suggesting that alterations in mitochondrial calcium can contribute to the development of arrhythmias.<sup>134,136</sup>

Recently, several groups developed MCU-knockout mice or mice without a functional MCU to study the role of mitochondrial calcium in modulating metabolism and cell death.<sup>137–141</sup> Because it is generally assumed that mPTP opening and subsequent cell death is initiated by calcium influx into the mitochondria via the MCU, it was hypothesized that the MCU-knockout hearts would have a reduced mPTP opening and reduced cell death after ischemia. There was consistency among the different groups in that mitochondria from the MCU-knockout hearts did not take up calcium and did not undergo calcium-activated mPTP<sup>137,139,140</sup>; however, there were interesting differences regarding whether these mice were protected from ischemia-and-reperfusion-mediated death. In the mice in which MCU was knocked out or mutated before birth, the hearts did not show a decrease in infarct size after ischemia-reperfusion.<sup>137,141</sup> In contrast, the mice in which loss of MCU was induced in adults by administration of tamoxifen showed smaller infarcts after ischemia and reperfusion.<sup>139,140</sup> One possible explanation for these differences is that when MCU is deleted before birth, compensatory mechanisms develop that somehow modify cell death pathways such that loss of MCU is not protective. A role for compensatory mechanisms is also consistent with the observation that loss of MCU is lethal on a C57B6 background.

### **Mitochondria and Cell Death**

Before the 1980s, cell death was viewed as a passive process. At odds with this concept were long-standing observations that specific cells die at specific times during development in multicellular organisms ranging from worms to mammals.<sup>142</sup> However, it was not until the identification of a small

network of genes that modulate developmental cell death in *Caenorhabditis elegans* that the concept of regulated cell death came into focus.<sup>143</sup> By the 1990s, the descendants of these genes were recognized to also mediate apoptotic cell death in adult organisms, including humans.<sup>144</sup> By the turn of the century, it became clear that a large proportion of necrotic cell deaths, thought to be the last bastion of passive cell death, were actually highly regulated.<sup>145–148</sup> In addition to apoptosis and necrosis, other regulated death programs (defined by morphology or the context in which they occur) likely exist,<sup>149</sup> including a form of cell death associated with autophagy (autosis).<sup>150</sup> What regulated forms of cell death share in common is a process mediated by signaling pathways whose components are constitutively present in the cell. These hardwired pathways remain inactive, however, until receipt of a “death signal” that originates from outside or inside the cell.

Apoptosis and necrosis have been studied most intensively. Although they share inciting death stimuli and are mediated by overlapping pathways, they differ in morphology and consequences to surrounding tissue.<sup>151</sup> Specifically, apoptosis is a stealth form of cell death, because plasma membrane integrity is maintained until the fragmented cellular corpses are eliminated by phagocytosis. In contrast, plasma and organelle membrane breakdown is a defining feature of necrosis and can be actively mediated. The end result in necrosis is the release of inflammatory mediators that cause collateral tissue damage in a paracrine manner and through the recruitment of leukocytes. On the basis of traditional pathological analysis, the major form of cardiomyocyte death in the infarct zone is thought to be necrosis,<sup>152</sup> while a delayed wave of apoptosis takes place in the peri-infarct region, especially with reperfusion.<sup>153,154</sup> Genetic experiments in mice have established that regulated necrosis and apoptosis both play important roles in the generation of the infarct (examples include those in references 95,147, and 155–163). In dilated cardiomyopathy, low but clearly elevated levels of cardiomyocyte apoptosis take place and are an important component in the pathogenesis of this syndrome.<sup>164</sup> Necrosis has also been reported to contribute to heart failure but has been less well studied.<sup>148</sup>

Apoptosis and necrosis can each be induced through 2 general pathways, one involving cell surface “death” receptors and the other the mitochondria.<sup>144,151,165</sup> Even when the signals are initiated through death receptors, the mitochondria are often part of a critical amplification loop. Regardless of the initiating pathway, the end game in apoptosis is to activate caspases, a class of cysteinyl proteases that cut after aspartic acid residues. Caspases then proteolyze multiple cellular substrates to bring about the demise of the cell. The molecular goal in necrosis, on the other hand, depends on the initiating pathway. Induction of necrosis through the death receptor pathway (necroptosis) is mediated through activation of receptor interacting protein (RIP) 1 and RIP3, homologous serine/threonine kinases whose targets are an area of active investigation.

Mitochondria have been recognized as playing a central role in both apoptotic and necrotic cell death. The triggering event in mitochondria-mediated apoptosis is permeabilization of the OMM, which allows the release of apoptogens, including cytochrome c, SMAC/DIABLO, Omi/HtrA2, AIF, and

EndoG.<sup>165</sup> What these proteins share in common is that they perform healthy functions within the mitochondria but are toxic in the cytosolic compartment. For example, in healthy cells, cytochrome c participates in electron transport at the IMM as part of oxidative phosphorylation. In contrast, once cytosolic during apoptosis, cytochrome c binds Apaf-1 to trigger assembly of the apoptosome in which procaspase-9 is activated. OMM permeabilization during apoptosis is promoted by BAX and BAK, pro-cell death members of the BCL-2 family of proteins.<sup>166</sup> Although it is not known precisely how these proteins bring about permeabilization (eg, one model involves pore formation), it is clear that homo-oligomerization and hetero-oligomerization are important. BAX and BAK are regulated primarily through changes in their conformations. In the case of BAX, which resides in the cytoplasm of healthy cells in an inactive conformation, conformational activation<sup>167,168</sup> is brought about by direct binding of BIM or a truncated form of BID (tBid), which are members of the BH3-only arm of the BCL-2 family. The function of BH3-only proteins is to bring death signals to BAX and BAK from other pathways in the cell. Activation of BAX exposes a transmembrane domain in its 9th  $\alpha$ -helix that has a predilection for the OMM and presumably facilitates BAX mitochondrial translocation. BAK resides constitutively in the OMM and is thought to be activated in a similar fashion, although this has been studied in less depth. Antiapoptotic BCL-2 proteins such as BCL-2, BCL-xL, and MCL-1 inhibit BAX and BAK by functioning as sinks for BIM and tBid and possibly also through direct interactions with BAX and BAK.

The triggering event in mitochondria-mediated necrosis is the sustained opening of mPTP in the IMM.<sup>151</sup> In healthy cells, the OMM is impermeant to apoptogens but allows the passage of ions and small molecules. Opening of the mPTP during necrosis results in rapid dissipation of the proton gradient across the IMM that is generated by pumping of protons into the intermembrane space during oxidation of substrates in the Krebs cycle. Because this transmembrane proton gradient is needed to drive ATP synthesis, mPTP opening abruptly stops production of new ATP. To further compound this energetic deficit, ATP consumption continues largely unabated during necrosis.<sup>169</sup> In contrast, apoptotic cells shut down ATP-requiring functions such as DNA repair, translation, and proteasome function<sup>170–172</sup> and experience less reduction in ATP synthesis. A second consequence of mPTP opening during necrosis is the ingress of water down its osmotic gradient into the solute-rich mitochondrial matrix. This causes matrix swelling, which results in expansion of the redundant IMM and sometimes rupture of the OMM, which lacks redundancy. Rupture of the OMM sets up the possibility that apoptogens could gain access to the cytoplasm in necrosis (albeit via OMM rupture rather than permeabilization) and trigger caspase activation.<sup>147</sup> Given the cataclysmic events that result from cessation of ATP synthesis, the extent to which subsequent engagement of the downstream apoptosis signaling contributes to cell death in necrosis is unclear.

The composition of the mPTP has been an area of great controversy.<sup>173</sup> The pore has often been depicted as a complex that involves the voltage-dependent anion channel in the OMM and the adenine nucleotide translocase (ANT) in

the IMM. Genetic studies, however, have demonstrated that neither the voltage-dependent anion channel<sup>147</sup> nor ANT<sup>174</sup> is required for pore opening. Similarly, the mitochondrial phosphate carrier in the IMM, more recently hypothesized to be part of the mPTP, has proved to be dispensable.<sup>175,176</sup> What then is the mPTP? Recent work suggests the unanticipated result that a core component is the F<sub>1</sub>-F<sub>0</sub> ATP synthase itself.<sup>177–179</sup> Although these data are exciting, additional studies will be required for *in vivo* proof.

The best characterized stimulus for mPTP opening is an increase in the concentration of Ca<sup>2+</sup> in the mitochondrial matrix.<sup>180</sup> The effects of increased [Ca<sup>2+</sup>] on mPTP opening are sensitized by oxidative stress, increases in phosphate, and decreases in ATP and ADP.<sup>180–182</sup> These conditions operate during ischemia and reperfusion.<sup>183</sup> The binding site through which Ca<sup>2+</sup> triggers mPTP opening is not known, however. A critical facilitator of mPTP opening is cyclophilin D, a peptidyl prolyl isomerase in the mitochondrial matrix.<sup>160,184</sup> Although it is known that cyclophilin D binds the F<sub>1</sub>-F<sub>0</sub> ATP synthase,<sup>178</sup> and it has been reported that cyclophilin D prolyl isomerase activity is required for facilitation of mPTP opening,<sup>184</sup> the precise mechanism is not understood. The drug cyclosporin A, which binds cyclophilin D, inhibits mPTP opening and necrosis.<sup>185</sup> Although not an essential component of the mPTP, ANT also functions as a positive regulator of pore opening.<sup>174</sup> Recently, the proapoptotic proteins BAX and BAK were found to be critical mediators of primary necrosis.<sup>163,186</sup> Mice lacking BAX and BAK or BAX alone exhibit markedly decreased cardiac necrosis, apoptosis, and infarct size after ischemia-reperfusion *in vivo*.<sup>158,163</sup> Analysis of BAX mutants shows that its apoptotic and necrotic functions are distinct. Current evidence supports 2 nonmutually exclusive models in which BAX functions as an OMM component of the mPTP or facilitates necrosis indirectly by promoting mitochondrial fusion.

Many questions remain concerning the mitochondrial events that mediate cell death. First, the complete composition of mPTP is not clear at this point. Second, the upstream signaling that feeds into both necrotic and apoptotic programs at the mitochondria remains incompletely understood, especially in the case of ischemia-reperfusion. Third, the molecular connections linking apoptotic and necrotic programs at the mitochondria and the factors that determine how a specific cell will die are not known in any depth.

Despite these deficits in knowledge, inhibition of cell death has been contemplated, especially for ischemic syndromes. We will limit the discussion here to 2 points. First, a small clinical trial of cyclosporin A, administered at the time of percutaneous coronary intervention for ST-segment-elevation myocardial infarction, suggested reductions in infarct size.<sup>187</sup> A follow-up study in a larger number of patients, however, failed to show smaller infarcts or improvement in clinical outcomes.<sup>187a,187b</sup> Given genetic data implicating mPTP opening as important in necrotic cell death during myocardial infarction,<sup>160,184</sup> possible interpretations include that cyclosporin A is not an optimal small molecule in this situation or that additional necrosis pathways require inhibition.<sup>184a</sup> Second, given that necrosis and apoptosis both contribute to the pathogenesis of myocardial infarction, selection of a

therapeutic target such as BAX, which mediates both forms of cell death,<sup>163,186</sup> is worthy of consideration.

### Generation of ROS

During electron transport, if there is any leakage of electrons, it can lead to the generation of ROS, and mitochondria are one of the major cellular sources of ROS. Mitochondria also contain antioxidant mechanisms to remove ROS. At low levels, ROS can act as a signaling molecule, whereas higher levels can lead to irreversible damage to mitochondria and cells and are a major contributor to cardiovascular disease.

In mitochondria, ROS formation results from sporadic, possibly undesired reactions that occur, especially at the level of the ETC.<sup>189–191</sup> Besides these occasional processes, mitochondria also contain enzymes that catalyze H<sub>2</sub>O<sub>2</sub> generation as the obligatory product.<sup>192</sup>

The ETC drives electrons from reduced coenzymes [NADH(H<sup>+</sup>) and FADH<sub>2</sub>] to oxygen that undergoes the complete reduction to water in the terminal reaction catalyzed by complex IV (ie, cytochrome c oxidase). A minor fraction (≈0.1%) of the electrons flowing through the ETC are suggested to cause the partial reduction of O<sub>2</sub> into superoxide.<sup>189</sup> In particular, flavins or quinones of the first 3 complexes are able to act as single-electron donors resulting in superoxide formation, especially under conditions that decrease the flow of electrons toward complex IV, where O<sub>2</sub> is fully reduced to H<sub>2</sub>O.<sup>189,190</sup> Notably, ROS formation can also result from reverse electron flow. Recently, this concept has been supported by demonstrating *in vivo* that succinate accumulated during ischemia is oxidized during reperfusion, resulting in large ROS formation that is likely attributable to the reverse electron flow within complex I.<sup>193</sup>

ROS formation is favored by high mitochondrial membrane potential (ie, low ATP synthesis), large NADH(H<sup>+</sup>), or when electron flow is hampered by alterations in respiratory complexes. Conversely, a decrease in ROS levels should follow the acceleration in electron flow caused by mitochondrial uncoupling,<sup>194</sup> yet conditions have been reported in which mitochondrial uncoupling and Δψ<sub>m</sub> dissipation are associated with increased ROS formation.<sup>135,195</sup> According to the model of redox-optimized ROS balance,<sup>196</sup> this apparent paradox might be explained by a concomitant depletion of the antioxidative capacity, which would result in H<sub>2</sub>O<sub>2</sub> accumulation despite decreased formation of superoxide by the ETC.<sup>197</sup>

Increased ROS formation is also associated with the uncoupling-like effect generated by opening of the mPTP. Indeed, this process has been proposed to amplify an initial oxidative stress through the so-called ROS-induced ROS release.<sup>191</sup> ROS can trigger PTP opening through oxidative modifications of mitochondrial proteins involved in PTP formation and control, such as FoF<sub>1</sub> ATP synthase e<sup>198</sup> or cyclophilin D.<sup>199</sup> However, despite evidence that ROS formation follows PTP opening,<sup>200,201</sup> the underlying mechanisms have not yet been elucidated. On the other hand, a slight increase in ROS formation resulting from opening of mitochondrial K<sup>+</sup> ATP channels has been proposed to prevent mPTP opening and elicit cardioprotection.<sup>202–204</sup> A similar process could contribute to protection induced by preconditioning or postconditioning that is abrogated by antioxidant treatment.<sup>188,205,206</sup> Therefore, the



notion that mild ROS accumulation increases the resistance to oxidative stress<sup>207</sup> might be explained by opposite effects on the susceptibility to PTP opening elicited by slight and large ROS formation, respectively.

Superoxide that does not cross the IMM is rapidly dismutated into the freely permeable H<sub>2</sub>O<sub>2</sub> by Mn-superoxide dismutase (Mn-SOD). The finding that Mn-SOD-deficient mice develop ROS toxicity and dilated cardiomyopathy<sup>208,209</sup> underscores the importance of ROS in this pathology and mitochondria as their source and target. This concept is further supported by the beneficial effects afforded by targeting catalase expression in mitochondria.<sup>210-212</sup>

Besides respiratory chain complexes, several other mitochondrial enzymes have been described as potential ROS producers. These include the flavin containing glycerol-3-phosphate-dehydrogenase, proline-dehydrogenase and dihydroorotate-dehydrogenase at the outer leaflet of the IMM; the electron transfer flavoprotein-ubiquinone (ETF:Q) oxidoreductase system of FAO within the IMM; and pyruvate- and 2-oxoglutarate dehydrogenase within the mitochondrial matrix.<sup>213</sup> However, the contribution of these enzymes to the overall ROS production of mitochondria within a given cell is difficult to establish. In fact, as is also the case with respiratory complexes, loss-of-function approaches (ie, pharmacological inhibition or genetic deletion) would inevitably hamper the physiological functions of these vital proteins, jeopardizing energy metabolism, ionic homeostasis, and cell viability. Convincing demonstration that mitochondria generate ROS *in vivo* is also provided by interventions targeting mitochondrial enzymes such as p66Shc and monoamine oxidases (MAOs) that generate H<sub>2</sub>O<sub>2</sub> as a direct and obligatory product.

In response to various stress stimuli, the cytosolic adaptor protein p66Shc translocates to mitochondria, where it catalyzes H<sub>2</sub>O<sub>2</sub> formation by means of electron transfer from cytochrome c to oxygen.<sup>214</sup> Indeed, ROS generation is reduced in cells lacking p66Shc and in p66Shc<sup>-/-</sup> mice, whose lifespan is increased by 30%.<sup>215,216</sup> Furthermore, genetic deletion of p66Shc protects against ischemia-reperfusion injury and diabetes mellitus-induced cardiovascular derangements.<sup>192,217</sup>

The 2 isoforms of MAO, A and B, are flavoenzymes located in the OMM. MAOs catalyze the oxidative deamination of catecholamines, serotonin, and biogenic amines generating the corresponding aldehydes, H<sub>2</sub>O<sub>2</sub> and ammonia. H<sub>2</sub>O<sub>2</sub> and aldehydes<sup>206</sup> produced by MAO have been shown to synergize in disrupting mitochondrial function associated with loss of function and viability of the heart.<sup>192</sup> In addition, ammonia might stimulate ROS formation by dihydrolipoyl dehydrogenase, the E3 component of pyruvate and oxoglutarate dehydrogenase.<sup>218</sup> Interestingly, in human atrial biopsy samples, MAO has been shown to produce 10 times more H<sub>2</sub>O<sub>2</sub> than the respiratory chain, and its expression is correlated with an increased risk for postoperative atrial fibrillation.<sup>219</sup> Major advantages of investigating the role of MAO in oxidative stress are given by a defined molecular structure, specific substrates, and clinically available inhibitors. However, the substrates used and the mechanisms of activation under injury conditions are still not clear. In addition, the clinical use of MAO inhibitors in cardiovascular diseases is perceived as problematic because of a hypertensive reaction that occurs when selective MAO-A

inhibition is combined with intake of tyramine-rich food, such as aged cheese and alcoholic beverages. Conversely, MAO-B inhibition is devoid of this potential risk.<sup>220</sup>

The list of dedicated enzymes for ROS formation in mitochondria includes nicotinamide adenine dinucleotide phosphate oxidase 4 (NOX4).<sup>221</sup> At variance from other NOX isoforms localized to the plasma membrane, NOX4 displays a preferential localization to intracellular sites, appears to be constitutively active, and generates H<sub>2</sub>O<sub>2</sub> in preference to superoxide.<sup>222,223</sup> Because localization to cardiac mitochondria has been established on the basis of reactivity to antibodies that were not tested in NOX4<sup>-/-</sup> cardiomyocytes, further studies are necessary. In addition, the role in the cardiovascular system is debated, because NOX4 appears to cause both beneficial and detrimental effects in models of cardiac pressure overload.<sup>28,29,77,221</sup>

As in the rest of the cell, in mitochondria, ROS generation is counterbalanced by efficacious removal systems. Besides superoxide dismutation by Mn-SOD, peroxide handling is performed by a thiol redox system centered on glutathione (GSH and GSSG in its reduced and oxidized form, respectively) and thioredoxin (Trx).<sup>224-226</sup> H<sub>2</sub>O<sub>2</sub> is reduced to water by glutathione peroxidases (Gpx1 and 4) and peroxiredoxin 3 (Prx3), which is maintained in the active reduced form by Trx. In addition, GSH is used by the mitochondrial glutathione-S-transferase K to detoxify products of oxidative damage, such as  $\alpha,\beta$ -unsaturated aldehydes and alkyl hydroperoxides, and by glutaredoxin 2, which catalyzes the formation and reversal of protein-GSH mixed disulfides.<sup>225</sup>

The oxidized forms of glutathione and Trx resulting from Gpx and Prx catalysis are reduced by the corresponding reductases at the expense of NADP(H<sup>+</sup>). The mitochondrial NADP<sup>+</sup> pool is reduced by malic enzyme,  $\Delta\psi_m$ -dependent nicotinamide nucleotide transhydrogenase, and Ca<sup>2+</sup>-modulated isocitrate dehydrogenase. Therefore, the NADP<sup>+</sup>/NADP(H<sup>+</sup>) ratio links oxidative metabolism and mitochondrial function with ROS signaling and antioxidant activities.<sup>197</sup> Prx3 is responsible for >90% of H<sub>2</sub>O<sub>2</sub> removal in mitochondria.<sup>227</sup> However, because Prx3 is highly susceptible to oxidation, under conditions of severe oxidative stress such as myocardial ischemia and reperfusion,<sup>228</sup> Gpx1 might become the major sink for H<sub>2</sub>O<sub>2</sub>.<sup>225</sup> Prx3 overexpression confers increased resistance to ischemia-reperfusion injury,<sup>229</sup> which lends further support to the relevance of mitochondria-generated ROS in cardiac diseases.

The occurrence and the relevance of ROS formation in mitochondria are supported by direct methods for *in vivo* detection,<sup>230</sup> effects of targeted antioxidants and enzymes,<sup>231</sup> and decreased ROS accumulation after inhibition or deletion of mitochondrial ROS sources.<sup>232</sup> The majority of studies relate mitochondrial ROS formation with cell injury, which suggests that beneficial effects are afforded by preventing ROS accumulation in a wide array of cardiovascular diseases, such as ischemia-reperfusion injury, heart failure, aging, and diabetic cardiomyopathy.<sup>190,192,217,233,234</sup>

Although it is undeniable that high levels of ROS impair the function and viability of any cell type, a large body of evidence indicates that ROS generated within mitochondria are involved in signaling processes that are crucial for optimal

response to physiological and pathological stimuli.<sup>192,235–237</sup> Indeed, several reports document the crucial role of mitochondrial ROS generation in a wide variety of cardiomyocyte functions. The physiological role of mitochondrial ROS is likely to be linked to PTMs of proteins, especially at the level of cysteine residues.<sup>238</sup> For instance, SNO has been recognized as a cardioprotective mechanism that prevents irreversible oxidation of proteins.<sup>225,230,239</sup> In addition, signaling pathways involving protein phosphorylation are modulated by oxidation of critical cysteines, especially in protein phosphatases.<sup>240</sup> In addition to these short-term responses, mitochondrial ROS are involved in long-lasting changes by acting on transcriptional factors, such as hypoxia-inducible factors and nuclear factor erythroid 2–related factor 2 (Nrf2).<sup>226,241–243</sup>

Far from always being beneficial, a decrease in mitochondrial ROS levels could be detrimental. A large increase in glutathione content or the administration of *N*-acetylcysteine was shown to elicit mitochondrial oxidation and cytotoxicity despite a decrease in ROS levels.<sup>244</sup> Suppression of mitochondrial ROS generation by mitochondria-targeted catalase hampered autophagy, which worsened heart failure caused by deletion of mitofusin 2.<sup>245</sup> Interventions aimed at reducing mitochondrial ROS levels, such as expression of dominant negative Nox,<sup>149</sup> deletion of p66Shc,<sup>246</sup> or ablation of thioredoxin-interacting protein,<sup>247</sup> were found to exacerbate the mild injury induced by ischemia-reperfusion protocols of short duration. This paradoxical notion, which contrasts with protection by antioxidant treatments in prolonged episodes of ischemia-reperfusion, suggests that mitochondrial ROS are involved in triggering self-defense mechanisms. Supporting this concept, antioxidants abrogate the powerful protection of both ischemic preconditioning and postconditioning.<sup>203,204,206</sup> In this respect, the term *mitohormesis* has been introduced to describe the J-shaped curve whereby low doses of mitochondrial ROS trigger beneficial adaptive responses that are replaced by detrimental processes at high doses.<sup>241,248</sup> Although this concept appears to accommodate the protective effects of exercise and calorie restriction,<sup>248</sup> especially in clinical settings, methods are not available to define the threshold that separate beneficial from harmful ROS levels. Other relevant issues to address are the interactions among the various ROS sources and the conditions involved in local compartmentalized ROS formation compared with diffusion of ROS and oxidized products to the entire cell and surrounding tissues.

## Mitochondrial Quality Control

### *Fission/Fusion/Mitochondrial Dynamics*

As cells and organisms reproduce, their mitochondria divide to repopulate the progeny. Mitochondria also divide and fuse back together in nondividing, quiescent, and postmitotic cells such as cardiomyocytes and neurons; however, the rates in cardiomyocytes appear to be quite low. This continual fission and fusion cycle, a process also called mitochondrial dynamics, is known to be essential for the healthy maintenance of mitochondria and their host cells and organisms. Mitochondrial dynamics participate in mitophagy, apoptosis, differentiation, and a variety of stress responses. The adverse consequences that an interruption in the *in vivo* cardiomyocyte mitochondrial

dynamics has on mitochondrial stress, mitochondrial biogenesis, and programmed cardiomyocyte death were recently demonstrated in side-by-side comparative studies after conditional genetic deletion of either cardiac mitochondrial fusion or fission pathways.<sup>249</sup>

Mitochondrial morphology reflects the relative rates of fission and fusion and can be visualized in fixed cells and tissues by immunostaining. Perturbing the ratio of fission and fusion rates will lead to either fragmented, punctiform mitochondria or excessively long or interconnected mitochondria. However, because mitochondrial morphology is dynamic, fission and fusion rates are best visualized in live cells. Quantification of mitochondrial fusion rates can be performed with photoactivatable green fluorescent protein (PAGFP) that is targeted to the mitochondrial matrix. When the mito-PAGFP is activated with a laser targeted to 1 mitochondrion, the PAGFP fluorescence is increased  $\approx 100$  times, and as this mitochondrion fuses with others, the fluorescence is diluted.<sup>250</sup> Quantification of this dilution rate reflects the organelle fusion rate independent of the fission rate and shows remarkable differences among cell types and changes, for example, early during apoptosis. An alternate approach to assess fusion uses 2 cell populations, one expressing green fluorescent protein in mitochondria and another expressing red fluorescent protein in the mitochondria. When cells from these 2 populations are fused with polyethylene glycol, the rate that the green fluorescent protein and red fluorescent protein merge to form yellow fluorescence reflects the mitochondrial fusion rate.<sup>251</sup> These techniques have been used extensively to characterize proteins that mediate the fusion process<sup>252</sup> and the physiological consequences of mitochondrial dynamics.<sup>253</sup>

The molecular machinery that mediates mitochondrial fusion uses large GTPases in the dynamin family.<sup>252,254</sup> Mitofusins (Mfn1, Mfn2) mediate fusion of the OMM, whereas Opa1 mediates fusion of the IMM. Mfn1, Mfn2, and Opa1 all require GTPase activity for fusion activity. Mfn1 and Mfn2 span the OMM, with most of the protein and the GTPase domain facing the cytosolic compartment. Opa1 is localized within the intermembrane space anchored to the IMM. Mitofusins and Opa1 usually work in concert to coordinately fuse both mitochondrial membranes. Opa1 activity is regulated by proteolytic processing, but how Mfn1 and Mfn2 are regulated is not yet clear.

Mitochondrial fission uses a large GTPase called Drp1 (dynamin-related protein 1), a homologue of dynamin that is well understood to mediate fission of endocytic vesicles from the plasma membrane. Like dynamin during endocytosis, Drp1 assembles into spirals that wrap around mitochondria and appear to constrict the inner and outer membranes during GTP cleavage to start the fission process. Drp1 exists free in the cytosol, from which it docks to mitochondrial fission sites by interacting with the OMM-spanning proteins Mff, Mid49, and Mid52.<sup>252,254</sup> Fis1 is a protein required for Dnm1 (a Drp1 orthologue)-mediated fission in yeast but is not required for fission in metazoans. Instead, Fis1 in metazoans participates in mitophagy.<sup>255</sup> Drp1 activity is regulated by phosphorylation at several sites on the protein. Phosphorylation at some sites stimulates fission, for example, during the cell cycle, and at other sites, phosphorylation inhibits fission. Interestingly,

endoplasmic reticulum tubules wrap around sites of mitochondria before their fission and might play a role in defining the site of mitochondrial fission or in assembling the fission complex at the proper location.<sup>256</sup>

Identification of these fission and fusion proteins has allowed generation of animal models and cell culture lines for the exploration of the physiological significance of mitochondrial dynamics. Mfn1, Mfn2, and Opa1 knockout mice are all embryonic lethal, which suggests that both fission and fusion are required for maintenance of mammalian embryos. However, fibroblasts generated from the embryos survive in culture, albeit with altered mitochondrial morphology and in some cases, metabolic deficits.<sup>252</sup> Cardiac myocyte-specific knockout of Mfn1 and 2 in adults causes cardiomyopathy. Interestingly, myocytes die after only 3 to 4 cycles of mitochondrial fission without opposing fusion.<sup>83</sup> Surprisingly, mitochondrial fusion is also linked to cardiac development. Through regulation of calcium levels and calcineurin, mitochondrial dynamics control Notch signaling and stem cell differentiation into cardiomyocytes.<sup>257</sup>

Mutations in several of the mitochondrial fusion genes have been identified as causing human disease.<sup>252,254</sup> Dominant optic atrophy, the most common form of hereditary blindness, is caused by haploinsufficiency in Opa1. Thus, retinal ganglion cells are highly dependent, and more so than other human tissues, on fusion of the IMM. Another example is mutations in Mfn2 that cause Charcot-Marie-Tooth disease type 2A. Understanding the intriguing tissue specificity of defects from mutations in mitochondrial dynamics genes, which have what might be considered housekeeping duties, remains a major challenge in discerning the roles of mitochondria in vivo. Because of the links of mitochondrial dynamics to human and animal health, there are efforts to drug the pathway. For example, mDIVI is a small molecule that inhibits Drp1 and mitochondrial fission that has been reported to have protective activity in numerous animal disease models, including heart ischemia-reperfusion injury.<sup>258</sup>

It is clear that mitochondria have to continually divide and fuse, but what are the essential roles of mitochondrial dynamics at the molecular level? Mitochondrial fission has been linked to damage avoidance through segregation of debris within mitochondria. As discussed elsewhere in this statement (Mitophagy and Mitochondrial Autophagy: Mechanisms, Overlaps, and Distinctions), mitophagy after fission allows the clearance of damaged mitochondria and selective elimination of damaged proteins.<sup>253,259</sup> Mitochondrial fission has been linked to apoptosis, which can also function as a severe form of stress response. Mitochondrial dynamics are also required for transport of mitochondria to proper locations within cells. On the other hand, fusion between mitochondria is thought to allow compensation to help rescue organelles from damage by the exchange of proteins and RNAs from 1 mitochondrion to another.<sup>260</sup> Mitochondria accumulate mtDNA deletions and mutations over time, and these mutations can generate mitochondrial proteins that are dysfunctional or misfolded. If mitochondria did not fuse, dysfunctional proteins could lead to serious loss-of-function consequences. However, fusion with another mitochondrion that might have mutations in other genes would allow compensation between organelles

and avoid the serious consequences of mutation accumulation. Mitochondrial hyperfusion is a broadly active stress response that might facilitate such compensation.<sup>261</sup>

### **Mitophagy and Mitochondrial Autophagy: Mechanisms, Overlap, and Distinctions**

*Mitophagy*, which literally means “eating mitochondria,” is the term applied to the cellular mechanism for identifying and selectively eliminating dysfunctional mitochondria as part of the overall mitochondrial quality control process.<sup>262</sup> Mitophagy is essential to sequester and remove senescent or damaged mitochondria that could otherwise accumulate and become sources of cytotoxic ROS (Generation of ROS). Although the distal components of the mitophagy pathway (ie, autophagosomal engulfment of mitochondria and their transfer to lysosomes for degradation and component recycling) are shared with macroautophagy, the proximal events that detect and select dysfunctional organelles for targeted elimination are highly specific for mitophagy. Two central proteins driving this detection/selection process are the cytosolic E3 ubiquitin ligase Parkin<sup>263</sup> and the mitochondrial kinase PINK1,<sup>56</sup> encoded by genes (*PARK2* and *PARK7*, respectively) for which loss-of-function mutations have been linked to autosomal recessive forms of Parkinson disease.<sup>264</sup>

The discovery that PINK1 and Parkin interact to promote mitochondrial fitness<sup>265,266</sup> and the elucidation of mitochondrial stabilization of PINK1 as the initiating event in mitophagy<sup>267,268</sup> were central to our current understanding of the mechanisms underlying mitochondrial quality control. Briefly, healthy mitochondria maintain an electrochemical inner membrane gradient,  $\Delta\psi_m$ , that drives ATP production by the electron transport complex (Generation of ATP: Bioenergetics and Metabolism). Senescent mitochondria are unable to sustain a normal  $\Delta\psi_m$ , and damaged mitochondria can completely dissipate  $\Delta\psi_m$ , resulting in depolarization. Mitochondrial  $\Delta\psi_m$  status is a key determinant of PINK1-Parkin pathway activity: Healthy, fully polarized mitochondria import and rapidly degrade PINK1, maintaining low kinase activity. On depolarization, however, PINK1 degradation is suppressed,<sup>268</sup> thereby increasing its abundance and promoting multiple PINK1 kinase-mediated events, including Parkin translocation to<sup>269</sup> and activation at<sup>270,271</sup> mitochondrial outer membranes. At the mitochondrion, Parkin ubiquitylates dozens of mitochondrial proteins,<sup>272</sup> thereby promoting autophagosomal engulfment of the damaged organelle. The overall result for the cell is selective mitophagic destruction of depolarized mitochondria.

Mitophagy is inextricably linked to mitochondrial dynamism (ie, mitochondrial fission and fusion). In many cells, mitochondria form highly interconnected reticular networks that are constantly remodeling through periodic fission and fusion. However, in adult cardiac myocytes, mitochondria fission/fusion is rare.<sup>273</sup> For this reason, it is likely that mitochondrial dynamism is dispensable for morphometric remodeling in hearts, but nevertheless, it plays an important role in cardiac mitophagic quality control through the process of Drp1-mediated asymmetric fission.<sup>274</sup> Accordingly, a mitochondrion in the early stages of senescence or one that has sustained moderate damage will segregate its dysfunctional components into 1 of the 2 daughter organelles generated

by a fission event. The damaged (and therefore depolarized) daughter mitochondrion will be promptly identified as such and removed via PINK1-Parkin mediated mitophagy, whereas the healthy daughter will rejoin the cellular mitochondria pool, likely by fusing with other similarly fit mitochondria. The particular role for Parkin-dependent versus Parkin-independent or “alternate” mitophagy mechanisms in healthy and diseased hearts is only beginning to be investigated.<sup>275,276</sup>

Mfn1 and Mfn2, so designated because they promote physical tethering between mitochondria and subsequent GTPase-dependent mitochondrial fusion, also have a role in mitophagy. In addition to promoting fusion of the healthy daughters after asymmetric fission, PINK1 kinase stabilization in damaged mitochondria results in phosphorylation of Mfn2 on 2 domains, thus conferring Parkin binding activity to this mitochondrial outer membrane protein and facilitating both Parkin translocation and its subsequent ubiquitination of mitochondrial proteins.<sup>55</sup> For this reason, hearts deficient in Mfn2 that do not exhibit defects in mitochondrial fusion (because Mfn1 is still present) instead develop a defect in mitochondrial quality control.<sup>55,277</sup>

There are surprising consequences of the mechanistic involvement of mitochondrial dynamism in mitochondrial quality control. For example, if mitophagy is malfunctioning but dynamism is intact, then the process of asymmetric fission will generate a highly dysfunctional daughter organelle that cannot be removed through the usual quality control process. Instead, the improperly retained damaged mitochondrion can fuse with (and by exchanging cellular components, thereby damage) normal mitochondria within the same cell. An example of fusion-mediated mitochondrial contagion was recently uncovered in Parkin-deficient *Drosophila* fruit fly heart tubes.<sup>245</sup> In this model, because fusion contributed to the spread of mitochondrial damage, heart failure was attenuated by cardiomyocyte-specific suppression of *Drosophila* mitofusin (MARF).

An important role for PINK1-Parkin-mediated mitophagy in normal functioning of the nervous system is clear from Parkinson disease.<sup>278</sup> Surprisingly, although genetic suppression of PINK1 or Parkin in fruit flies is detrimental to mitochondrial fitness and normal functioning of neural tissue, skeletal muscle, and myocardium,<sup>279</sup> germline gene ablation of the orthologous mouse genes evokes only modest phenotypes.<sup>280</sup> In mouse hearts, germline ablation of PINK1 and Parkin appears to produce only mild and slowly progressive basal cardiac dysfunction but increased sensitivity to ischemic injury.<sup>84,93,281</sup> Likewise, cardiomyocyte-specific Parkin ablation in adult mice provoked no detectable phenotype, and conditional cardiac Parkin overexpression had no detectable adverse consequences.<sup>275</sup> Thus, it is possible that PINK1-Parkin-mediated mitophagy is relatively unimportant to mitochondrial homeostasis in normal mammalian hearts. On the other hand, the absence of notable nervous system dysfunction (ie, Parkinson disease phenotypes) in these same mice,<sup>280</sup> evidence of compensatory upregulation of alternate E3 ligases in hearts of germline Parkin knockout mice,<sup>245</sup> and the cardiomyopathy that is evoked by cardiomyocyte-specific interruption of PINK1-Parkin signaling (through Mfn2 ablation)<sup>55,277</sup> suggest that this pathway of mitochondrial quality control

could indeed be important under specific and as yet incompletely understood circumstances. The true role of PINK1 and Parkin in mammalian hearts might only be uncovered by the creation of new experimental models or by additional human genetic testing for rare PINK1 and Parkin mutations in clinical cardiac disease. Of note, Parkin can regulate fat uptake.<sup>282</sup>

If it is correct that maintaining mitochondrial quality is essential to cell health, then the absence of damaging mouse phenotypes in PINK1 and Parkin knockout mice and the focal degeneration of dopaminergic neurons (rather than larger systemwide effects) in Parkinson disease linked to human PINK1 or Parkin mutations suggest the presence of  $\geq 1$  alternative pathways of mitochondrial quality control.<sup>283</sup> Indeed, mitochondria can be eliminated independent of PINK1 and Parkin by an autophagic mechanism that uses the proapoptotic Bcl2 family proteins Nix and Bnip3 to target dysfunctional mitochondria and connect them to autophagosomes.<sup>284</sup> Conceptually, this mechanism resembles so-called mitoptosis, in which opening of the mPTP activates mitochondrial autophagy.<sup>285</sup> In this context, Nix and Bnip3 accumulate on damaged mitochondria, facilitate the permeability transition, and promote mitochondrial autophagy by serving as mitochondrial adaptor proteins that bind to autophagosomal LC3 or GABARAP.<sup>286–289</sup> Although Nix and Bnip3 are widely recognized for their proapoptotic effects in cardiac failure after pressure-overload hypertrophy and myocardial infarction, respectively,<sup>290–293</sup> the possibility that they also promote homeostatic mitochondrial autophagy in hearts merits further investigation.

Dissipation of  $\Delta\psi_m$ , aka mitochondrial depolarization, contributes to the signal for PINK1 stabilization and initiation of Parkin-mediated mitophagy. Evidence is accumulating that ROS, which are also markers of mitochondrial dysfunction, can play a similar role in Parkin-independent mitochondrial autophagy.<sup>277,294</sup> In vivo disruption of cardiomyocyte Parkin signaling by ablation of its Mfn2 mitochondrial receptor evokes a cardiomyopathy. As expected, normalization of ROS with mitochondria-directed catalase improves this mitophagic cardiomyopathy. In contrast, supersuppression of ROS (with mitochondria-directed catalase expressed at higher levels) is detrimental, both accelerating and exacerbating the cardiomyopathy.<sup>277</sup> These findings reveal an essential signaling function for mitochondria-derived ROS in compensatory mitochondrial autophagy pathways induced when the Parkin pathway is interrupted.

### **Protein Turnover Independent of Mitophagy**

As discussed in the section on Mitophagy and Mitochondrial Autophagy: Mechanisms, Overlap, and Distinctions, damaged mitochondria can be removed by mitophagy. However, individual mitochondrial proteins can also be damaged and could underlie several pathological phenotypes.<sup>295</sup> It is therefore paramount that the renewal, or turnover, of proteins within mitochondria be sustained in times of enhanced cellular stress, because failure to maintain normal protein turnover can lead to accumulation of damaged/misfolded proteins and could underlie the pathogenesis of various diseases. Protein turnover has been deemed “a missing dimension” in proteomics,<sup>296</sup> because quantitative proteomic measurements typically involve the

profiling of static protein abundance between different disease states or conditions. Recent advances in protein dynamics methodologies have enabled the simultaneous measurement of individual proteins comprising entire mitochondrial<sup>244,297–299</sup> proteomes. A recent study provided the first assessment of global mitochondrial proteome kinetic signatures in a disease model of cardiac remodeling, which demonstrated that protein turnover rates are under independent control, indicative of diverse regulatory processes driving remodeling of the mitochondria in disease.<sup>297</sup>

Protein turnover measurements rely on the ability to track the rate at which individual proteins are being replaced by de novo synthesized proteins. Several methodologies have been used for these measurements, and all involve the introduction of an isotope precursor into a living system to mark individual proteins and determine their longevity in cells. For an excellent comprehensive review of strategies used to measure protein turnover, including the experimental model, stable isotope label, labeling protocol, relative isotope abundance transition, and calculation of turnover rate, see Claydon and Beynon.<sup>300</sup>

Protein turnover rate is evaluated by tracking the integration or loss of a label into a protein pool. Proteins exhibit a diverse range of half-lives, with housekeeping proteins tending toward longer half-lives and regulatory proteins toward shorter half-lives. Thus, sampling times after initiation of labeling must cover an adequate range of time to accurately model proteins that exhibit both fast and slow rates of turnover. Moreover, the number of sampling time points is directly correlated to the accuracy of the labeling trajectory. An additional consideration for complex organisms is the slow equilibration of the stable isotope label (eg, <sup>2</sup>H) in a precursor pool (eg, body water), which is incompletely labeled in the *in vivo* labeling strategies and requires complex analysis to determine precursor pool enrichment. Although each stable isotope methodology has its strengths and weaknesses, heavy water labeling has distinct advantages for translational research in that at low enrichment levels, it is safe for humans over years,<sup>301</sup> it is easy to maintain constant enrichment levels of <sup>2</sup>H in body water after <sup>2</sup>H<sub>2</sub>O intake,<sup>302,303</sup> and it is the most cost-effective stable isotope. Detailed methods and equations underlying computational analysis are outlined in Kim et al,<sup>244</sup> and the automated software, ProTurn,<sup>297</sup> is available at <http://www.heartproteome.org/proturn/>.

Four recent studies have interrogated protein dynamics in mitochondria in whole animals or humans using oral consumption of either deuterated leucine-labeled protein<sup>298</sup> or drinking water.<sup>244,297,299</sup> Two recent studies investigated mitochondrial protein turnover changes in cardiac pathologies. In a translational study by Lam et al,<sup>297</sup> <sup>2</sup>H<sub>2</sub>O labeling was used to investigate changes in protein dynamics of cardiac proteins in mouse and blood proteins in both mouse and human. Turnover rates were determined for 496 human plasma proteins spanning a 50-fold range of turnover rates from albumin (half-life 18.3 days) to insulin-like growth factor 2 (half-life 8 hours). Mice undergoing cardiac remodeling via chronic isoproterenol infusion were compared with controls, and turnover rates for 2964 mouse proteins were assessed in mouse cardiac mitochondrial and cytosolic fractions and in blood. Rates were highly diverse and ranged from <1 day to >3 weeks (100-fold range).

Cytosolic proteins turned over  $\approx 10\%$  per day (average half-life of 6.5 days) and mitochondrial proteins  $\approx 5\%$  per day (average half-life 15 days). Consistent with enhanced protein synthesis occurring in cardiac hypertrophy during remodeling, turnover rates in isoproterenol-treated mice were on average 1.2 times faster than in wild-type hearts, with turnover rate increases detected in 972 proteins (>1.3 fold) and decreases in 216 proteins. In contrast, isoproterenol withdrawal, or reverse remodeling, led to an average 20% decrease in protein turnover rate. Importantly, this study identified proteins that exhibited super-normal elevations or attenuations in protein turnover during cardiac remodeling, which suggests that these proteins might be pathogenic in the cardiac remodeling process. Proteins involved in mitochondrial dynamics showed heterogeneous results in that some mitochondrial dynamics proteins exhibited elevated turnover (MIRO1/2, LONP, and PHB), whereas others were unchanged (MFN1/2 and FIS1). Subunits residing in the same respiratory complex (ETC I through V) displayed widespread changes, which provided insight into proteins that could be rate-limiting factors in complex formation and highlights the important finding that synthesis-degradation cycles of proteins within the same functional group (ie, complexes, organelles) are under independent control. Interestingly, turnover measurements also unveiled markedly enhanced turnover in virtually all glycolytic enzymes (HK1 half-life decreased from 16.7 to 9.8 days, GAPDH from 10.8 to 6.7 days, and phosphoglycerate mutase-1 from 12.2 to 6.9 days) in the absence of any changes in static protein abundance, thus providing mechanistic insights to support the alteration in substrate utilization, from fatty acids to glucose, known to occur in cardiac disease. These novel mechanistic insights into cardiac remodeling are masked in measurements of static protein abundance, which highlights the unique biological dimension unveiled by protein turnover measurements. Lastly, a study by Shekar et al<sup>299</sup> used <sup>2</sup>H<sub>2</sub>O labeling in rats to measure turnover in heart failure from 2 cardiac mitochondrial subpopulations, subsarcolemmal mitochondria and interfibrillar mitochondria. This group investigated the hypothesis that mitochondrial protein synthesis (and thus, oxidative capacity) is decreased in transverse aorta constriction-induced heart failure, and interfibrillar mitochondria exhibit more pronounced detriments than subsarcolemmal mitochondria. Results from this study showed an overall decrease in mitochondrial content in interfibrillar mitochondria but not subsarcolemmal mitochondria populations, coordinate with a more pronounced detriment in basal and stimulated respiratory rate in interfibrillar mitochondria.

The physiological and pathophysiological implications gleaned from turnover measurements of individual proteins within functional mitochondrial subproteomes are many. Dynamic equilibria of proteins fluctuate in times of cellular stimulation or altered cellular stress, and protein turnover measurements provide a missing dimension of protein behavior that will enable mechanistic studies on the governance of protein synthesis and degradation. Very little is known regarding the interplay of these processes in tuning the abundance of individual proteins or protein complexes in the cell. Global turnover measurements with individual protein resolution, now possible for all detectable proteins within the

mitochondrial proteome, have indicated that diverse regulatory mechanisms exist in metabolic pathways. Furthermore, it is now understood that protein half-life is an exquisitely regulated cellular parameter that is correlated with phenotype; however, it is mostly disassociated with static protein abundance. Protein dynamics provide a unique understanding of the biological regulation of mitochondrial proteins that, when related to static protein abundance and mRNA expression, can inform on the poorly understood process of protein degradation in basal and diseased conditions.

Mitochondrial protein dynamics measurements have high translational significance with regard to mitochondrial biomarker discovery and treatment of mitochondrial diseases. Mitochondrial diseases are a heterogeneous class of conditions that require sensitive and specific biomarkers for their accurate diagnosis and prognostic assessment. The advantages of using protein turnover measurements, rather than the commonly used protein abundance, for early detection of pathophysiological states has been discussed<sup>304</sup> and clearly demonstrated.<sup>305,306</sup> The sensitivity of protein dynamics is in many ways superior to static protein abundance in that alterations in turnover measurements will likely be more pronounced and could precede alterations in static protein abundance in the pathological progression of diseases. Protein turnover rate is also a critical factor in biomarker discovery (Biomarkers), because markers with lower clearance rates within the systemic circulation would be more robust indicators of disease states. Protein dynamics measurements will also unveil novel disease mechanisms (ie, protein degradation insufficiencies), which will spawn the development of novel therapeutic classes.

Questions underlying the relationship between protein turnover and abundance remain. For example, certain mitochondrial proteins exhibit rapid turnover rates (and thus consume a sizeable amount of ATP for their renewal), with little to no change in static abundance. Observations such as these might begin to challenge the conventional school of thought that the abundance of a protein present in a cell directly correlates with its magnitude of impact in the cell. Although several educated guesses have been put forth regarding questions like these, scientific evidence is lacking.

### Signaling by Release of mtDNA and Proteins

As discussed in the section on Mitochondria and Cell Death, mitochondria are involved in the intrinsic pathway of apoptosis, where they release soluble proteins, including cytochrome c, from the intermembrane space into the cytosol to initiate caspase activation.<sup>307</sup> The release of these proteins is a consequence of OMM permeabilization. Other examples of functional molecules released from mitochondria include (1) ROS to activate hypoxic gene expression, ROS-dependent mitogen-activated protein kinase, and damaged macromolecules, including DNA and proteins; and (2) calcium, which participates in calcium cross talk between mitochondria and the plasma membrane and between mitochondria and the endoplasmic-sarcoplasmic reticulum and ATP from apoptotic and necrotic cells as a danger signal.<sup>308</sup> Recently, it has been reported that mtDNA and proteins are involved in innate immunity. In this section, we will focus on the role of mitochondria in inflammation.<sup>309</sup>

The immune system is activated not only by microorganism infection but also by endogenous molecules.<sup>310</sup> The endogenous molecules are separated from immune system sensors by plasma membrane and compartmentalization within the cell. However, endogenous molecules are released into circulation during necrosis or into the cytoplasm during degradation of organelles. These endogenous molecules, which can induce inflammatory responses, are referred to as damaged-associated molecular patterns (DAMPs). Pattern recognition receptors (PRRs) are responsible for sensing the presence of microorganisms by recognizing structures that are conserved among microbial species, which are called pathogen-associated molecular patterns (PAMP). Moreover, PRRs are capable of recognizing DAMP. To date, 4 different classes of PRR families have been identified, including transmembrane proteins such as Toll-like receptors (TLR) and C-type lectin receptors, as well as cytoplasmic sensors such as retinoic acid-inducible gene (RIG)-I-like receptors and NOD-like receptors (NLRs). In addition to PRRs, inflammasomes are multiprotein complexes that contribute to the intracellular identification of potentially harmful substances, bacteria, or viruses. Inflammasomes are composed of 3 major components: a characteristic scaffolding protein, the small adapter molecule ASC, and procaspase-1, which is responsible for activation of proinflammatory cytokines. Those scaffolding proteins include the NLR family, pyrin domain-containing 1 (NLRP1), absent in melanoma 2 (AIM2), NLR family CARD domain-containing protein 4 (NLRC4), RIG-I, and NLRP3, and each protein forms the corresponding inflammasome in concert with ASC and procaspase 1.

Because mitochondria are evolutionary endosymbionts derived from bacteria, they retain many morphological and biochemical features of their bacterial ancestors, including a double membrane, membrane lipid (cardiolipin), unmethylated CpG motifs in mtDNA, absence of histones, and the ability to form *N*-formyl peptides, which are synthesized by the use of separate sets of ribosomal RNAs and tRNAs encoded by the mitochondrial genome.<sup>311</sup> Unmethylated CpG motifs and *N*-formyl peptides are inflammatogenic and mitochondrial DAMPs.

In response to pressure overload, mitochondria are damaged, and damaged mitochondria are degraded by autophagy or mitophagy (Mitophagy and Mitochondrial Autophagy: Mechanisms, Overlap, and Distinctions). Among PRRs, TLR9 senses unmethylated CpG motifs in bacteria and virus. mtDNA is degraded by DNase II in the autolysosome, which is an acidic DNase and localized in the lysosome. When induction of autophagy is insufficient in pressure-overloaded hearts, mtDNA escapes from autophagy-mediated degradation and binds to TLR9 to induce inflammatory responses cell-autonomously in cardiomyocytes, myocarditis, and dilated cardiomyopathy. However, it has been reported that depletion of autophagic proteins promotes cytosolic translocation of mtDNA and caspase-1-dependent cytokines mediated by the NALP3 inflammasome in response to lipopolysaccharide in macrophages.<sup>312</sup> In addition to TLR9, the NALP3 inflammasome might be involved in inflammation in the failing heart. The role of autophagy in innate immunity could be dependent on the cell type.

In the case of myocardial infarction, in which necrosis is a main feature of cell death, mtDNA is released into circulation.

The serum from patients after coronary intervention contains mtDNA.<sup>313</sup> Cellular disruption by trauma releases mitochondrial molecules, including DNA, into circulation to activate neutrophils and cause systemic inflammation.<sup>314</sup> Thus, it is possible that mtDNA in circulation after myocardial infarction could contribute to the inflammatory responses in infarct hearts.

Mitochondrial *N*-formyl peptides are released from degenerating mitochondria upon tissue damage<sup>314,315</sup> and recognized by formyl peptide receptors, which have evolved to mediate phagocyte migration to sites of tissue injury. Although the role of the *N*-formyl peptide–FRP signaling pathway in heart diseases, specifically myocardial infarction, remains to be elucidated, it is possible that the pathway could play a role in inflammation in infarcted hearts.

The newly discovered role of mitochondria as DAMP-containing organelles places mitochondria in a central position as initiators and modulators of sterile inflammation in failing or infarcted hearts. In case of pressure-overloaded hearts, autophagy regulates degradation of mtDNA and resultant inflammation in cardiomyocytes. In infarcted hearts, accompanied by necrosis, mtDNA released into circulation could activate and recruit various inflammatory cells in the lesion.

## Mitochondria and Cardiovascular Disease

### Mitochondrial Myopathies: Mitochondrial Pathogenesis of Cardiomyopathy

Cardiomyocytes have among the highest concentrations on mitochondria of any human cell. Because of the high mitochondrial ATP demands of the heart, relatively subtle defects in the mitochondrial ATP-generating apparatus, oxidative phosphorylation (OXPHOS), can preferentially affect cardiac function.

If we rearrange the classification of the common diseases based on bioenergetics rather than anatomy, it becomes clear that all of the complex diseases can be envisioned as having the same underlying pathophysiological basis: partial bioenergetics dysfunction. Because the mitochondria are assembled from between 1000 and 2000 nuclear DNA (nDNA) genes plus thousands of copies of the maternally inherited mtDNA genes, and the mitochondria both process the calories in our diet into usable energy and are acutely sensitive to a wide range of toxins, it follows that perturbation of mitochondrial bioenergetics can readily explain the pathogenesis of the full range of common clinical disease symptoms (Figure 2).<sup>2,318</sup>

The nDNA-coded genes relevant to mitochondrial function include the  $\approx$ 1000 proteins located within the mitochondrion<sup>319</sup> plus all of the genes involved in regulating cellular bioenergetics, including the signal transduction enzymes (AMPK, SIRTUINS, etc); nuclear receptor transcription factors (the peroxisome proliferator-activated receptor [PPAR] family, the heteromeric partners of the PPARs [RXR], the PPAR- $\gamma$  coactivator-1- $\alpha$  [PGC-1 $\alpha$ ] family of coactivators, etc); environmentally regulated transcription factors (hypoxia-inducible factor-1 $\alpha$ , nuclear factor- $\kappa$ B, etc), nutrient-sensing systems (PTEN [phosphatase and tensin homolog], TSC [tuberous sclerosis complex], mTOR [mammalian target of rapamycin],


etc); regulators of mtDNA biogenesis (replication [POLG and Trinkle], transcription [POLRMT], and translation [mitochondrial ribosomal proteins and elongation factors]); and those chromatin remodeling systems that permit nDNA-mitochondrial gene expression. Because of their high energetic demand, the tissues most commonly affected by partial mitochondrial dysfunction are the heart, brain, muscle, renal, and endocrine systems.<sup>2,320–323</sup>

Although the nDNA codes for the great majority of mitochondrial proteins, the mtDNA codes for the 13 most critical OXPHOS polypeptides plus the 22 tRNAs and 2 ribosomal RNAs for their expression. OXPHOS generates energy by coupling electron transport (complexes I, II, and IV) with ATP synthesis (complex V) through the electrochemical gradient.

Severe mitochondrial diseases can result from homozygous mutations in nDNA-coded mitochondrial genes<sup>321,324,325</sup> or severe mtDNA mutations. Milder mitochondrial disease can result from heterozygous nDNA mutations, from mild mtDNA mutations, or from severe mtDNA mutations that are heteroplasmic, a mixture within the cytoplasm of mutant and normal mtDNA. Milder mtDNA mutations result in symptoms when approximating homoplasmic (pure mutant), whereas more severe mutations can lead to disease when heteroplasmic.

There are 3 classes of clinically relevant mtDNA variants: ancient adaptive variants, recent deleterious mutations, and somatic mutations that accumulate in tissues during development and with age. Ancient adaptive mutations have accumulated along radiating maternal lineages as women migrated out of Africa to populate Eurasia and the Americas. A subset of these mtDNA mutations changed OXPHOS function and human physiology, which permitted descendent populations to adapt to the new environments. mtDNAs harboring these locally beneficial variants became regionally enriched by adaptive selection, and as their descendants acquired additional mutations, a group of related haplotypes developed, known collectively as a haplogroup. Although beneficial in one environment, these variants can be maladaptive in another. Various mtDNA haplogroups have now been correlated with a broad spectrum of diseases, including Alzheimer and Parkinson disease, macular degeneration, psychiatric disorders, stroke, diabetes mellitus, cardiovascular disease, sepsis, asthma, AIDS progression, various forms of cancer, types of athletic performance, and longevity.<sup>2,323,325–327</sup>

Recent deleterious mutations continually arise within modern female lineages. Hundreds of such pathogenic mutations have been identified and are cataloged in the mtDNA database, MITOMAP.<sup>328</sup> An example of a frequently homoplasmic “mild” pathogenic mutation is the common Leber hereditary optic neuropathy (LHON) complex I gene missense mutation, *ND4* nt 11778 G>A (R340H).<sup>325,329,330</sup> Examples of more severe heteroplasmic mtDNA mutations are the tRNA<sup>Lys</sup> nt 8344 A>G mutations, which can manifest as hearing loss at low heteroplasmy but cardiomyopathy and myoclonic epilepsy and ragged red fiber (MERRF) disease at higher heteroplasmy,<sup>331,332</sup> and the tRNA<sup>Leu(UUR)</sup> nt 3243A>G mutation, which at 50% to 90% mutant heteroplasmy can manifest as myopathy and cardiomyopathy<sup>333</sup> or stereotypically as mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS),<sup>334</sup> but at 10% to 30% mutant can



**Figure 2.** Bioenergetic paradigm for degenerative and metabolic diseases, cancer, and aging. Mitochondrial oxidative phosphorylation (OXPHOS) can be perturbed by nuclear DNA (nDNA) genetic alterations or epigenomic regulation, by mitochondrial DNA (mtDNA) ancient adaptive polymorphisms or recent deleterious mutations, or by variation in the availability of calories and in caloric demands. Alterations in mitochondrial structure and function can impair OXPHOS, which in turn can reduce energy production, alter the cellular redox state, increase production of reactive oxygen species (ROS), deregulate  $\text{Ca}^{2+}$  homeostasis, and ultimately activate the mitochondrial permeability transition pore, leading to apoptosis. These and other consequences of OXPHOS perturbation can destabilize mtDNA. This results in progressive accumulation of somatic mtDNA mutations and decline of mitochondrial function, which accounts for aging and the delayed-onset and progressive course of degenerative diseases. As energy output declines, the most energetic tissues are preferentially affected, which results in degenerative diseases of the heart, muscle, nervous system, and kidney. Aberrant mitochondrial caloric metabolism also leads to metabolic deregulation, endocrine dysfunction, and symptoms such as diabetes mellitus, obesity, and cardiovascular disease. Energetic failure of apoptosis can result in the release into the bloodstream of mitochondrial antigenic cardiolipin, *N*-formylmethionine polypeptides, and mtDNA (mitochondrial damage-associated molecular patterns [DAMPs]<sup>311,314,316,317</sup>) can initiate the inflammatory response, contributing to autoimmune diseases (eg, multiple sclerosis and type 1 diabetes mellitus) and possibly also to the inflammatory component of late-onset degenerative diseases. Finally, cancer cells must manage energy resources to permit rapid replication. Figure reprinted with permission from Wallace.<sup>318</sup> Copyright © 2011, Cold Spring Harbor Laboratory Press.

present as type 1 or type 2 diabetes mellitus<sup>335,336</sup> or autism.<sup>337</sup> Somatic mtDNA mutations accumulate throughout life, progressively eroding mitochondrial function. The rate of accumulation of these mutation can be modulated by nDNA gene variants,<sup>40,210,338,339</sup> which results in degenerative diseases such as Alzheimer disease and Parkinson disease,<sup>340–342</sup> and can be induced by environmental challenges.

A major reason for the complexity of mitochondrial diseases is the reliance of every aspect of cellular function on energy flux. Thus, the energy status of the mitochondrion must be monitored for every functional change in the cell. This is accomplished by all cellular functions being either driven or regulated by mitochondrial high energy or metabolic intermediates. The importance of this mitochondrial signaling to the nuclear-cytosolic epigenome and signal transduction systems has been demonstrated by examining the cellular and transcriptional changes that occur in cells with the same nucleus by different percentages of the tRNA<sup>Leu(UUR)</sup> nt3243G mutation. This revealed cellular structure and gene transcription changed in discrete phases in response to the progressive increase in percentage of mutant mtDNA, relative to homoplasmic normal mtDNAs, with 20% to 30% 3243G mutant having one transcriptional profile, 50% to 90% mutant a second, and 100% a third. These phase shifts in the transcriptome exactly correspond to the changes in patient

phenotypes that are associated with this mutation: 10% to 30% diabetes mellitus and autism, 50% to 90% cardiomyopathy and MELAS, and 100% perinatal lethality.<sup>343</sup>

#### mtDNA Variation and Cardiomyopathy

Cardiomyopathy has been associated with all 3 classes of mtDNA variants (ancient adaptive mutations, recent maternal mutations, and somatic mutations). Ancient adaptive mutations have been linked to increased risk of metabolic and cardiovascular disease,<sup>344,345</sup> and mice heterozygous for the mitochondrial antioxidant enzyme, MnSOD (*Sod2*), are prone to hypertension.<sup>346</sup>

Recent deleterious mtDNA mutations have repeatedly been linked to cardiomyopathy.<sup>325</sup> Although heteroplasmic mtDNA mutations are commonly accepted as causal for cardiomyopathy, homoplasmic mutations are more difficult to distinguish from ancient adaptive variants that may or may not be contributory. One approach to identify potentially pathological homoplasmic mutations is to first determine the mtDNA haplogroup by use of MITOMAP and MITOMASTER<sup>328</sup> in association with PHYLOTREE,<sup>347</sup> and then to determine whether the putatively deleterious homoplasmic mutation has been observed previously with that haplogroup in the normal population. If not, it is increasingly likely that the homoplasmic



variant could be contributory to the disease.<sup>348</sup> The pathogenicity of the mutation must still be confined by functional tests in cybrids.<sup>349</sup> However, it is also possible that a variant has been observed before but in a different haplogroup context. Such variants could be deleterious on the wrong mtDNA background and thus might contribute to the diseases.<sup>350</sup> Proof that a homoplasmic mtDNA mutation can cause cardiomyopathy comes from the generation of a mouse that harbors an mtDNA missense mutation in the *COI* nt 6598T>C V421A and develops hypertrophic cardiomyopathy.<sup>351</sup>

De novo and somatic mtDNA mutations also cause cardiac disease. Spontaneous single-event heteroplasmic deletions in the mtDNA can cause the Kearns-Sayre syndrome, which frequently presents with cardiac conduction defects and heart block in association with chronic external ophthalmoplegia.<sup>325</sup> The accumulation of a heterogeneous array of somatic mtDNA mutations has also been shown to be associated with cardiomyopathy in the hearts of patients who have received heart transplants, as monitored with the common mtDNA 5-kb deletion.<sup>6,352</sup>

#### **nDNA Mitochondrial Gene Mutations and Cardiomyopathy**

Cardiomyopathy is one of the primary presentations of boys with Barth Syndrome, which results from mutations in the nDNA-coded X-linked Tafazzin gene required for cardiolipin metabolism.<sup>353</sup> Cardiomyopathy is also the primary symptom of homozygous mutations that inactivate the chromosome 4 heart-muscle-brain isoform of the adenine nucleotide translocator (*ANT1*).<sup>354,355</sup> The ANT<sub>s</sub>, of which there are 4 in humans, exchange mitochondrial ATP for cytoplasmic ADP across the mitochondrial inner membrane. *ANT1*-inactivating mutations result in mitochondrial cardiomyopathy and myopathy.<sup>356–358</sup> This has been confirmed by the generation of a mouse lacking the *Ant1* gene, which also develops mitochondrial myopathy and hypertrophic cardiomyopathy. The *Ant1*-deficient mouse has a partial defect in cardiac mitochondrial ATP production, because the heart also expresses a second ANT isoform, Ant2. The *Ant1*-deficient mice develop lactic acidosis, mitochondrial ROS production, and a striking increase in the accumulation of cardiac mtDNA somatic mutations.<sup>209,359</sup> The hypertrophic cardiomyopathy of these mice progresses to dilated cardiomyopathy as the mice age.<sup>360</sup> Presumably this is because of the age-related accumulation of somatic mutations that exacerbate the inherited nuclear *Ant1* mutation.

Patients who develop dilated cardiomyopathy associated with myocarditis develop antibodies to ANT.<sup>361,362</sup> These antibodies could be either the initiating or promoting factor in development of the cardiomyopathy. In either case, a mitochondrial bioenergetic defect caused by viral infection or a preexisting mitochondrial genetic defect that impairs mitochondrial energetics could inhibit the energy-demanding apoptotic process, permitting the release of mitochondrial antigens (DAMPs; cardiolipin, mtDNA, *N*-formyl methionine-initiated polypeptides, ANT1, etc)<sup>311,314,316,317</sup> into the bloodstream, where they can initiate a cardiac inflammatory response.

Mutations in many other mitochondria-encoded genes have been reported to cause cardiovascular disease. For example, defects in the mitochondrial matrix protein frataxin are involved in Friedreich's ataxia.<sup>363</sup> Defects in the

mitochondrial phosphate transporter have also been associated with cardiac defects.<sup>364</sup>

#### **nDNA-mtDNA Interactions and Cardiomyopathy**

The genetic complexity of cardiac diseases is further enhanced by the potential for deleterious interaction of nDNA and mtDNA genetic variants. This pathogenic nuclear-mitochondrial interaction was first demonstrated by the discovery that mutations in the nDNA-coded mtDNA polymerase- $\gamma$  gene (*POLG*) can result in autosomal dominant multiple mtDNA deletion syndrome, with the mtDNA damage causing chronic external ophthalmoplegia and (potentially) cardiac symptoms.<sup>325,339</sup> Mitochondrial disease has also been shown to result from the interaction of nDNA-coded partial mitochondrial genetic defects and homoplasmic mtDNA mutations. This was exemplified in a family segregating a missense mutation (G32R) in the X-linked complex I *NDUFA1* gene, which resulted in an  $\approx 30\%$  reduction in complex I, plus a pair of non-haplogroup-associated homoplasmic missense mutations in the mtDNA complex I genes *ND1* 3308T>C (M21T) and *ND5* 12599T>C (M88T). Both the X chromosome and the mtDNA in boys are inherited from the mother, which results in affected boys along the maternal lineage.<sup>365</sup>

The severity of cardiac disease resulting from an nDNA mitochondrial gene defect can also be modulated by the inheritance of an otherwise normal mtDNA haplogroup. In a 13-generation pedigree segregating a frameshift mutation in the *ANT1* gene, multiple homozygous patients were identified with mitochondrial myopathy and cardiomyopathy. However, the severity of the cardiomyopathy varied strikingly, with some individuals progressing to dilated cardiomyopathy that necessitated heart transplantation and others maintaining a relatively stable hypertrophic cardiomyopathy. Sequencing of the mtDNAs from the homozygous *Ant1* frameshift patients revealed that those who progressed to heart transplantation had mtDNA haplogroup U2, whereas those who manifested stable hypertrophic cardiomyopathy had haplogroup H.<sup>358</sup>

This augmentation of deleterious nDNA mutations by mtDNA variants might be a more general phenomenon. Analysis of the mtDNA of cardiomyopathy patients with mutations in the nDNA-coded cardiac contractile apparatus proteins has found that the mtDNA contains potentially contributory mtDNA mutations.<sup>8,366</sup>

#### **Conclusions**

The high energetic demands of the heart are primarily met by mitochondrial OXPHOS. Hence, it follows that defects in mitochondrial bioenergetics should preferentially affect the heart. This is proven by the fact that cardiomyopathy is the most obvious phenotypic manifestation in both humans and mice harboring null mutations in the heart-muscle-brain isoform of the ANT. If mutations in nDNA-coded mitochondrial genes can generate cardiomyopathy, it follows that mtDNA mutations that cause partial OXPHOS defects should also contribute to cardiomyopathy. This is supported by the observations that mtDNA haplogroups and de novo mtDNA mutations can augment the deleterious consequences of nDNA mutations. If inherited homoplasmic or heteroplasmic mtDNA mutations can cause cardiomyopathy, the mitochondrial dysfunction that results from

the accumulation of somatic mtDNA mutations could also cause cardiomyopathy. This leads to the conclusion that the age-related accumulation of mtDNA mutations that augment inherited or acquired mitochondrial defects, in addition to the effects of secondary inflammation from the release of mitochondrial DAMPs, could provide a coherent conceptual framework for understanding the progression of multiple forms of cardiomyopathy.

### Cardiotoxicity

Anticancer treatments have improved significantly over the past few years; however, despite the improvement in their target effects on cancer cells, anticancer treatments have also been associated with an increase in the incidence of side effects. One of the major side effects of anticancer drugs is their toxicity toward cardiac muscle cells. This cardiotoxicity can manifest at an early stage of therapy (within days) or many years after treatment. Thus, patients undergoing these treatments should be monitored closely. More importantly, patients at high risk should be identified before treatment is started to reduce morbidity from cardiotoxicity. This would require close collaboration between cardiologists and oncologists.

Two forms of cardiac damage have been characterized. One form, typically seen with the use of anthracyclines, is associated with irreversible damage and death of cardiac cells, whereas the second form generally occurs with protein kinase inhibitors and is associated with reversible myocardial dysfunction. These 2 forms are discussed below.

#### *Anthracycline-Related Cardiotoxicity (Type 1)*

Anthracyclines have been used for the treatment of various forms of cancer for several decades. They constitute one of the major successes in the field of cancer. For example, in pediatric oncology, the 5-year survival rate has increased from  $\approx 30\%$  in the 1960s to 70% to 80% today,<sup>367,368</sup> and  $>50\%$  of childhood cancer patients have received anthracyclines.<sup>369</sup> Different statistics have been published on the incidence of anthracycline-mediated cardiotoxicity, ranging from  $\approx 1\%$  to up to 48%.<sup>370</sup> However, a strong correlation exists between the incidence of cardiotoxicity and the dosage of the drug.<sup>371</sup>

Although the effects of anthracyclines on cancer prevention are thought to occur mainly through inhibition of DNA replication, RNA replication, DNA cross-linking, and topoisomerases,<sup>372</sup> their cardiotoxic effects appear to be through distinct mechanisms. The pathophysiology of anthracycline-mediated cardiotoxicity is likely multifactorial, and multiple mechanisms have been proposed. It has been suggested that anthracyclines induce an increase in ROS production.<sup>373,374</sup> According to this model, oxidation of the aglycone portion of doxorubicin results in the formation of a semiquinone radical, which can rapidly revert to its parent compound by using  $O_2$  as an electron acceptor.<sup>375</sup> This futile redox cycle leads to the formation of superoxide, which is converted to  $H_2O_2$  spontaneously or by superoxide dismutase. Subsequently,  $H_2O_2$  may be converted to highly toxic hydroxyl radicals in the presence of heavy metals, such as iron, through the Fenton reaction. In addition, doxorubicin can interact with iron directly to form a doxorubicin-iron complex.<sup>375,376</sup> In

addition to production of ROS, other mechanisms including mitochondrial dysfunction and depletion of energy, induction of apoptosis, and changes in topoisomerase IIb activity have been proposed.<sup>377,378</sup>

Although different mechanisms have been proposed for the cardiotoxicity of anthracycline, the mitochondrial effects are likely the major contributor to this disorder. Mitochondrial dysfunction, including mitochondrial swelling, mitochondrial cristae disruption, and accumulation of myelin figures, has been observed after treatment with anthracyclines. There is also evidence that anthracyclines penetrate into the mitochondria (although the mechanism for this transport is not clear). After translocation of anthracyclines into the mitochondria, they can then interact with a number of molecules, including mtDNA, ETC/OXPHOS, mPTP, and mitochondrial iron. Anthracyclines can cause damage by inducing large-scale deletions within mtDNA, form covalent bonds with mtDNA after transformation of the quinone ring to quinone methide, and cause damage to mtDNA indirectly by producing ROS.<sup>379</sup> Anthracyclines can cause damage to ETC and OXPHOS proteins through ROS production or by forming a complex with cardiolipins present in the mitochondrial membrane.<sup>380,381</sup> The latter can also cause an increase in ROS or could lead to cardiolipin dysfunction, which is needed for normal activity of several enzymes in the ETC/OXPHOS pathway. mPTP plays a major role in the regulation of cell death.<sup>382</sup> Anthracyclines have been shown to induce mPTP opening, and cyclosporine A (which inhibits mPTP by binding to cyclophilin D) prevents mitochondrial failure and cell killing.<sup>383</sup> Iron has been known to mediate some of the cardiotoxic effects of anthracyclines; however, iron chelators were shown not to be effective against anthracycline-mediated cardiotoxicity. It has been demonstrated recently that anthracyclines cause mitochondrial iron accumulation and that a reduction in mitochondrial iron is protective against the cardiotoxic effects of anthracyclines.<sup>384</sup>

#### *Drugs for Other Disorders*

Several drugs that are currently routinely used for common diseases also have cardiac side effects. For example, it is now known that glitazones can worsen heart failure, and their mechanism of action might be through modulation of the activity of PPAR proteins in the heart.<sup>385</sup> Although PPARs regulate metabolic processes, they might also have an effect on the mitochondria through indirect mechanisms.

#### **Biomarkers**

Primary mitochondrial diseases constitute a broad spectrum of disorders that affect multiple tissues and organ systems. It is estimated that mitochondrial diseases affect 1 in 5000 people<sup>386</sup>; however, it is suspected that 1 in 250 might be more accurate,<sup>387</sup> because many cases likely go undiagnosed. Clinical diagnosis of mitochondrial diseases is complicated by diverse phenotypical manifestations, in part caused by variably affected genomes (ie, mitochondrial or nuclear) or organs (eg, muscle, liver) and age of onset. Thus, clinical protocols required for definitive diagnosis are labor intensive and routinely involve invasive procedures with variable success. It would therefore be of great clinical use

to discover biomarkers in accessible biofluids (eg, blood, urine) that specifically inform on primary mitochondrial diseases. Mitochondria-derived biomarkers, including mtDNA (Signaling by Release of mtDNA and Proteins), proteins, and metabolites, have been explored; however, these have exhibited limited specificity, sensitivity, and diagnostic/prognostic accuracy. Current markers can only add weight to the likelihood that a patient might have a primary mitochondrial disorder, and at best may only substantiate a more invasive diagnostic testing regimen.

mtDNA sequencing from intact cells acquired through tissue biopsy (most commonly skeletal muscle) in symptomatic patients constitutes the most definitive current measure for diagnosing mitochondrial disease. However, this method is invasive and is not amenable to routine screening or suitable for high-risk populations. The noninvasive quantification of cell-free mtDNA in plasma has gained substantial interest for diagnosing certain cancers<sup>388,389</sup> and for other clinical scenarios, such as predicting mortality of patients in the intensive care unit,<sup>390</sup> but it has not yet been successfully interrogated for the diagnosis of primary mitochondrial disorders. Mitochondrial proteins and metabolites quantified in accessible biofluids have received limited interest; however, they show great promise as biomarkers of mitochondrial diseases in that they are highly specific and sensitive indicators of underlying metabolic changes.

Improved strategies are warranted for the specific diagnosis of mitochondrial disorders, and biomarkers are most promising in this effort, because disease-specific mitochondria-derived proteins, metabolites, or mtDNA would likely offer superior sensitivity and specificity in diagnosis and risk assessment and could be accurately and consistently measured across all clinical settings. An overview of mitochondria-derived markers (mtDNA, proteins, and metabolites) that have been the subject of intense investigation follows.

Blood and urine are readily accessible biofluids acquired with minimal invasiveness. Blood can be subjected to centrifugation to separate aqueous plasma or serum from blood cells. Mitochondria-derived biomarkers found in plasma or serum are cell-free circulating (cfc)-mtDNA, metabolites, and proteins. Thrombocytes and leukocytes, but not erythrocytes, contain mitochondria, and thus, mtDNA and proteins can be obtained from intact blood cells in the more dense fraction. However, because mitochondrial genomes are heteroplasmic, and primary mitochondrial diseases can affect various organs, disease markers will likely be tissue derived rather than blood cell derived; thus, cell-free markers in plasma likely represent a more relevant and unbiased assessment of mitochondrial disorders. Urine would also provide an unbiased source of metabolites. cfc-mtDNA in plasma and serum has been a subject of intense interest as a biomarker of disease since the first published study showing a mutation in cfc-mtDNA in patients with type 2 diabetes mellitus.<sup>391</sup> mtDNA is a 16.5-kbp circular strand of DNA, and hundreds to thousands of copies of mtDNA can be found in a single cell. Although the precise physiology is unclear, it is thought that cfc-mtDNA enters the bloodstream through cell necrosis, apoptosis, or active secretion.<sup>392</sup> cfc-mtDNA in plasma exists in both particle-associated and free forms, and methodology

to measure amounts in whole blood are exquisitely dependent on the preparatory protocols used (eg, size exclusion filtration), which indicates that cfc-mtDNA exists in various conformations.<sup>393</sup> mtDNA can be reliably assayed by a quantitative real-time polymerase chain reaction approach, which exhibits a dynamic range of 5 orders of magnitude and a sensitivity of detection down to 1 copy of mtDNA.<sup>393</sup> Thus, mtDNA possesses favorable physical characteristics for a good candidate biomarker of various physiological states. However, although cfc-mtDNA has shown promise for early detection and tumor classification in oncology patients,<sup>388,389</sup> its role in diagnosis and prognosis of mitochondrial diseases remains to be determined.

Despite the sophisticated and sensitive technologies we have available to measure mitochondria-derived biomarkers, no noninvasive biomarkers for mitochondrial disorders have materialized from the discovery phase to the clinic. One of the most prominent reasons for this is that studies aimed at biomarker discovery have been poorly designed, having little clinical translational potential.<sup>394</sup> Plasma biomarker studies should ideally proceed through an evolution of systematic tests that appropriately credential markers for clinical use (eg, Addona et al<sup>395</sup>). A gap exists between biomarker discovery studies, in which thousands of biomarkers exhibit differential profiles in case versus control subjects, and clinical tests, for which assays are optimized and standardized for rapid and efficient measurement in the clinic. Within this gap is the narrowing and prioritizing of likely biomarker candidates, followed by rigorous steps of validation. Despite the overall lack of clinically available biomarkers, there are promising candidates that have surfaced in recent studies that, with appropriate validation strategies in large clinical cohorts, could add value or replace current clinical markers and diagnostic or prognostic regimens. A study by Suomalainen et al<sup>396</sup> found that serum fibroblast growth factor 21 (FGF-21) was a sensitive and specific marker for primary muscle-manifesting respiratory chain deficiencies in adults and children. This study included 67 patients with mitochondrial diseases diagnosed by muscular biopsy and DNA analysis, 34 control subjects with non-mitochondrial neurological disease, and 74 healthy control subjects. FGF-21 had superior diagnostic accuracy to conventionally used, more nonspecific mitochondrial disease indicators, including lactate, pyruvate, lactate-to-pyruvate ratio, and CK. A later prospective study supported these results and indicated that FGF-21 is a superiorly sensitive biomarker for diagnosing both mtDNA and nDNA-encoded mitochondrial diseases.<sup>397</sup> Taken together, these results showed that FGF-21 might provide a first-tier, noninvasive biomarker for diagnosing mitochondrial diseases that could diminish the need for invasive muscular biopsies. Rigorous validation using large, well-characterized patient cohorts is warranted to verify the utility of FGF-21 in the clinic. Another recent study by Enns et al<sup>398</sup> examined GSH and GSSH protein levels in whole blood from 58 control subjects and 59 patients with primary mitochondrial disease of varying causes, including Leigh syndrome, ETC abnormalities, mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes, mtDNA deletion syndrome, and mtDNA depletion syndrome. Quantitative mass spectrometric analysis determined that in patients with

mitochondrial disease, redox status was significantly more oxidized (lower GSH and higher GSSH), showing the greatest change in patients who were hospitalized with metabolic crisis. Hence, GSH and GSSH might be clinically useful biomarkers for all primary mitochondrial disease subtypes, and should be rigorously evaluated in clinical trials to demarcate clinical prognosis and patient response to redox-modulating treatments.

In conclusion, the low diagnostic and prognostic accuracy of primary mitochondrial diseases warrants intense research on mitochondrial biomarkers. The proper experimental design utilizing cutting edge “omics” technologies will undoubtedly propel this area of research in fields of study and is the best response to the challenge of mitochondrial biomarker realization.

### Summary and Recommendations

The data in the literature show that mitochondria play a key role in cardiovascular disease, specifically in the response to myocardial ischemia and the transition to heart failure. The accumulation of defects in mitochondrial electron transport, ion transport, metabolism, redox regulation, and mitochondrial quality control leads to a feed-forward cycle of further acquired defects. Ultimately, the mitochondria can no longer meet the high energetic demands of the cardiac cell, and this, coupled with an increase in activation of cell death pathways, leads to the death of the myocytes. The role of mitochondrial defects in heart failure and other cardiovascular diseases needs to be considered and evaluated.

There are a number of gaps in our understanding that need to be addressed in future studies. We need a better understanding of the effects of PTMs on protein function. In recent years, we have made great strides in defining mitochondrial PTM, but the consequences of the modification is poorly understood in many cases. We need additional information on the mechanisms by which mitochondria regulate apoptosis and necroptosis. We need to define the mPTP. The  $F_1F_0$ -ATPase has been proposed as the pore; this need to be verified by other groups, and the mechanism of its regulation needs to be defined. We need to define the redox-sensitive component of this pore. We need to more completely define the mechanisms that regulate mitochondrial dynamics and elucidate how this regulates cell function and metabolism. We also need additional information on the mechanisms that regulate mitochondrial turnover at the level of mitochondrial proteins and the organelle. What are the signals for turnover of mitochondrial proteins, and how is this accomplished?

Additionally, the interrelationship between mitochondria and other intracellular compartments (endoplasmic reticulum, lysosomes, etc) and intracellular structures (mitochondria-associated membranes) in the regulation of mitochondrial function and overall cellular homeostasis is increasingly being recognized.<sup>399–401</sup> An understanding of how mitochondrial function and pathophysiology integrate within this more complex intracellular environment will also be necessary to enable the modulation of quality-control programs to sustain cardiomyocyte homeostasis and stress resistance.

## Disclosures

### Writing Group Disclosures

Writing Group Member	Employment	Research Grant	Other Research Support	Speakers' Bureau/Honoraria	Expert Witness	Ownership Interest	Consultant/Advisory Board	Other
Elizabeth Murphy	National Heart, Lung, and Blood Institute	None	None	None	None	None	None	None
Hossein Ardehali	Northwestern University	None	None	None	None	None	None	None
Robert S. Balaban	National Heart, Lung, and Blood Institute	None	None	None	None	None	None	None
Fabio DiLisa	University of Padova	None	None	None	None	None	None	None
Gerald W. Dorn II	Washington University School of Medicine	NIH*	None	None	None	None	None	None
Richard N. Kitsis	Albert Einstein College of Medicine	NIH†; AHA†; Fondation LeDucq†	None	None	None	None	Neuprotect*	None
Kinya Otsu	King's College London	British Heart Foundation†	None	None	None	None	None	None
Peipei Ping	UCLA School of Medicine	None	None	None	None	None	None	None
Rosario Rizzuto	University of Padua	None	None	None	None	None	None	None

(Continued)

## Writing Group Disclosures (Continued)

Writing Group Member	Employment	Research Grant	Other Research Support	Speakers' Bureau/Honoraria	Expert Witness	Ownership Interest	Consultant/Advisory Board	Other
Michael N. Sack	National Heart, Lung, and Blood Institute	None	None	None	None	None	None	None
Douglas Wallace	Children's Hospital of Philadelphia	GlaxoSmithKline†	None	Various Symposia*	None	None	None	None
Richard J. Youle	National Institute of Neurological Disorders and Stroke	None	None	None	None	JNPJ†; GE†	None	None

This table represents the relationships of writing group members that may be perceived as actual or reasonably perceived conflicts of interest as reported on the Disclosure Questionnaire, which all members of the writing group are required to complete and submit. A relationship is considered to be "significant" if (a) the person receives \$10 000 or more during any 12-month period, or 5% or more of the person's gross income; or (b) the person owns 5% or more of the voting stock or share of the entity, or owns \$10 000 or more of the fair market value of the entity. A relationship is considered to be "modest" if it is less than "significant" under the preceding definition.

\*Modest.

†Significant.

## Reviewer Disclosures

Reviewer	Employment	Research Grant	Other Research Support	Speakers' Bureau/Honoraria	Expert Witness	Ownership Interest	Consultant/Advisory Board	Other
Christopher Baines	University of Missouri	NIH (R01 that is studying the role of mitochondria in cardiac disease)†	None	None	None	None	None	None
Lorrie Kirshenbaum	University of Manitoba (Canada)	None	None	None	None	None	None	None
Tibor Kristian	University of Maryland Baltimore	VA Merit (determine the role of cell-type specific mitochondrial dysfunction in mechanisms of acute brain injury)*	None	None	None	None	None	None
Yibin Wang	University of California, Los Angeles	None	None	None	None	None	None	None

This table represents the relationships of reviewers that may be perceived as actual or reasonably perceived conflicts of interest as reported on the Disclosure Questionnaire, which all reviewers are required to complete and submit. A relationship is considered to be "significant" if (a) the person receives \$10 000 or more during any 12-month period, or 5% or more of the person's gross income; or (b) the person owns 5% or more of the voting stock or share of the entity, or owns \$10 000 or more of the fair market value of the entity. A relationship is considered to be "modest" if it is less than "significant" under the preceding definition.

\*Modest.

†Significant.

## References

- Ingwall JS, Weiss RG. Is the failing heart energy starved? On using chemical energy to support cardiac function. *Circ Res*. 2004;95:135–145. doi: 10.1161/01.RES.0000137170.41939.d9.
- Wallace DC. A mitochondrial bioenergetic etiology of disease. *J Clin Invest*. 2013;123:1405–1412. doi: 10.1172/JCI61398.
- Opie LH. Fuels: aerobic and anaerobic metabolism. In: Opie LH, ed. *Heart Physiology: From Cell to Circulation*. 4th ed. Philadelphia, PA: Lippincott-Raven; 2004:306–354.
- Schaper J, Meiser E, Stämmler G. Ultrastructural morphometric analysis of myocardium from dogs, rats, hamsters, mice, and from human hearts. *Circ Res*. 1985;56:377–391.
- Skulachev VP. Uncoupling: new approaches to an old problem of bioenergetics. *Biochim Biophys Acta*. 1998;1363:100–124.
- Corral-Debrinski M, Shoffner JM, Lott MT, Wallace DC. Association of mitochondrial DNA damage with aging and coronary atherosclerotic heart disease. *Mutat Res*. 1992;275:169–180.
- Santorelli FM, Mak SC, El-Schahawi M, Casali C, Shanske S, Baram TZ, Madrid RE, DiMauro S. Maternally inherited cardiomyopathy and hearing loss associated with a novel mutation in the mitochondrial tRNA(Lys) gene (G8363A). *Am J Hum Genet*. 1996;58:933–939.
- Arbustini E, Diegoli M, Fasani R, Grasso M, Morbini P, Banchieri N, Bellini O, Dal Bello B, Pilotto A, Magrini G, Campana C, Fortina P, Gavazzi A, Narula J, Viganò M. Mitochondrial DNA mutations and mitochondrial abnormalities in dilated cardiomyopathy. *Am J Pathol*. 1998;153:1501–1510. doi: 10.1016/S0002-9440(10)65738-0.
- Grad LI, Sayles LC, Lemire BD. Introduction of an additional pathway for lactate oxidation in the treatment of lactic acidosis and mitochondrial dysfunction in *Caenorhabditis elegans*. *Proc Natl Acad Sci U S A*. 2005;102:18367–18372. doi: 10.1073/pnas.0506939102.
- Neubauer S. The failing heart: an engine out of fuel. *N Engl J Med*. 2007;356:1140–1151. doi: 10.1056/NEJMr063052.
- Taegtmeyer H. Energy metabolism of the heart: from basic concepts to clinical applications. *Curr Probl Cardiol*. 1994;19:59–113.
- Lopaschuk GD, Ussher JR, Folmes CD, Jaswal JS, Stanley WC. Myocardial fatty acid metabolism in health and disease. *Physiol Rev*. 2010;90:207–258. doi: 10.1152/physrev.00015.2009.
- Karamanlidis G, Lee CF, Garcia-Menendez L, Kolwicz SC Jr, Suthammarak W, Gong G, Sedensky MM, Morgan PG, Wang W, Tian

- R. Mitochondrial complex I deficiency increases protein acetylation and accelerates heart failure. *Cell Metab.* 2013;18:239–250. doi: 10.1016/j.cmet.2013.07.002.
14. Sack MN, Kelly DP. The energy substrate switch during development of heart failure: gene regulatory mechanisms (review). *Int J Mol Med.* 1998;1:17–24.
  15. Opie LH, Sack MN. Metabolic plasticity and the promotion of cardiac protection in ischemia and ischemic preconditioning. *J Mol Cell Cardiol.* 2002;34:1077–1089.
  16. Ardehali H, Sabbah HN, Burke MA, Sarma S, Liu PP, Cleland JG, Maggioni A, Fonarow GC, Abel ED, Campia U, Gheorghiu M. Targeting myocardial substrate metabolism in heart failure: potential for new therapies. *Eur J Heart Fail.* 2012;14:120–129. doi: 10.1093/eurjhf/hfr173.
  17. Sack MN, Rader TA, Park S, Bastin J, McCune SA, Kelly DP. Fatty acid oxidation enzyme gene expression is downregulated in the failing heart. *Circulation.* 1996;94:2837–2842.
  18. Sack MN, Disch DL, Rockman HA, Kelly DP. A role for Sp and nuclear receptor transcription factors in a cardiac hypertrophic growth program. *Proc Natl Acad Sci U S A.* 1997;94:6438–6443.
  19. Barger PM, Brandt JM, Leone TC, Weinheimer CJ, Kelly DP. Deactivation of peroxisome proliferator-activated receptor- $\alpha$  during cardiac hypertrophic growth. *J Clin Invest.* 2000;105:1723–1730. doi: 10.1172/JCI9056.
  20. Huss JM, Kelly DP. Nuclear receptor signaling and cardiac energetics. *Circ Res.* 2004;95:568–578. doi: 10.1161/01.RES.0000141774.29937.e3.
  21. Aitman TJ, Glazier AM, Wallace CA, Cooper LD, Norsworthy PJ, Wahid FN, Al-Majali KM, Trembling PM, Mann CJ, Shoulders CC, Graf D, St Lezin E, Kurtz TW, Kren V, Pravenec M, Ibrahim A, Abumrad NA, Stanton LW, Scott J. Identification of Cd36 (Fat) as an insulin-resistance gene causing defective fatty acid and glucose metabolism in hypertensive rats. *Nat Genet.* 1999;21:76–83. doi: 10.1038/5013.
  22. van der Vusse GJ, van Bilsen M, Glatz JF. Cardiac fatty acid uptake and transport in health and disease. *Cardiovasc Res.* 2000;45:279–293.
  23. Sorokina N, O'Donnell JM, McKinney RD, Pound KM, Woldegiorgis G, LaNoue KF, Ballal K, Taegtmeyer H, Buttrick PM, Lewandowski ED. Recruitment of compensatory pathways to sustain oxidative flux with reduced carnitine palmitoyltransferase I activity characterizes inefficiency in energy metabolism in hypertrophied hearts. *Circulation.* 2007;115:2033–2041. doi: 10.1161/CIRCULATIONAHA.106.668665.
  24. Allard MF, Schönekeess BO, Henning SL, English DR, Lopaschuk GD. Contribution of oxidative metabolism and glycolysis to ATP production in hypertrophied hearts. *Am J Physiol.* 1994;267(pt 2):H742–H750.
  25. Taegtmeyer H, Overturf ML. Effects of moderate hypertension on cardiac function and metabolism in the rabbit. *Hypertension.* 1988;11:416–426.
  26. Kantor PF, Robertson MA, Coe JY, Lopaschuk GD. Volume overload hypertrophy of the newborn heart slows the maturation of enzymes involved in the regulation of fatty acid metabolism. *J Am Coll Cardiol.* 1999;33:1724–1734.
  27. Lu Z, Scott I, Webster BR, Sack MN. The emerging characterization of lysine residue deacetylation on the modulation of mitochondrial function and cardiovascular biology. *Circ Res.* 2009;105:830–841. doi: 10.1161/CIRCRESAHA.109.204974.
  28. Sack MN. Mitochondrial depolarization and the role of uncoupling proteins in ischemia tolerance. *Cardiovasc Res.* 2006;72:210–219. doi: 10.1016/j.cardiores.2006.07.010.
  29. Boehm EA, Jones BE, Radda GK, Veech RL, Clarke K. Increased uncoupling proteins and decreased efficiency in palmitate-perfused hyperthyroid rat heart. *Am J Physiol Heart Circ Physiol.* 2001;280:H977–H983.
  30. Korvald C, Elvenes OP, Myrnes T. Myocardial substrate metabolism influences left ventricular energetics in vivo. *Am J Physiol Heart Circ Physiol.* 2000;278:H1345–H1351.
  31. Chavez PN, Stanley WC, McElfresh TA, Huang H, Sterk JP, Chandler MP. Effect of hyperglycemia and fatty acid oxidation inhibition during aerobic conditions and demand-induced ischemia. *Am J Physiol Heart Circ Physiol.* 2003;284:H1521–H1527. doi: 10.1152/ajpheart.00974.2002.
  32. Scheuermann-Freestone M, Madsen PL, Manners D, Blamire AM, Buckingham RE, Styles P, Radda GK, Neubauer S, Clarke K. Abnormal cardiac and skeletal muscle energy metabolism in patients with type 2 diabetes. *Circulation.* 2003;107:3040–3046. doi: 10.1161/01.CIR.0000072789.89096.10.
  33. Nikolaidis LA, Sturzu A, Stolarski C, Elahi D, Shen YT, Shannon RP. The development of myocardial insulin resistance in conscious dogs with advanced dilated cardiomyopathy. *Cardiovasc Res.* 2004;61:297–306.
  34. Anderson PG, Allard MF, Thomas GD, Bishop SP, Digerness SB. Increased ischemic injury but decreased hypoxic injury in hypertrophied rat hearts. *Circ Res.* 1990;67:948–959.
  35. Allard MF, Wambolt RB, Longnus SL, Grist M, Lydell CP, Parsons HL, Rodrigues B, Hall JL, Stanley WC, Bondy GP. Hypertrophied rat hearts are less responsive to the metabolic and functional effects of insulin. *Am J Physiol Endocrinol Metab.* 2000;279:E487–E493.
  36. Lydell CP, Chan A, Wambolt RB, Sambandam N, Parsons H, Bondy GP, Rodrigues B, Popov KM, Harris RA, Brownsey RW, Allard MF. Pyruvate dehydrogenase and the regulation of glucose oxidation in hypertrophied rat hearts. *Cardiovasc Res.* 2002;53:841–851.
  37. Russell RR 3rd, Taegtmeyer H. Pyruvate carboxylation prevents the decline in contractile function of rat hearts oxidizing acetoacetate. *Am J Physiol.* 1991;261(pt 2):H1756–H1762.
  38. Schmidt-Schweda S, Holubarsch C. First clinical trial with etomoxir in patients with chronic congestive heart failure. *Clin Sci (Lond).* 2000;99:27–35.
  39. Holubarsch CJ, Rohrbach M, Karrasch M, Boehm E, Polonski L, Ponikowski P, Rhein S. A double-blind randomized multicentre clinical trial to evaluate the efficacy and safety of two doses of etomoxir in comparison with placebo in patients with moderate congestive heart failure: the ERGO (etomoxir for the recovery of glucose oxidation) study. *Clin Sci (Lond).* 2007;113:205–212. doi: 10.1042/CS20060307.
  40. Kujoth GC, Hiona A, Pugh TD, Someya S, Panzer K, Wohlgenuth SE, Hofer T, Seo AY, Sullivan R, Jobling WA, Morrow JD, Van Remmen H, Sedivy JM, Yamasoba T, Tanokura M, Weindruch R, Leeuwenburgh C, Prolla TA. Mitochondrial DNA mutations, oxidative stress, and apoptosis in mammalian aging. *Science.* 2005;309:481–484. doi: 10.1126/science.1112125.
  41. Fragasso G, Pallosi A, Puccetti P, Silipigni C, Rossodivita A, Pala M, Calori G, Alfieri O, Margonato A. A randomized clinical trial of trimetazidine, a partial free fatty acid oxidation inhibitor, in patients with heart failure. *J Am Coll Cardiol.* 2006;48:992–998. doi: 10.1016/j.jacc.2006.03.060.
  42. Morrow DA, Scirica BM, Karwatowska-Prokopczuk E, Murphy SA, Budaj A, Varshavsky S, Wolff AA, Skene A, McCabe CH, Braunwald E; MERLIN-TIMI 36 Trial Investigators. Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial. *JAMA.* 2007;297:1775–1783. doi: 10.1001/jama.297.16.1775.
  43. Wargovich TJ, MacDonald RG, Hill JA, Feldman RL, Stacpoole PW, Pepine CJ. Myocardial metabolic and hemodynamic effects of dichloroacetate in coronary artery disease. *Am J Cardiol.* 1988;61:65–70.
  44. Ingwall JS, Kramer MF, Fifer MA, Lorell BH, Shemin R, Grossman W, Allen PD. The creatine kinase system in normal and diseased human myocardium. *N Engl J Med.* 1985;313:1050–1054. doi: 10.1056/NEJM198510243131704.
  45. Alcaide P, Merinero B, Ruiz-Sala P, Richard E, Navarrete R, Arias A, Ribes A, Artuch R, Campistol J, Ugarte M, Rodríguez-Pombo P. Defining the pathogenicity of creatine deficiency syndrome. *Hum Mutat.* 2011;32:282–291. doi: 10.1002/humu.21421.
  46. Lygate CA, Aksentijevic D, Dawson D, ten Hove M, Phillips D, de Bono JP, Medway DJ, Sebag-Montefiore L, Hunyor I, Channon KM, Clarke K, Zervou S, Watkins H, Balaban RS, Neubauer S. Living without creatine: unchanged exercise capacity and response to chronic myocardial infarction in creatine-deficient mice. *Circ Res.* 2013;112:945–955. doi: 10.1161/CIRCRESAHA.112.300725.
  47. Aksentijević D, Zervou S, Faller KM, McAndrew DJ, Schneider JE, Neubauer S, Lygate CA. Myocardial creatine levels do not influence response to acute oxidative stress in isolated perfused heart. *PLoS One.* 2014;9:e109021. doi: 10.1371/journal.pone.0109021.
  48. Wei MC, Zong WX, Cheng EH, Lindsten T, Panoutsakopoulou V, Ross AJ, Roth KA, MacGregor GR, Thompson CB, Korsmeyer SJ. Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. *Science.* 2001;292:727–730. doi: 10.1126/science.1059108.
  49. Weiss RG, Gerstenblith G, Bottomley PA. ATP flux through creatine kinase in the normal, stressed, and failing human heart. *Proc Natl Acad Sci U S A.* 2005;102:808–813. doi: 10.1073/pnas.0408962102.
  50. Bottomley PA, Panjra PA, Panjra GS, Lai S, Hirsch GA, Wu K, Najjar SS, Steinberg A, Gerstenblith G, Weiss RG. Metabolic rates of ATP transfer through creatine kinase (CK Flux) predict clinical heart failure events and death. *Sci Transl Med.* 2013;5:215re3. doi: 10.1126/scitranslmed.3007328.
  51. Boudina S, Abel ED. Diabetic cardiomyopathy, causes and effects. *Rev Endocr Metab Disord.* 2010;11:31–39. doi: 10.1007/s11154-010-9131-7.

52. Zhao S, Xu W, Jiang W, Yu W, Lin Y, Zhang T, Yao J, Zhou L, Zeng Y, Li H, Li Y, Shi J, An W, Hancock SM, He F, Qin L, Chin J, Yang P, Chen X, Lei Q, Xiong Y, Guan KL. Regulation of cellular metabolism by protein lysine acetylation. *Science*. 2010;327:1000–1004. doi: 10.1126/science.1179689.
53. Scott I, Webster BR, Chan CK, Okonkwo JU, Han K, Sack MN. GCN5-like protein 1 (GCN5L1) controls mitochondrial content through coordinated regulation of mitochondrial biogenesis and mitophagy. *J Biol Chem*. 2014;289:2864–2872. doi: 10.1074/jbc.M113.521641.
54. Peng C, Lu Z, Xie Z, Cheng Z, Chen Y, Tan M, Luo H, Zhang Y, He W, Yang K, Zwaans BM, Tishkoff D, Ho L, Lombard D, He TC, Dai J, Verdin E, Ye Y, Zhao Y. The first identification of lysine malonylation substrates and its regulatory enzyme. *Mol Cell Proteomics*. 2011;10:M111.012658. doi: 10.1074/mcp.M111.012658.
55. Chen Y, Dorn GW 2nd. PINK1-phosphorylated mitofusin 2 is a Parkin receptor for culling damaged mitochondria. *Science*. 2013;340:471–475. doi: 10.1126/science.1231031.
56. Deas E, Plun-Favreau H, Wood NW. PINK1 function in health and disease. *EMBO Mol Med*. 2009;1:152–165. doi: 10.1002/emmm.200900024.
57. Riccio A. New endogenous regulators of class I histone deacetylases. *Sci Signal*. 2010;3:pe1. doi: 10.1126/scisignal.3103pe1.
58. Bitterman KJ, Anderson RM, Cohen HY, Latorre-Esteves M, Sinclair DA. Inhibition of silencing and accelerated aging by nicotinamide, a putative negative regulator of yeast sir2 and human SIRT1. *J Biol Chem*. 2002;277:45099–45107. doi: 10.1074/jbc.M205670200.
59. Cargile BJ, Bundy JL, Grunden AM, Stephenson JL Jr. Synthesis/degradation ratio mass spectrometry for measuring relative dynamic protein turnover. *Anal Chem*. 2004;76:86–97. doi: 10.1021/ac034841a.
60. Cantó C, Menzies KJ, Auwerx J. NAD(+) metabolism and the control of energy homeostasis: a balancing act between mitochondria and the nucleus. *Cell Metab*. 2015;22:31–53. doi: 10.1016/j.cmet.2015.05.023.
61. Stein LR, Imai S. The dynamic regulation of NAD metabolism in mitochondria. *Trends Endocrinol Metab*. 2012;23:420–428. doi: 10.1016/j.tem.2012.06.005.
62. Gomes AP, Price NL, Ling AJ, Moslehi JJ, Montgomery MK, Rajman L, White JP, Teodoro JS, Wrann CD, Hubbard BP, Mercken EM, Palmeira CM, de Cabo R, Rolo AP, Turner N, Bell EL, Sinclair DA. Declining NAD(+) induces a pseudohypoxic state disrupting nuclear-mitochondrial communication during aging. *Cell*. 2013;155:1624–1638. doi: 10.1016/j.cell.2013.11.037.
63. Frye RA. Phylogenetic classification of prokaryotic and eukaryotic Sir2-like proteins. *Biochem Biophys Res Commun*. 2000;273:793–798. doi: 10.1006/bbrc.2000.3000.
64. Sack MN, Finkel T. Mitochondrial metabolism, sirtuins, and aging. *Cold Spring Harb Perspect Biol*. 2012;4:a013102. doi: 10.1101/cshperspect.a013102.
65. Boisvert FM, Ahmad Y, Gierliński M, Charrière F, Lamont D, Scott M, Barton G, Lamond AI. A quantitative spatial proteomics analysis of proteome turnover in human cells. *Mol Cell Proteomics*. 2012;11:M111.011429. doi: 10.1074/mcp.M111.011429.
66. Balas E, Féry F. Ketone body production and disposal: effects of fasting, diabetes, and exercise. *Diabetes Metab Rev*. 1989;5:247–270.
67. Fan J, Shan C, Kang HB, Elf S, Xie J, Tucker M, Gu TL, Aguiar M, Lonning S, Chen H, Mohammadi M, Britton LM, Garcia BA, Alečković M, Kang Y, Kaluz S, Devi N, Van Meir EG, Hitosugi T, Seo JH, Lonial S, Gaddh M, Arellano M, Khoury HJ, Khuri FR, Boggon TJ, Kang S, Chen J. Tyr phosphorylation of PDP1 toggles recruitment between ACAT1 and SIRT3 to regulate the pyruvate dehydrogenase complex. *Mol Cell*. 2014;53:534–548. doi: 10.1016/j.molcel.2013.12.026.
68. Paik WK, Pearson D, Lee HW, Kim S. Nonenzymatic acetylation of histones with acetyl-CoA. *Biochim Biophys Acta*. 1970;213:513–522.
69. Wagner GR, Payne RM. Widespread and enzyme-independent Nε-acetylation and Nε-succinylation of proteins in the chemical conditions of the mitochondrial matrix. *J Biol Chem*. 2013;288:29036–29045. doi: 10.1074/jbc.M113.486753.
70. Muoio DM, Noland RC, Kovalik JP, Seiler SE, Davies MN, DeBalsi KL, Ilkayeva OR, Stevens RD, Khetarpal I, Zhang J, Covington JD, Bajpeyi S, Ravussin E, Kraus W, Koves TR, Mynatt RL. Muscle-specific deletion of carnitine acetyltransferase compromises glucose tolerance and metabolic flexibility. *Cell Metab*. 2012;15:764–777. doi: 10.1016/j.cmet.2012.04.005.
71. Schrenk DF, Bisswanger H. Measurements of electron spin resonance with the pyruvate dehydrogenase complex from *Escherichia coli*: studies on the allosteric binding site of acetyl-coenzyme A. *Eur J Biochem*. 1984;143:561–566.
72. Ghanta S, Grossmann RE, Brenner C. Mitochondrial protein acetylation as a cell-intrinsic, evolutionary driver of fat storage: chemical and metabolic logic of acetyl-lysine modifications. *Crit Rev Biochem Mol Biol*. 2013;48:561–574. doi: 10.3109/10409238.2013.838204.
73. Hebert AS, Dittenhafer-Reed KE, Yu W, Bailey DJ, Selen ES, Boersma MD, Carson JJ, Tonelli M, Balloon AJ, Higbee AJ, Westphall MS, Pagliarini DJ, Prolla TA, Assadi-Porter F, Roy S, Denu JM, Coon JJ. Calorie restriction and SIRT3 trigger global reprogramming of the mitochondrial protein acetylome. *Mol Cell*. 2013;49:186–199. doi: 10.1016/j.molcel.2012.10.024.
74. Bao J, Lu Z, Joseph JJ, Carabenciov D, Dimond CC, Pang L, Samsel L, McCoy JP Jr, Leclerc J, Nguyen P, Gius D, Sack MN. Characterization of the murine SIRT3 mitochondrial localization sequence and comparison of mitochondrial enrichment and deacetylase activity of long and short SIRT3 isoforms. *J Cell Biochem*. 2010;110:238–247. doi: 10.1002/jcb.22531.
75. Scher MB, Vaquero A, Reinberg D. SirT3 is a nuclear NAD<sup>+</sup>-dependent histone deacetylase that translocates to the mitochondria upon cellular stress. *Genes Dev*. 2007;21:920–928. doi: 10.1101/gad.1527307.
76. Sundaresan NR, Samant SA, Pillai VB, Rajamohan SB, Gupta MP. SIRT3 is a stress-responsive deacetylase in cardiomyocytes that protects cells from stress-mediated cell death by deacetylation of Ku70. *Mol Cell Biol*. 2008;28:6384–6401. doi: 10.1128/MCB.00426-08.
77. Kong X, Wang R, Xue Y, Liu X, Zhang H, Chen Y, Fang F, Chang Y. Sirtuin 3, a new target of PGC-1α, plays an important role in the suppression of ROS and mitochondrial biogenesis. *PLoS One*. 2010;5:e11707. doi: 10.1371/journal.pone.0011707.
78. Lombard DB, Alt FW, Cheng HL, Bunkenborg J, Streeper RS, Mostoslavsky R, Kim J, Yancopoulos G, Valenzuela D, Murphy A, Yang Y, Chen Y, Hirschey MD, Bronson RT, Haigis M, Guarente LP, Farese RV Jr, Weissman S, Verdin E, Schwer B. Mammalian Sir2 homolog SIRT3 regulates global mitochondrial lysine acetylation. *Mol Cell Biol*. 2007;27:8807–8814. doi: 10.1128/MCB.01636-07.
79. Hirschey MD, Shimazu T, Goetzman E, Jing E, Schwer B, Lombard DB, Grueter CA, Harris C, Biddinger S, Ilkayeva OR, Stevens RD, Li Y, Saha AK, Ruderman NB, Bain JR, Newgard CB, Farese RV Jr, Alt FW, Kahn CR, Verdin E. SIRT3 regulates mitochondrial fatty-acid oxidation by reversible enzyme deacetylation. *Nature*. 2010;464:121–125. doi: 10.1038/nature08778.
80. Kendrick AA, Choudhury M, Rahman SM, McCurdy CE, Friederich M, Van Hove JL, Watson PA, Birdsey N, Bao J, Gius D, Sack MN, Jing E, Kahn CR, Friedman JE, Jonscher KR. Fatty liver is associated with reduced SIRT3 activity and mitochondrial protein hyperacetylation. *Biochem J*. 2011;433:505–514. doi: 10.1042/BJ20100791.
81. Someya S, Yu W, Hallows WC, Xu J, Vann JM, Leeuwenburgh C, Tanokura M, Denu JM, Prolla TA. Sirt3 mediates reduction of oxidative damage and prevention of age-related hearing loss under caloric restriction. *Cell*. 2010;143:802–812. doi: 10.1016/j.cell.2010.10.002.
82. Hirschey MD, Shimazu T, Jing E, Grueter CA, Collins AM, Aouizerat B, Stančáková A, Goetzman E, Lam MM, Schwer B, Stevens RD, Muehlbauer MJ, Kakar S, Bass NM, Kuusisto J, Laakso M, Alt FW, Newgard CB, Farese RV Jr, Kahn CR, Verdin E. SIRT3 deficiency and mitochondrial protein hyperacetylation accelerate the development of the metabolic syndrome. *Mol Cell*. 2011;44:177–190. doi: 10.1016/j.molcel.2011.07.019.
83. Chen Y, Liu Y, Dorn GW 2nd. Mitochondrial fusion is essential for organellar function and cardiac homeostasis. *Circ Res*. 2011;109:1327–1331. doi: 10.1161/CIRCRESAHA.111.258723.
84. Billia F, Hauck L, Konecny F, Rao V, Shen J, Mak TW. PTEN-inducible kinase 1 (PINK1)/Park6 is indispensable for normal heart function. *Proc Natl Acad Sci U S A*. 2011;108:9572–9577. doi: 10.1073/pnas.1106291108.
85. Hallows WC, Yu W, Smith BC, Devries MK, Devires MK, Ellinger JJ, Someya S, Shortreed MR, Prolla T, Markley JL, Smith LM, Zhao S, Guan KL, Denu JM. Sirt3 promotes the urea cycle and fatty acid oxidation during dietary restriction [published correction appears in *Mol Cell*. 2011;41:493]. *Mol Cell*. 2011;41:139–149. doi: 10.1016/j.molcel.2011.01.002.
86. Ahn BH, Kim HS, Song S, Lee IH, Liu J, Vassilopoulos A, Deng CX, Finkel T. A role for the mitochondrial deacetylase Sirt3 in regulating energy homeostasis. *Proc Natl Acad Sci U S A*. 2008;105:14447–14452. doi: 10.1073/pnas.0803790105.
87. Tao R, Coleman MC, Pennington JD, Ozden O, Park SH, Jiang H, Kim HS, Flynn CR, Hill S, Hayes McDonald W, Olivier AK, Spitz DR, Gius D. Sirt3-mediated deacetylation of evolutionarily conserved lysine 122 regulates MnSOD activity in response to stress. *Mol Cell*. 2010;40:893–904. doi: 10.1016/j.molcel.2010.12.013.

88. Hafner AV, Dai J, Gomes AP, Xiao CY, Palmeira CM, Rosenzweig A, Sinclair DA. Regulation of the mPTP by SIRT3-mediated deacetylation of CypD at lysine 166 suppresses age-related cardiac hypertrophy. *Aging (Albany NY)*. 2010;2:914–923.
89. Palacios OM, Carmona JJ, Michan S, Chen KY, Manabe Y, Ward JL 3rd, Goodyear LJ, Tong Q. Diet and exercise signals regulate SIRT3 and activate AMPK and PGC-1 $\alpha$  in skeletal muscle. *Aging (Albany NY)*. 2009;1:771–783.
90. Sundaresan NR, Gupta M, Kim G, Rajamohan SB, Isbatan A, Gupta MP. Sirt3 blocks the cardiac hypertrophic response by augmenting Foxo3a-dependent antioxidant defense mechanisms in mice. *J Clin Invest*. 2009;119:2758–2771. doi: 10.1172/JCI39162.
91. Alrob OA, Sankaralingam S, Ma C, Wagg CS, Fillmore N, Jaswal JS, Sack MN, Lehner R, Gupta MP, Michelakis ED, Padwal RS, Johnstone DE, Sharma AM, Lopaschuk GD. Obesity-induced lysine acetylation increases cardiac fatty acid oxidation and impairs insulin signalling. *Cardiovasc Res*. 2014;103:485–497. doi: 10.1093/cvr/cvu156.
92. Wagner GR, Pride PM, Babbey CM, Payne RM. Friedreich's ataxia reveals a mechanism for coordinate regulation of oxidative metabolism via feedback inhibition of the SIRT3 deacetylase. *Hum Mol Genet*. 2012;21:2688–2697. doi: 10.1093/hmg/ddc095.
93. Kubli DA, Zhang X, Lee Y, Hanna RA, Quinsay MN, Nguyen CK, Jimenez R, Petrosyan S, Murphy AN, Gustafsson AB. Parkin protein deficiency exacerbates cardiac injury and reduces survival following myocardial infarction. *J Biol Chem*. 2013;288:915–926. doi: 10.1074/jbc.M112.411363.
94. East DA, Campanella M. Ca<sup>2+</sup> in quality control: an unresolved riddle critical to autophagy and mitophagy. *Autophagy*. 2013;9:1710–1719. doi: 10.4161/auto.25367.
95. Pyo JO, Nah J, Kim HJ, Chang JW, Song YW, Yang DK, Jo DG, Kim HR, Chae HJ, Chae SW, Hwang SY, Kim SJ, Kim HJ, Cho C, Oh CG, Park WJ, Jung YK. Protection of cardiomyocytes from ischemic/hypoxic cell death via Drbp1 and pMe2GlyDH in cardio-specific ARC transgenic mice. *J Biol Chem*. 2008;283:30707–30714. doi: 10.1074/jbc.M804209200.
96. Xiong Y, Guan KL. Mechanistic insights into the regulation of metabolic enzymes by acetylation. *J Cell Biol*. 2012;198:155–164. doi: 10.1083/jcb.201202056.
97. Jing E, O'Neill BT, Rardin MJ, Kleinridders A, Ilkeyeva OR, Ussar S, Bain JR, Lee KY, Verdin EM, Newgard CB, Gibson BW, Kahn CR. Sirt3 regulates metabolic flexibility of skeletal muscle through reversible enzymatic deacetylation. *Diabetes*. 2013;62:3404–3417. doi: 10.2337/db12-1650.
98. Bharathi SS, Zhang Y, Mohsen AW, Uppala R, Balasubramani M, Schreiber E, Uechi G, Beck ME, Rardin MJ, Vockley J, Verdin E, Gibson BW, Hirschey MD, Goetzman ES. Sirtuin 3 (SIRT3) protein regulates long-chain acyl-CoA dehydrogenase by deacetylating conserved lysines near the active site. *J Biol Chem*. 2013;288:33837–33847. doi: 10.1074/jbc.M113.510354.
99. Samant SA, Zhang HJ, Hong Z, Pillai VB, Sundaresan NR, Wolfgeher D, Archer SL, Chan DC, Gupta MP. SIRT3 deacetylates and activates OPA1 to regulate mitochondrial dynamics during stress. *Mol Cell Biol*. 2014;34:807–819. doi: 10.1128/MCB.01483-13.
100. Tseng AH, Shieh SS, Wang DL. SIRT3 deacetylates FOXO3 to protect mitochondria against oxidative damage. *Free Radic Biol Med*. 2013;63:222–234. doi: 10.1016/j.freeradbiomed.2013.05.002.
101. Scott I, Webster BR, Li JH, Sack MN. Identification of a molecular component of the mitochondrial acetyltransferase programme: a novel role for GCN5L1. *Biochem J*. 2012;443:655–661. doi: 10.1042/BJ20120118.
102. Papa L, Germain D. Sirt3 regulates a novel arm of the mitochondrial unfolded protein response. *Mol Cell Biol*. 2014;34:699–710. doi: 10.1128/MCB.01337-13.
103. Parker BL, Shepherd NE, Trefely S, Hoffman NJ, White MY, Engholm-Keller K, Hambly BD, Larsen MR, James DE, Cordwell SJ. Structural basis for phosphorylation and lysine acetylation cross-talk in a kinase motif associated with myocardial ischemia and cardioprotection. *J Biol Chem*. 2014;289:25890–25906. doi: 10.1074/jbc.M114.556035.
104. Covian R, Balaban RS. Cardiac mitochondrial matrix and respiratory complex protein phosphorylation. *Am J Physiol Heart Circ Physiol*. 2012;303:H940–H966. doi: 10.1152/ajpheart.00077.2012.
105. O'Rourke B, Van Eyk JE, Foster DB. Mitochondrial protein phosphorylation as a regulatory modality: implications for mitochondrial dysfunction in heart failure. *Congest Heart Fail*. 2011;17:269–282. doi: 10.1111/j.1751-7133.2011.00266.x.
106. Deng N, Zhang J, Zong C, Wang Y, Lu H, Yang P, Wang W, Young GW, Wang Y, Korge P, Lotz C, Doran P, Liem DA, Apweiler R, Weiss JN, Duan H, Ping P. Phosphoproteome analysis reveals regulatory sites in major pathways of cardiac mitochondria. *Mol Cell Proteomics*. 2011;10:M110.000117. doi: 10.1074/mcp.M110.000117.
107. Boja ES, Phillips D, French SA, Harris RA, Balaban RS. Quantitative mitochondrial phosphoproteomics using iTRAQ on an LTQ-Orbitrap with high energy collision dissociation. *J Proteome Res*. 2009;8:4665–4675. doi: 10.1021/pr900387b.
108. Lagranha CJ, Deschamps A, Aponte A, Steenbergen C, Murphy E. Sex differences in the phosphorylation of mitochondrial proteins result in reduced production of reactive oxygen species and cardioprotection in females. *Circ Res*. 2010;106:1681–1691. doi: 10.1161/CIRCRESAHA.109.213645.
109. Acin-Perez R, Salazar E, Kamenetsky M, Buck J, Levin LR, Manfredi G. Cyclic AMP produced inside mitochondria regulates oxidative phosphorylation. *Cell Metab*. 2009;9:265–276. doi: 10.1016/j.cmet.2009.01.012.
110. Covian R, French S, Kusnetz H, Balaban RS. Stimulation of oxidative phosphorylation by calcium in cardiac mitochondria is not influenced by cAMP and PKA activity. *Biochim Biophys Acta*. 2014;1837:1913–1921. doi: 10.1016/j.bbabi.2014.08.006.
111. Murphy E, Kohr M, Menazza S, Nguyen T, Evangelista A, Sun J, Steenbergen C. Signaling by S-nitrosylation in the heart. *J Mol Cell Cardiol*. 2014;73:18–25. doi: 10.1016/j.yjmcc.2014.01.003.
112. Murphy E, Kohr M, Sun J, Nguyen T, Steenbergen C. S-nitrosylation: a radical way to protect the heart. *J Mol Cell Cardiol*. 2012;52:568–577. doi: 10.1016/j.yjmcc.2011.08.021.
113. Chung HS, Wang SB, Venkatraman V, Murray CI, Van Eyk JE. Cysteine oxidative posttranslational modifications: emerging regulation in the cardiovascular system. *Circ Res*. 2013;112:382–392. doi: 10.1161/CIRCRESAHA.112.268680.
114. Obal D, Dai S, Keith R, Dimova N, Kingery J, Zheng YT, Zweier J, Velayutham M, Prabhu SD, Li Q, Conklin D, Yang D, Bhatnagar A, Bolli R, Rokosh G. Cardiomyocyte-restricted overexpression of extracellular superoxide dismutase increases nitric oxide bioavailability and reduces infarct size after ischemia/reperfusion. *Basic Res Cardiol*. 2012;107:305. doi: 10.1007/s00395-012-0305-1.
115. Hare JM, Stamler JS. NO/redox disequilibrium in the failing heart and cardiovascular system. *J Clin Invest*. 2005;115:509–517. doi: 10.1172/JCI24459.
116. Sun J, Morgan M, Shen RF, Steenbergen C, Murphy E. Preconditioning results in S-nitrosylation of proteins involved in regulation of mitochondrial energetics and calcium transport. *Circ Res*. 2007;101:1155–1163. doi: 10.1161/CIRCRESAHA.107.155879.
117. Wang SB, Foster DB, Rucker J, O'Rourke B, Kass DA, Van Eyk JE. Redox regulation of mitochondrial ATP synthase: implications for cardiac resynchronization therapy. *Circ Res*. 2011;109:750–757. doi: 10.1161/CIRCRESAHA.111.246124.
118. Baughman JM, Perocchi F, Girgis HS, Plovanich M, Belcher-Timme CA, Sancak Y, Bao XR, Strittmatter L, Goldberger O, Bogorad RL, Kotliansky V, Mootha VK. Integrative genomics identifies MCU as an essential component of the mitochondrial calcium uniporter. *Nature*. 2011;476:341–345. doi: 10.1038/nature10234.
119. De Stefani D, Raffaello A, Teardo E, Szabò I, Rizzuto R. A forty-kilodalton protein of the inner membrane is the mitochondrial calcium uniporter. *Nature*. 2011;476:336–340. doi: 10.1038/nature10230.
120. Glancy B, Willis WT, Chess DJ, Balaban RS. Effect of calcium on the oxidative phosphorylation cascade in skeletal muscle mitochondria. *Biochemistry*. 2013;52:2793–2809. doi: 10.1021/bi3015983.
121. Williams GS, Boyman L, Chikando AC, Khairallah RJ, Lederer WJ. Mitochondrial calcium uptake. *Proc Natl Acad Sci U S A*. 2013;110:10479–10486. doi: 10.1073/pnas.1300410110.
122. Williams GS, Boyman L, Lederer WJ. Mitochondrial calcium and the regulation of metabolism in the heart. *J Mol Cell Cardiol*. 2015;78:35–45. doi: 10.1016/j.yjmcc.2014.10.019.
123. Liu T, O'Rourke B. Regulation of mitochondrial Ca<sup>2+</sup> and its effects on energetics and redox balance in normal and failing heart. *J Bioenerg Biomembr*. 2009;41:127–132. doi: 10.1007/s10863-009-9216-8.
124. Denton RM, McCormack JG, Edgell NJ. Role of calcium ions in the regulation of intramitochondrial metabolism: effects of Na<sup>+</sup>, Mg<sup>2+</sup> and ruthenium red on the Ca<sup>2+</sup>-stimulated oxidation of oxoglutarate and on pyruvate dehydrogenase activity in intact rat heart mitochondria. *Biochem J*. 1980;190:107–117.
125. Hunter DR, Haworth RA. The Ca<sup>2+</sup>-induced membrane transition in mitochondria. I: the protective mechanisms. *Arch Biochem Biophys*. 1979;195:453–459.



126. Di Lisa F, Carpi A, Giorgio V, Bernardi P. The mitochondrial permeability transition pore and cyclophilin D in cardioprotection. *Biochim Biophys Acta*. 2011;1813:1316–1322. doi: 10.1016/j.bbamcr.2011.01.031.
127. Sancak Y, Markhard AL, Kitami T, Kovács-Bogdán E, Kamer KJ, Udeshi ND, Carr SA, Chaudhuri D, Clapham DE, Li AA, Calvo SE, Goldberger O, Mootha VK. EMRE is an essential component of the mitochondrial calcium uniporter complex. *Science*. 2013;342:1379–1382. doi: 10.1126/science.1242993.
128. Kamer KJ, Mootha VK. MICU1 and MICU2 play nonredundant roles in the regulation of the mitochondrial calcium uniporter. *EMBO Rep*. 2014;15:299–307. doi: 10.1002/embr.201337946.
129. Harrington J, Murphy E. The mitochondrial calcium uniporter: mice can live and die without it. *J Mol Cell Cardiol*. 2015;78:46–53. doi: 10.1016/j.yjmcc.2014.10.013.
130. Csordás G, Golenár T, Seifert EL, Kamer KJ, Sancak Y, Perocchi F, Moffat C, Weaver D, de la Fuente Perez S, Bogorad R, Kotliansky V, Adjianto J, Mootha VK, Hajnóczky G. MICU1 controls both the threshold and cooperative activation of the mitochondrial Ca<sup>2+</sup> uniporter. *Cell Metab*. 2013;17:976–987. doi: 10.1016/j.cmet.2013.04.020.
131. Patron M, Checchetto V, Raffaello A, Teardo E, Vecellio Reane D, Mantoan M, Granatiero V, Szabó I, De Stefani D, Rizzuto R. MICU1 and MICU2 finely tune the mitochondrial Ca<sup>2+</sup> uniporter by exerting opposite effects on MCU activity. *Mol Cell*. 2014;53:726–737. doi: 10.1016/j.molcel.2014.01.013.
132. Finkel T, Menazza S, Holmström KM, Parks RJ, Liu J, Sun J, Liu J, Pan X, Murphy E. The ins and outs of mitochondrial calcium. *Circ Res*. 2015;116:1810–1819. doi: 10.1161/CIRCRESAHA.116.305484.
133. Boyman L, Williams GS, Khananshvilii D, Sekler I, Lederer WJ. NCLX: the mitochondrial sodium calcium exchanger. *J Mol Cell Cardiol*. 2013;59:205–213. doi: 10.1016/j.yjmcc.2013.03.012.
134. Liu T, Takimoto E, Dimaano VL, DeMazumder D, Kettlewell S, Smith G, Sidor A, Abraham TP, O'Rourke B. Inhibiting mitochondrial Na<sup>+</sup>/Ca<sup>2+</sup> exchange prevents sudden death in a Guinea pig model of heart failure. *Circ Res*. 2014;115:44–54. doi: 10.1161/CIRCRESAHA.115.303062.
135. Kohlhaas M, Liu T, Knopp A, Zeller T, Ong MF, Böhm M, O'Rourke B, Maack C. Elevated cytosolic Na<sup>+</sup> increases mitochondrial formation of reactive oxygen species in failing cardiac myocytes. *Circulation*. 2010;121:1606–1613. doi: 10.1161/CIRCULATIONAHA.109.914911.
136. Shimizu H, Schredelseker J, Huang J, Lu K, Naghdi S, Lu F, Franklin S, Fiji HD, Wang K, Zhu H, Tian C, Lin B, Nakano H, Ehrlich A, Nakai J, Stieg AZ, Gimzewski JK, Nakano A, Goldhaber JJ, Vondriska TM, Hajnóczky G, Kwon O, Chen JN. Mitochondrial Ca<sup>2+</sup> uptake by the voltage-dependent anion channel 2 regulates cardiac rhythmicity. *Life*. 2015;4:e04801. doi: 10.7554/eLife.04801.
137. Pan X, Liu J, Nguyen T, Liu C, Sun J, Teng Y, Fergusson MM, Rovira II, Allen M, Springer DA, Aponte AM, Gucek M, Balaban RS, Murphy E, Finkel T. The physiological role of mitochondrial calcium revealed by mice lacking the mitochondrial calcium uniporter. *Nat Cell Biol*. 2013;15:1464–1472. doi: 10.1038/ncb2868.
138. Wu Y, Rasmussen TP, Koval OM, Joiner ML, Hall DD, Chen B, Luczak ED, Wang Q, Rokita AG, Wehrens XH, Song LS, Anderson ME. The mitochondrial uniporter controls fight or flight heart rate increases. *Nat Commun*. 2015;6:6081. doi: 10.1038/ncomms7081.
139. Luongo TS, Lambert JP, Yuan A, Zhang X, Gross P, Song J, Shanmughapriya S, Gao E, Jain M, Houser SR, Koch WJ, Cheung JY, Madesh M, Elrod JW. The mitochondrial calcium uniporter matches energetic supply with cardiac workload during stress and modulates permeability transition. *Cell Rep*. 2015;12:23–34. doi: 10.1016/j.celrep.2015.06.017.
140. Kwong JQ, Lu X, Correll RN, Schwanekamp JA, Vagnozzi RJ, Sargent MA, York AJ, Zhang J, Bers DM, Molkentin JD. The mitochondrial calcium uniporter selectively matches metabolic output to acute contractile stress in the heart. *Cell Rep*. 2015;12:15–22. doi: 10.1016/j.celrep.2015.06.002.
141. Rasmussen TP, Wu Y, Joiner ML, Koval OM, Wilson NR, Luczak ED, Wang Q, Chen B, Gao Z, Zhu Z, Wagner BA, Soto J, McCormick ML, Kutschke W, Weiss RM, Yu L, Boudreau RL, Abel ED, Zhan F, Spitz DR, Buettner GR, Song LS, Zingman LV, Anderson ME. Inhibition of MCU forces extramitochondrial adaptations governing physiological and pathological stress responses in heart. *Proc Natl Acad Sci U S A*. 2015;112:9129–9134. doi: 10.1073/pnas.1504705112.
142. Clarke PG. Developmental cell death: morphological diversity and multiple mechanisms. *Anat Embryol (Berl)*. 1990;181:195–213.
143. Ellis HM, Horvitz HR. Genetic control of programmed cell death in the nematode *C. elegans*. *Cell*. 1986;44:817–829.
144. Danial NN, Korsmeyer SJ. Cell death: critical control points. *Cell*. 2004;116:205–219.
145. Holler N, Zaru R, Micheau O, Thome M, Attinger A, Valitutti S, Bodmer JL, Schneider P, Seed B, Tschopp J. Fas triggers an alternative, caspase-8-independent cell death pathway using the kinase RIP as effector molecule. *Nat Immunol*. 2000;1:489–495. doi: 10.1038/82732.
146. Xu K, Tavernarakis N, Driscoll M. Necrotic cell death in *C. elegans* requires the function of calreticulin and regulators of Ca<sup>2+</sup> release from the endoplasmic reticulum. *Neuron*. 2001;31:957–971.
147. Baines CP, Kaiser RA, Sheiko T, Craigen WJ, Molkentin JD. Voltage-dependent anion channels are dispensable for mitochondrial-dependent cell death. *Nat Cell Biol*. 2007;9:550–555. doi: 10.1038/ncb1575.
148. Nakayama H, Chen X, Baines CP, Klevitsky R, Zhang X, Zhang H, Jaleel N, Chua BH, Hewett TE, Robbins J, Houser SR, Molkentin JD. Ca<sup>2+</sup>- and mitochondrial-dependent cardiomyocyte necrosis as a primary mediator of heart failure. *J Clin Invest*. 2007;117:2431–2444. doi: 10.1172/JCI31060.
149. Galluzzi L, Bravo-San Pedro JM, Vitale I, Aaronson SA, Abrams JM, Adam D, Alnemri ES, Altucci L, Andrews D, Annicchiarico-Petruzzelli M, Baehrecke EH, Bazan NG, Bertrand MJ, Bianchi K, Blagosklonny MV, Blomgren K, Borner C, Bredesen DE, Brenner C, Campanella M, Candi E, Cecconi F, Chan FK, Chandel NS, Cheng EH, Chipuk JE, Cidlowski JA, Ciechanover A, Dawson TM, Dawson VL, De Laurenzi V, De Maria R, Debatin KM, Di Daniele N, Dixit VM, Dynlacht BD, El-Deiry WS, Fimia GM, Flavell RA, Fulda S, Garrido C, Gougeon ML, Green DR, Gronemeyer H, Hajnóczky G, Hardwick JM, Hengartner MO, Ichijo H, Joseph B, Jost PJ, Kaufmann T, Kepp O, Klionsky DJ, Knight RA, Kumar S, Lemasters JJ, Levine B, Linkermann A, Lipton SA, Lockshin RA, López-Otín C, Lugli E, Madeo F, Malorni W, Marine JC, Martin SJ, Martinou JC, Medema JP, Meier P, Melino S, Mizushima N, Moll U, Muñoz-Pinedo C, Nuñez G, Oberst A, Panaretakis T, Penninger JM, Peter ME, Piacentini M, Pinton P, Prehn JH, Puthalakath H, Rabinovich GA, Ravichandran KS, Rizzuto R, Rodrigues CM, Rubinsztein DC, Rudel T, Shi Y, Simon HU, Stockwell BR, Szabadkai G, Tait SW, Tang HL, Tavernarakis N, Tsujimoto Y, Vanden Berghe T, Vandenabeele P, Villunger A, Wagner EF, Walczak H, White E, Wood WG, Yuan J, Zakeri Z, Zhivotovskiy B, Melino G, Kroemer G. Essential versus accessory aspects of cell death: recommendations of the NCCD 2015. *Cell Death Differ*. 2015;22:58–73. doi: 10.1038/cdd.2014.137.
150. Liu Y, Shoji-Kawata S, Sumpter RM Jr, Wei Y, Ginet V, Zhang L, Posner B, Tran KA, Green DR, Xavier RJ, Shaw SY, Clarke PG, Puyal J, Levine B. Autosis is a Na<sup>+</sup>,K<sup>+</sup>-ATPase-regulated form of cell death triggered by autophagy-inducing peptides, starvation, and hypoxia-ischemia. *Proc Natl Acad Sci U S A*. 2013;110:20364–20371. doi: 10.1073/pnas.1319661110.
151. Kung G, Konstantinidis K, Kitsis RN. Programmed necrosis, not apoptosis, in the heart. *Circ Res*. 2011;108:1017–1036. doi: 10.1161/CIRCRESAHA.110.225730.
152. Jennings RB, Sommers HM, Smyth GA, Flack HA, Linn H. Myocardial necrosis induced by temporary occlusion of a coronary artery in the dog. *Arch Pathol*. 1960;70:68–78.
153. Gottlieb RA, Burleson KO, Kloner RA, Babior BM, Engler RL. Reperfusion injury induces apoptosis in rabbit cardiomyocytes. *J Clin Invest*. 1994;94:1621–1628. doi: 10.1172/JCI117504.
154. Fliiss H, Gattlinger D. Apoptosis in ischemic and reperfused rat myocardium. *Circ Res*. 1996;79:949–956.
155. Brocheriou V, Hagege AA, Oubenaïssa A, Lambert M, Mallet VO, Duriez M, Wassef M, Kahn A, Menasché P, Gilgenkrantz H. Cardiac functional improvement by a human Bcl-2 transgene in a mouse model of ischemia/reperfusion injury. *J Gene Med*. 2000;2:326–333. doi: 10.1002/1521-2254(200009/10)2:5<326::AID-JGM133>3.0.CO;2-1.
156. Jeremias I, Kupatt C, Martin-Villalba A, Habazettl H, Schenkel J, Boekstegers P, Debatin KM. Involvement of CD95/Apo1/Fas in cell death after myocardial ischemia. *Circulation*. 2000;102:915–920.
157. Chen Z, Chua CC, Ho YS, Hamdy RC, Chua BH. Overexpression of Bcl-2 attenuates apoptosis and protects against myocardial I/R injury in transgenic mice. *Am J Physiol Heart Circ Physiol*. 2001;280:H2313–H2320.
158. Hochhauser E, Kivity S, Offen D, Maulik N, Otani H, Barhum Y, Pannet H, Shneyvays V, Shainberg A, Goldshtaub V, Tobar A, Vidne BA. Bax ablation protects against myocardial ischemia-reperfusion injury in transgenic mice. *Am J Physiol Heart Circ Physiol*. 2003;284:H2351–H2359. doi: 10.1152/ajpheart.00783.2002.
159. Lee P, Sata M, Lefter DJ, Factor SM, Walsh K, Kitsis RN. Fas pathway is a critical mediator of cardiac myocyte death and MI

- during ischemia-reperfusion in vivo. *Am J Physiol Heart Circ Physiol*. 2003;284:H456–H463. doi: 10.1152/ajpheart.00777.2002.
160. Nakagawa T, Shimizu S, Watanabe T, Yamaguchi O, Otsu K, Yamagata H, Inohara H, Kubo T, Tsujimoto Y. Cyclophilin D-dependent mitochondrial permeability transition regulates some necrotic but not apoptotic cell death. *Nature*. 2005;434:652–658. doi: 10.1038/nature03317.
  161. Toth A, Jeffers JR, Nickson P, Min JY, Morgan JP, Zambetti GP, Erhardt P. Targeted deletion of Puma attenuates cardiomyocyte death and improves cardiac function during ischemia-reperfusion. *Am J Physiol Heart Circ Physiol*. 2006;291:H52–H60. doi: 10.1152/ajpheart.01046.2005.
  162. Chua CC, Gao J, Ho YS, Xiong Y, Xu X, Chen Z, Hamdy RC, Chua BH. Overexpression of IAP-2 attenuates apoptosis and protects against myocardial ischemia/reperfusion injury in transgenic mice. *Biochim Biophys Acta*. 2007;1773:577–583. doi: 10.1016/j.bbamcr.2007.01.007.
  163. Whelan RS, Konstantinidis K, Wei AC, Chen Y, Reyna DE, Jha S, Yang Y, Calvert JW, Lindsten T, Thompson CB, Crow MT, Gavathiotis E, Dorn GW 2nd, O'Rourke B, Kitsis RN. Bax regulates primary necrosis through mitochondrial dynamics. *Proc Natl Acad Sci U S A*. 2012;109:6566–6571. doi: 10.1073/pnas.1201608109.
  164. Wencker D, Chandra M, Nguyen K, Miao W, Garantzios S, Factor SM, Shirani J, Armstrong RC, Kitsis RN. A mechanistic role for cardiac myocyte apoptosis in heart failure. *J Clin Invest*. 2003;111:1497–1504. doi: 10.1172/JCI17664.
  165. Whelan RS, Kaplinskiy V, Kitsis RN. Cell death in the pathogenesis of heart disease: mechanisms and significance. *Annu Rev Physiol*. 2010;72:19–44. doi: 10.1146/annurev.physiol.010908.163111.
  166. Chipuk JE, Moldoveanu T, Llambi F, Parsons MJ, Green DR. The BCL-2 family reunion. *Mol Cell*. 2010;37:299–310. doi: 10.1016/j.molcel.2010.01.025.
  167. Gavathiotis E, Suzuki M, Davis ML, Pitter K, Bird GH, Katz SG, Tu HC, Kim H, Cheng EH, Tjandra N, Walensky LD. BAX activation is initiated at a novel interaction site. *Nature*. 2008;455:1076–1081. doi: 10.1038/nature07396.
  168. Gavathiotis E, Reyna DE, Davis ML, Bird GH, Walensky LD. BH3-triggered structural reorganization drives the activation of proapoptotic BAX. *Mol Cell*. 2010;40:481–492. doi: 10.1016/j.molcel.2010.10.019.
  169. Leist M, Single B, Castoldi AF, Kühnle S, Nicotera P. Intracellular adenosine triphosphate (ATP) concentration: a switch in the decision between apoptosis and necrosis. *J Exp Med*. 1997;185:1481–1486.
  170. Soldani C, Scovassi AI. Poly(ADP-ribose) polymerase-1 cleavage during apoptosis: an update. *Apoptosis*. 2002;7:321–328.
  171. Sun XM, Butterworth M, MacFarlane M, Dubiel W, Ciechanover A, Cohen GM. Caspase activation inhibits proteasome function during apoptosis. *Mol Cell*. 2004;14:81–93.
  172. Saelens X, Festjens N, Parthoens E, Vanoverberghe I, Kalai M, van Kuppeveld F, Vandenabeele P. Protein synthesis persists during necrotic cell death. *J Cell Biol*. 2005;168:545–551. doi: 10.1083/jcb.200407162.
  173. Karch J, Molkentin JD. Identifying the components of the elusive mitochondrial permeability transition pore. *Proc Natl Acad Sci U S A*. 2014;111:10396–10397. doi: 10.1073/pnas.1410104111.
  174. Kokoszka JE, Waymire KG, Levy SE, Sligh JE, Cai J, Jones DP, MacGregor GR, Wallace DC. The ADP/ATP translocator is not essential for the mitochondrial permeability transition pore. *Nature*. 2004;427:461–465. doi: 10.1038/nature02229.
  175. Gutiérrez-Aguilar M, Douglas DL, Gibson AK, Domeier TL, Molkentin JD, Baines CP. Genetic manipulation of the cardiac mitochondrial phosphate carrier does not affect permeability transition. *J Mol Cell Cardiol*. 2014;72:316–325. doi: 10.1016/j.yjmcc.2014.04.008.
  176. Kwong JQ, Davis J, Baines CP, Sargent MA, Karch J, Wang X, Huang T, Molkentin JD. Genetic deletion of the mitochondrial phosphate carrier desensitizes the mitochondrial permeability transition pore and causes cardiomyopathy. *Cell Death Differ*. 2014;21:1209–1217. doi: 10.1038/cdd.2014.36.
  177. Bonora M, Bononi A, De Marchi E, Giorgi C, Lebedzinska M, Marchi S, Patergnani S, Rimessi A, Suski JM, Wojtala A, Wiecekowski MR, Kroemer G, Galluzzi L, Pinton P. Role of the c subunit of the FO ATP synthase in mitochondrial permeability transition. *Cell Cycle*. 2013;12:674–683. doi: 10.4161/cc.23599.
  178. Giorgio V, von Stockum S, Antoniel M, Fabbro A, Fogolari F, Forte M, Glick GD, Petronilli V, Zoratti M, Szabó I, Lippe G, Bernardi P. Dimers of mitochondrial ATP synthase form the permeability transition pore. *Proc Natl Acad Sci U S A*. 2013;110:5887–5892. doi: 10.1073/pnas.1217823110.
  179. Alavian KN, Beutner G, Lazrove E, Sacchetti S, Park HA, Licznarski P, Li H, Nabili P, Hockensmith K, Graham M, Porter GA Jr, Jonas EA. An uncoupling channel within the c-subunit ring of the F1FO ATP synthase is the mitochondrial permeability transition pore. *Proc Natl Acad Sci U S A*. 2014;111:10580–10585. doi: 10.1073/pnas.1401591111.
  180. Crompton M, Costi A, Hayat L. Evidence for the presence of a reversible Ca<sup>2+</sup>-dependent pore activated by oxidative stress in heart mitochondria [published correction appears in *Biochem J*. 1987;246:following 806]. *Biochem J*. 1987;245:915–918.
  181. Crompton M, Ellinger H, Costi A. Inhibition by cyclosporin A of a Ca<sup>2+</sup>-dependent pore in heart mitochondria activated by inorganic phosphate and oxidative stress. *Biochem J*. 1988;255:357–360.
  182. Halestrap AP. Calcium-dependent opening of a non-specific pore in the mitochondrial inner membrane is inhibited at pH values below 7. Implications for the protective effect of low pH against chemical and hypoxic cell damage. *Biochem J*. 1991;278 (pt 3):715–719.
  183. Griffiths EJ, Halestrap AP. Mitochondrial non-specific pores remain closed during cardiac ischaemia, but open upon reperfusion. *Biochem J*. 1995;307 (pt 1):93–98.
  184. Baines CP, Kaiser RA, Purcell NH, Blair NS, Osinska H, Hambleton MA, Brunskill EW, Sayen MR, Gottlieb RA, Dorn GW, Robbins J, Molkentin JD. Loss of cyclophilin D reveals a critical role for mitochondrial permeability transition in cell death. *Nature*. 2005;434:658–662. doi: 10.1038/nature03434.
  - 184a. Lim SY, Davidson SM, Mocanu MM, Yellon DM, Smith CC. The cardioprotective effect of necrostatin requires the cyclophilin-D component of the mitochondrial permeability transition pore. *Cardiovasc Drugs Ther*. 2007;21:467–469.
  185. Griffiths EJ, Halestrap AP. Further evidence that cyclosporin A protects mitochondria from calcium overload by inhibiting a matrix peptidyl-prolyl cis-trans isomerase: implications for the immunosuppressive and toxic effects of cyclosporin. *Biochem J*. 1991;274 (pt 2):611–614.
  186. Karch J, Kwong JQ, Burr AR, Sargent MA, Elrod JW, Peixoto PM, Martinez-Caballero S, Osinska H, Cheng EH, Robbins J, Kinnally KW, Molkentin JD. Bax and Bak function as the outer membrane component of the mitochondrial permeability pore in regulating necrotic cell death in mice. *Elife*. 2013;2:e00772. doi: 10.7554/eLife.00772.
  187. Piot C, Croisille P, Staat P, Thibault H, Rioufol G, Mewton N, Elbelghiti R, Cung TT, Bonnefoy E, Angoulvant D, Macia C, Raczka F, Sportouch C, Gahide G, Finet G, André-Fouët X, Revel D, Kirkorian G, Monassier JP, Derumeaux G, Ovize M. Effect of cyclosporine on reperfusion injury in acute myocardial infarction. *N Engl J Med*. 2008;359:473–481. doi: 10.1056/NEJMoa071142.
  - 187a. Cung TT, Morel O, Cayla G, Rioufol G, Garcia-Dorado D, Angoulvant D, Bonnefoy-Cudraz E, Guérin P, Elbaz M, Delarche N, Coste P, Vanzetto G, Metge M, Aupetit JF, Jouve B, Motreff P, Tron C, Labeque JN, Stieg PG, Cottin Y, Range G, Clerc J, Claeys MJ, Coussement P, Prunier F, Moulin F, Roth O, Belle L, Dubois P, Barragan P, Gilard M, Piot C, Colin P, De Poli F, Morice MC, Ider O, Dubois-Randé JL, Untersee T, Le Breton H, Béard T, Blanchard D, Grollier G, Malquarti V, Staat P, Sudre A, Elmer E, Hansson MJ, Bergerot C, Boussaha I, Jossan C, Derumeaux G, Mewton N, Ovize M. Cyclosporine before PCI in patients with acute myocardial infarction. *N Engl J Med*. 2015;373:1021–1031.
  - 187b. Linkermann A, Konstantinidis K, Kitsis RN. Catch me if you can: targeting the mitochondrial permeability transition pore in myocardial infarction. *Cell Death Differ*. 2016;23:1–2.
  188. Deleted in proof.
  189. Murphy MP. How mitochondria produce reactive oxygen species. *Biochem J*. 2009;417:1–13. doi: 10.1042/BJ20081386.
  190. Chen YR, Zweier JL. Cardiac mitochondria and reactive oxygen species generation. *Circ Res*. 2014;114:524–537. doi: 10.1161/CIRCRESAHA.114.300559.
  191. Zorov DB, Juhaszova M, Sollott SJ. Mitochondrial reactive oxygen species (ROS) and ROS-induced ROS release. *Physiol Rev*. 2014;94:909–950. doi: 10.1152/physrev.00026.2013.
  192. Carpi A, Menabò R, Kaludercic N, Pelicci P, Di Lisa F, Giorgio M. The cardioprotective effects elicited by p66(Shc) ablation demonstrate the crucial role of mitochondrial ROS formation in ischemia/reperfusion injury. *Biochim Biophys Acta*. 2009;1787:774–780. doi: 10.1016/j.bbatio.2009.04.001.
  193. Chouchani ET, Pell VR, Gaude E, Aksentijevic D, Sundier SY, Robb EL, Logan A, Nadtochiy SM, Ord EN, Smith AC, Eyassu F, Shirley R, Hu CH, Dare AJ, James AM, Rogatti S, Hartley RC, Eaton S, Costa AS, Brookes PS, Davidson SM, Duchon MR, Saeb-Parsy K, Shattock MJ, Robinson AJ, Work LM, Frezza C, Krieg T, Murphy MP. Ischaemic accumulation of succinate controls reperfusion injury through mitochondrial ROS. *Nature*. 2014;515:431–435. doi: 10.1038/nature13909.

194. Korshunov SS, Skulachev VP, Starkov AA. High protonic potential activates a mechanism of production of reactive oxygen species in mitochondria. *FEBS Lett.* 1997;416:15–18.
195. Aon MA, Cortassa S, Marbán E, O'Rourke B. Synchronized whole cell oscillations in mitochondrial metabolism triggered by a local release of reactive oxygen species in cardiac myocytes. *J Biol Chem.* 2003;278:44735–44744. doi: 10.1074/jbc.M302673200.
196. Aon MA, Cortassa S, O'Rourke B. Redox-optimized ROS balance: a unifying hypothesis. *Biochim Biophys Acta.* 2010;1797:865–877. doi: 10.1016/j.bbabi.2010.02.016.
197. Nickel A, Kohlhaas M, Maack C. Mitochondrial reactive oxygen species production and elimination. *J Mol Cell Cardiol.* 2014;73:26–33. doi: 10.1016/j.yjmcc.2014.03.011.
198. Giorgio M, Trinei M, Migliaccio E, Pelicci PG. Hydrogen peroxide: a metabolic by-product or a common mediator of ageing signals? *Nat Rev Mol Cell Biol.* 2007;8:722–728. doi: 10.1038/nrm2240.
199. Cambridge SB, Gnad F, Nguyen C, Bermejo JL, Krüger M, Mann M. Systems-wide proteomic analysis in mammalian cells reveals conserved, functional protein turnover. *J Proteome Res.* 2011;10:5275–5284. doi: 10.1021/pr101183k.
200. Zorov DB, Filburn CR, Klotz LO, Zweier JL, Sollott SJ. Reactive oxygen species (ROS)-induced ROS release: a new phenomenon accompanying induction of the mitochondrial permeability transition in cardiac myocytes. *J Exp Med.* 2000;192:1001–1014.
201. Juhaszova M, Wang S, Zorov DB, Nuss HB, Gleichmann M, Mattson MP, Sollott SJ. The identity and regulation of the mitochondrial permeability transition pore: where the known meets the unknown. *Ann N Y Acad Sci.* 2008;1123:197–212. doi: 10.1196/annals.1420.023.
202. Andrukhiv A, Costa AD, West IC, Garlid KD. Opening mitoKATP increases superoxide generation from complex I of the electron transport chain. *Am J Physiol Heart Circ Physiol.* 2006;291:H2067–H2074. doi: 10.1152/ajpheart.00272.2006.
203. Pain T, Yang XM, Critz SD, Yue Y, Nakano A, Liu GS, Heusch G, Cohen MV, Downey JM. Opening of mitochondrial K(ATP) channels triggers the preconditioned state by generating free radicals. *Circ Res.* 2000;87:460–466.
204. Forbes RA, Steenbergen C, Murphy E. Diazoxide-induced cardioprotection requires signaling through a redox-sensitive mechanism. *Circ Res.* 2001;88:802–809.
205. Barja G. Mitochondrial oxygen radical generation and leak: sites of production in states 4 and 3, organ specificity, and relation to aging and longevity. *J Bioenerg Biomembr.* 1999;31:347–366.
206. Penna C, Rastaldo R, Mancardi D, Raimondo S, Cappello S, Gattullo D, Losano G, Pagliaro P. Post-conditioning induced cardioprotection requires signaling through a redox-sensitive mechanism, mitochondrial ATP-sensitive K<sup>+</sup> channel and protein kinase C activation. *Basic Res Cardiol.* 2006;101:180–189. doi: 10.1007/s00395-006-0584-5.
207. Vanden Hoek TL, Becker LB, Shao Z, Li C, Schumacker PT. Reactive oxygen species released from mitochondria during brief hypoxia induce preconditioning in cardiomyocytes. *J Biol Chem.* 1998;273:18092–18098.
208. Ahmad S, Singh N, Glazer RI. Role of AKT1 in 17 $\beta$ -estradiol- and insulin-like growth factor I (IGF-I)-dependent proliferation and prevention of apoptosis in MCF-7 breast carcinoma cells. *Biochem Pharmacol.* 1999;58:425–430.
209. Esposito LA, Melov S, Panov A, Cottrell BA, Wallace DC. Mitochondrial disease in mouse results in increased oxidative stress. *Proc Natl Acad Sci U S A.* 1999;96:4820–4825.
210. Schriener SE, Linford NJ, Martin GM, Treuting P, Ogburn CE, Emond M, Coskun PE, Ladiges W, Wolf N, Van Remmen H, Wallace DC, Rabinovitch PS. Extension of murine life span by overexpression of catalase targeted to mitochondria. *Science.* 2005;308:1909–1911. doi: 10.1126/science.1106653.
211. Anderson EJ, Lustig ME, Boyle KE, Woodlief TL, Kane DA, Lin CT, Price JW 3rd, Kang L, Rabinovitch PS, Szeto HH, Houmard JA, Cortright RN, Wasserman DH, Neuffer PD. Mitochondrial H<sub>2</sub>O<sub>2</sub> emission and cellular redox state link excess fat intake to insulin resistance in both rodents and humans. *J Clin Invest.* 2009;119:573–581. doi: 10.1172/JCI37048.
212. Dai DF, Chen T, Szeto H, Nieves-Cintrón M, Kutuyavin V, Santana LF, Rabinovitch PS. Mitochondrial targeted antioxidant peptide ameliorates hypertensive cardiomyopathy. *J Am Coll Cardiol.* 2011;58:73–82. doi: 10.1016/j.jacc.2010.12.044.
213. Brand MD. The sites and topology of mitochondrial superoxide production. *Exp Gerontol.* 2010;45:466–472. doi: 10.1016/j.exger.2010.01.003.
214. Giorgio M, Migliaccio E, Orsini F, Paolucci D, Moroni M, Contursi C, Pelliccia G, Luzi L, Minucci S, Marcaccio M, Pinton P, Rizzuto R, Bernardi P, Paolucci F, Pelicci PG. Electron transfer between cytochrome c and p66Shc generates reactive oxygen species that trigger mitochondrial apoptosis. *Cell.* 2005;122:221–233. doi: 10.1016/j.cell.2005.05.011.
215. Migliaccio E, Giorgio M, Mele S, Pelicci G, Reboldi P, Pandolfi PP, Lanfrancone L, Pelicci PG. The p66shc adaptor protein controls oxidative stress response and life span in mammals. *Nature.* 1999;402:309–313. doi: 10.1038/46311.
216. Affaitati A, Cardone L, de Cristofaro T, Carlucci A, Ginsberg MD, Varrone S, Gottesman ME, Avvedimento EV, Feliciello A. Essential role of A-kinase anchor protein 121 for cAMP signaling to mitochondria. *J Biol Chem.* 2003;278:4286–4294. doi: 10.1074/jbc.M209941200.
217. Camici GG, Schiavoni M, Francia P, Bachschmid M, Martin-Padura I, Hersberger M, Tanner FC, Pelicci P, Volpe M, Anversa P, Lüscher TF, Cosentino F. Genetic deletion of p66(Shc) adaptor protein prevents hyperglycemia-induced endothelial dysfunction and oxidative stress. *Proc Natl Acad Sci U S A.* 2007;104:5217–5222. doi: 10.1073/pnas.0609656104.
218. Kareyeva AV, Grivennikova VG, Cecchini G, Vinogradov AD. Molecular identification of the enzyme responsible for the mitochondrial NADH-supported ammonium-dependent hydrogen peroxide production. *FEBS Lett.* 2011;585:385–389. doi: 10.1016/j.febslet.2010.12.019.
219. Anderson EJ, Efrid JT, Davies SW, O'Neal WT, Darden TM, Thayne KA, Katunga LA, Kindell LC, Ferguson TB, Anderson CA, Chitwood WR, Koutlas TC, Williams JM, Rodriguez E, Kypson AP. Monoamine oxidase is a major determinant of redox balance in human atrial myocardium and is associated with postoperative atrial fibrillation. *J Am Heart Assoc.* 2014;3:e000713. doi: 10.1161/JAHA.113.000713.
220. Weinreb O, Bar-Am O, Amit T, Chillag-Talmor O, Youdim MB. Neuroprotection via pro-survival protein kinase C isoforms associated with Bcl-2 family members. *FASEB J.* 2004;18:1471–1473. doi: 10.1096/fj.04-1916fje.
221. Ago T, Kuroda J, Pain J, Fu C, Li H, Sadoshima J. Upregulation of Nox4 by hypertrophic stimuli promotes apoptosis and mitochondrial dysfunction in cardiac myocytes. *Circ Res.* 2010;106:1253–1264. doi: 10.1161/CIRCRESAHA.109.213116.
222. Martyn KD, Frederick LM, von Loehneysen K, Dinauer MC, Knaus UG. Functional analysis of Nox4 reveals unique characteristics compared to other NADPH oxidases. *Cell Signal.* 2006;18:69–82. doi: 10.1016/j.cellsig.2005.03.023.
223. Montezano AC, Touyz RM. Oxidative stress, Nox, and hypertension: experimental evidence and clinical controversies. *Ann Med.* 2012;44(suppl 1):S2–16. doi: 10.3109/07853890.2011.653393.
224. Berndt C, Lillig CH, Holmgren A. Thiol-based mechanisms of the thioredoxin and glutaredoxin systems: implications for diseases in the cardiovascular system. *Am J Physiol Heart Circ Physiol.* 2007;292:H1227–H1236. doi: 10.1152/ajpheart.01162.2006.
225. Chalmers S, Caldwell ST, Quin C, Prime TA, James AM, Cairns AG, Murphy MP, McCarron JG, Hartley RC. Selective uncoupling of individual mitochondria within a cell using a mitochondria-targeted photoactivated protonophore. *J Am Chem Soc.* 2012;134:758–761. doi: 10.1021/ja207792z.
226. Cortassa S, O'Rourke B, Aon MA. Redox-optimized ROS balance and the relationship between mitochondrial respiration and ROS. *Biochim Biophys Acta.* 2014;1837:287–295. doi: 10.1016/j.bbabi.2013.11.007.
227. Cox AG, Winterbourn CC, Hampton MB. Mitochondrial peroxiredoxin involvement in antioxidant defence and redox signalling. *Biochem J.* 2010;425:313–325. doi: 10.1042/BJ20091541.
228. Galluzzi L, Aaronson SA, Abrams J, Alnemri ES, Andrews DW, Baehrecke EH, Bazan NG, Blagosklonny MV, Blomgren K, Borner C, Breiden DE, Brenner C, Castedo M, Cidlowski JA, Ciechanover A, Cohen GM, De Laurenzi V, De Maria R, Deshmukh M, Dynlacht BD, El-Deiry WS, Flavell RA, Fulda S, Garrido C, Golstein P, Gougeon ML, Green DR, Gronemeyer H, Hajnóczky G, Hardwick JM, Hengartner MO, Ichijo H, Jäättelä M, Kepp O, Kimchi A, Klionsky DJ, Knight RA, Kornbluth S, Kumar S, Levine B, Lipton SA, Lugli E, Madeo F, Malomi W, Marine JC, Martin SJ, Medema JP, Mehlen P, Melino G, Moll UM, Morselli E, Nagata S, Nicholson DW, Nicotera P, Nuñez G, Oren M, Penninger J, Pervaiz S, Peter ME, Piacentini M, Prehn JH, Puthalakath H, Rabinovich GA, Rizzuto R, Rodrigues CM, Rubinsztein DC, Rudel T, Scorrano L, Simon HU, Steller H, Tschopp J, Tsujimoto Y, Vandenabeele P, Vitale I, Vousden KH, Youle RJ, Yuan J, Zhivotovskiy B, Kroemer G. Guidelines for the use and interpretation of assays for monitoring cell death in higher eukaryotes. *Cell Death Differ.* 2009;16:1093–1107. doi: 10.1038/cdd.2009.44.

229. Matsushima S, Ide T, Yamato M, Matsusaka H, Hattori F, Ikeuchi M, Kubota T, Sunagawa K, Hasegawa Y, Kurihara T, Oikawa S, Kinugawa S, Tsutsui H. Overexpression of mitochondrial peroxiredoxin-3 prevents left ventricular remodeling and failure after myocardial infarction in mice. *Circulation*. 2006;113:1779–1786. doi: 10.1161/CIRCULATIONAHA.105.582239.
230. Chouchani ET, Methner C, Nadochiy SM, Logan A, Pell VR, Ding S, James AM, Cochemé HM, Reinhold J, Lilley KS, Partridge L, Fearnley IM, Robinson AJ, Hartley RC, Smith RA, Krieg T, Brookes PS, Murphy MP. Cardioprotection by S-nitrosation of a cysteine switch on mitochondrial complex I. *Nat Med*. 2013;19:753–759. doi: 10.1038/nm.3212.
231. Smith RA, Hartley RC, Cochemé HM, Murphy MP. Mitochondrial pharmacology. *Trends Pharmacol Sci*. 2012;33:341–352. doi: 10.1016/j.tips.2012.03.010.
232. Di Lisa F, Kaludercic N, Carpi A, Menabò R, Giorgio M. Mitochondrial pathways for ROS formation and myocardial injury: the relevance of p66(Shc) and monoamine oxidase. *Basic Res Cardiol*. 2009;104:131–139. doi: 10.1007/s00395-009-0008-4.
233. Bugger H, Abel ED. Mitochondria in the diabetic heart. *Cardiovasc Res*. 2010;88:229–240. doi: 10.1093/cvr/cvq239.
234. Lesnefsky EJ, Guduz TI, Moghaddas S, Migita CT, Ikeda-Saito M, Turkaly PJ, Hoppel CL. Aging decreases electron transport complex III activity in heart interfibrillar mitochondria by alteration of the cytochrome c binding site. *J Mol Cell Cardiol*. 2001;33:37–47. doi: 10.1006/jmcc.2000.1273.
235. Balaban RS, Nemoto S, Finkel T. Mitochondria, oxidants, and aging. *Cell*. 2005;120:483–495. doi: 10.1016/j.cell.2005.02.001.
236. Janssen-Heininger YM, Mossman BT, Heintz NH, Forman HJ, Kalyanaraman B, Finkel T, Stamler JS, Rhee SG, van der Vliet A. Redox-based regulation of signal transduction: principles, pitfalls, and promises. *Free Radic Biol Med*. 2008;45:1–17. doi: 10.1016/j.freeradbiomed.2008.03.011.
237. Sena LA, Chandel NS. Physiological roles of mitochondrial reactive oxygen species. *Mol Cell*. 2012;48:158–167. doi: 10.1016/j.molcel.2012.09.025.
238. Finkel T. From sulfenylation to sulphydration: what a thiolate needs to tolerate. *Sci Signal*. 2012;5:pe10. doi: 10.1126/scisignal.2002943.
239. Prime TA, Blaikie FH, Evans C, Nadochiy SM, James AM, Dahm CC, Vitturi DA, Patel RP, Hiley CR, Abakumova I, Requejo R, Chouchani ET, Hurd TR, Garvey JF, Taylor CT, Brookes PS, Smith RA, Murphy MP. A mitochondria-targeted S-nitrosothiol modulates respiration, nitrosates thiols, and protects against ischemia-reperfusion injury. *Proc Natl Acad Sci U S A*. 2009;106:10764–10769. doi: 10.1073/pnas.0903250106.
240. Tonks NK. Redox redux: revisiting PTPs and the control of cell signaling. *Cell*. 2005;121:667–670. doi: 10.1016/j.cell.2005.05.016.
241. Jakob R, Beutner G, Sharma VK, Duan Y, Gross RA, Hurst S, Jhun BS, O-Uchi J, Sheu SS. Molecular and functional identification of a mitochondrial ryanodine receptor in neurons. *Neurosci Lett*. 2014;575:7–12. doi: 10.1016/j.neulet.2014.05.026.
242. Semenza GL. Hypoxia-inducible factor 1 and cardiovascular disease. *Annu Rev Physiol*. 2014;76:39–56. doi: 10.1146/annurev-physiol-021113-170322.
243. Hayes JD, Dinkova-Kostova AT. The Nrf2 regulatory network provides an interface between redox and intermediary metabolism. *Trends Biochem Sci*. 2014;39:199–218. doi: 10.1016/j.tibs.2014.02.002.
244. Kim TY, Wang D, Kim AK, Lau E, Lin AJ, Liem DA, Zhang J, Zong NC, Lam MP, Ping P. Metabolic labeling reveals proteome dynamics of mouse mitochondria. *Mol Cell Proteomics*. 2012;11:1586–1594. doi: 10.1074/mcp.M112.021162.
245. Bhandari P, Song M, Chen Y, Burelle Y, Dorn GW 2nd. Mitochondrial contagion induced by Parkin deficiency in Drosophila hearts and its containment by suppressing mitofusins. *Circ Res*. 2014;114:257–265. doi: 10.1161/CIRCRESAHA.114.302734.
246. Akhmedov A, Montecucco F, Braunersreuther V, Camici GG, Jakob P, Reiner MF, Glanzmann M, Burger F, Paneni F, Galan K, Pelli G, Vuilleumier N, Belin A, Vallée JP, Mach F, Lüscher TF. Genetic deletion of the adaptor protein p66Shc increases susceptibility to short-term ischaemic myocardial injury via intracellular salvage pathways. *Eur Heart J*. 2015;36:516–526. doi: 10.1093/eurheartj/ehu400.
247. Spindel ON, Berk BC. Redox redux: protecting the ischemic myocardium. *J Clin Invest*. 2012;122:30–32. doi: 10.1172/JCI61467.
248. Ristow M. Unraveling the truth about antioxidants: mitohormesis explains ROS-induced health benefits. *Nat Med*. 2014;20:709–711. doi: 10.1038/nm.3624.
249. Song M, Mihara K, Chen Y, Scorrano L, Dorn GW 2nd. Mitochondrial fission and fusion factors reciprocally orchestrate mitophagic culling in mouse hearts and cultured fibroblasts. *Cell Metab*. 2015;21:273–285. doi: 10.1016/j.cmet.2014.12.011.
250. Karbowski M, Arnoult D, Chen H, Chan DC, Smith CL, Youle RJ. Quantitation of mitochondrial dynamics by photolabeling of individual organelles shows that mitochondrial fusion is blocked during the Bax activation phase of apoptosis. *J Cell Biol*. 2004;164:493–499. doi: 10.1083/jcb.200309082.
251. Legros F, Lombès A, Frachon P, Rojo M. Mitochondrial fusion in human cells is efficient, requires the inner membrane potential, and is mediated by mitofusins. *Mol Biol Cell*. 2002;13:4343–4354. doi: 10.1091/mbc.E02-06-0330.
252. Mishra P, Chan DC. Mitochondrial dynamics and inheritance during cell division, development and disease. *Nat Rev Mol Cell Biol*. 2014;15:634–646. doi: 10.1038/nrm3877.
253. Liesa M, Shirihai OS. Mitochondrial dynamics in the regulation of nutrient utilization and energy expenditure. *Cell Metab*. 2013;17:491–506. doi: 10.1016/j.cmet.2013.03.002.
254. Friedman JR, Nunnari J. Mitochondrial form and function. *Nature*. 2014;505:335–343. doi: 10.1038/nature12985.
255. Shen Q, Yamano K, Head BP, Kawajiri S, Cheung JT, Wang C, Cho JH, Hattori N, Youle RJ, van der Bliek AM. Mutations in Fis1 disrupt orderly disposal of defective mitochondria. *Mol Biol Cell*. 2014;25:145–159. doi: 10.1091/mbc.E13-09-0525.
256. Friedman JR, Lackner LL, West M, DiBenedetto JR, Nunnari J, Voeltz GK. ER tubules mark sites of mitochondrial division. *Science*. 2011;334:358–362. doi: 10.1126/science.1207385.
257. Kasahara A, Cipolat S, Chen Y, Dorn GW 2nd, Scorrano L. Mitochondrial fusion directs cardiomyocyte differentiation via calcineurin and Notch signaling. *Science*. 2013;342:734–737. doi: 10.1126/science.1241359.
258. Sharp WW, Fang YH, Han M, Zhang HJ, Hong Z, Banathy A, Morrow E, Ryan JJ, Archer SL. Dynamin-related protein 1 (Drp1)-mediated diastolic dysfunction in myocardial ischemia-reperfusion injury: therapeutic benefits of Drp1 inhibition to reduce mitochondrial fission. *FASEB J*. 2014;28:316–326. doi: 10.1096/fj.12-226225.
259. Vincow ES, Merrihew G, Thomas RE, Shulman NJ, Beyer RP, MacCoss MJ, Pallanck LJ. The PINK1-Parkin pathway promotes both mitophagy and selective respiratory chain turnover in vivo. *Proc Natl Acad Sci U S A*. 2013;110:6400–6405. doi: 10.1073/pnas.1221132110.
260. Youle RJ, van der Bliek AM. Mitochondrial fission, fusion, and stress. *Science*. 2012;337:1062–1065. doi: 10.1126/science.1219855.
261. Tondera D, Grandemange S, Jourdain A, Karbowski M, Mattenberger Y, Herzig S, Da Cruz S, Clerc P, Raschke I, Merkwirth C, Ehse S, Krause F, Chan DC, Alexander C, Bauer C, Youle R, Langer T, Martinou JC. SLP-2 is required for stress-induced mitochondrial hyperfusion. *EMBO J*. 2009;28:1589–1600. doi: 10.1038/emboj.2009.89.
262. Youle RJ, Narendra DP. Mechanisms of mitophagy. *Nat Rev Mol Cell Biol*. 2011;12:9–14. doi: 10.1038/nrm3028.
263. Chan NC, Salazar AM, Pham AH, Sweredoski MJ, Kolawa NJ, Graham RL, Hess S, Chan DC. Broad activation of the ubiquitin-proteasome system by Parkin is critical for mitophagy. *Hum Mol Genet*. 2011;20:1726–1737. doi: 10.1093/hmg/ddr048.
264. Healy DG, Abou-Sleiman PM, Wood NW. PINK, PANK, or PARK? A clinicians' guide to familial parkinsonism. *Lancet Neurol*. 2004;3:652–662. doi: 10.1016/S1474-4422(04)00905-6.
265. Clark IE, Dodson MW, Jiang C, Cao JH, Huh JR, Seol JH, Yoo SJ, Hay BA, Guo M. Drosophila pink1 is required for mitochondrial function and interacts genetically with parkin. *Nature*. 2006;441:1162–1166. doi: 10.1038/nature04779.
266. Park J, Lee SB, Lee S, Kim Y, Song S, Kim S, Bae E, Kim J, Shong M, Kim JM, Chung J. Mitochondrial dysfunction in Drosophila PINK1 mutants is complemented by parkin. *Nature*. 2006;441:1157–1161. doi: 10.1038/nature04788.
267. Jin SM, Lazarou M, Wang C, Kane LA, Narendra DP, Youle RJ. Mitochondrial membrane potential regulates PINK1 import and proteolytic destabilization by PARL. *J Cell Biol*. 2010;191:933–942. doi: 10.1083/jcb.201008084.
268. Narendra DP, Jin SM, Tanaka A, Suen DF, Gautier CA, Shen J, Cookson MR, Youle RJ. PINK1 is selectively stabilized on impaired mitochondria to activate Parkin. *PLoS Biol*. 2010;8:e1000298. doi: 10.1371/journal.pbio.1000298.
269. Vives-Bauza C, Zhou C, Huang Y, Cui M, de Vries RL, Kim J, May J, Tocilescu MA, Liu W, Ko HS, Magrané J, Moore DJ, Dawson VL,

- Grailhe R, Dawson TM, Li C, Tieu K, Przedborski S. PINK1-dependent recruitment of Parkin to mitochondria in mitophagy. *Proc Natl Acad Sci U S A*. 2010;107:378–383. doi: 10.1073/pnas.0911187107.
270. Kane LA, Lazarou M, Fogel AI, Li Y, Yamano K, Sarraf SA, Banerjee S, Youle RJ. PINK1 phosphorylates ubiquitin to activate Parkin E3 ubiquitin ligase activity. *J Cell Biol*. 2014;205:143–153. doi: 10.1083/jcb.201402104.
271. Koyano F, Okatsu K, Kosako H, Tamura Y, Go E, Kimura M, Kimura Y, Tsuchiya H, Yoshihara H, Hirokawa T, Endo T, Fon EA, Trempe JF, Saeki Y, Tanaka K, Matsuda N. Ubiquitin is phosphorylated by PINK1 to activate parkin. *Nature*. 2014;510:162–166. doi: 10.1038/nature13392.
272. Sarraf SA, Raman M, Guarani-Pereira V, Sowa ME, Huttlin EL, Gygi SP, Harper JW. Landscape of the PARKIN-dependent ubiquitylome in response to mitochondrial depolarization. *Nature*. 2013;496:372–376. doi: 10.1038/nature12043.
273. Dorn GW 2nd, KR. The mitochondrial dynamism-mitophagy-cell death interactome: multiple roles performed by members of a mitochondrial molecular ensemble. *Circ Res*. 2015;116:167–182. doi: 10.1161/CIRCRESAHA.116.303554.
274. Twig G, Elorza A, Molina AJ, Mohamed H, Wikstrom JD, Walzer G, Stiles L, Haigh SE, Katz S, Las G, Alroy J, Wu M, Py BF, Yuan J, Deeney JT, Corkey BE, Shirihai OS. Fission and selective fusion govern mitochondrial segregation and elimination by autophagy. *EMBO J*. 2008;27:433–446. doi: 10.1038/sj.emboj.7601963.
275. Song M, Gong G, Burelle Y, Gustafsson AB, Kitsis RN, Matkovich SJ, Dorn GW 2nd. Interdependence of Parkin-mediated mitophagy and mitochondrial fission in adult mouse hearts. *Circ Res*. 2015;117:346–351. doi: 10.1161/CIRCRESAHA.117.306859.
276. Kageyama Y, Hoshijima M, Seo K, Bedja D, Sysa-Shah P, Andrabi SA, Chen W, Höke A, Dawson VL, Dawson TM, Gabrielson K, Kass DA, Iijima M, Sesaki H. Parkin-independent mitophagy requires Drp1 and maintains the integrity of mammalian heart and brain. *EMBO J*. 2014;33:2798–2813. doi: 10.15252/emboj.201488658.
277. Song M, Chen Y, Gong G, Murphy E, Rabinovitch PS, Dorn GW 2nd. Super-suppression of mitochondrial reactive oxygen species signaling impairs compensatory autophagy in primary mitophagic cardiomyopathy. *Circ Res*. 2014;115:348–353. doi: 10.1161/CIRCRESAHA.115.304384.
278. Corti O, Lesage S, Brice A. What genetics tells us about the causes and mechanisms of Parkinson's disease. *Physiol Rev*. 2011;91:1161–1218. doi: 10.1152/physrev.00022.2010.
279. Guo M. Drosophila as a model to study mitochondrial dysfunction in Parkinson's disease. *Cold Spring Harb Perspect Med*. 2012;2:a009944. doi: 10.1101/cshperspect.a009944.
280. Dawson TM, Ko HS, Dawson VL. Genetic animal models of Parkinson's disease. *Neuron*. 2010;66:646–661. doi: 10.1016/j.neuron.2010.04.034.
281. Siddall HK, Yellon DM, Ong SB, Mukherjee UA, Burke N, Hall AR, Angelova PR, Ludtmann MH, Deas E, Davidson SM, Mocanu MM, Hausenloy DJ. Loss of PINK1 increases the heart's vulnerability to ischemia-reperfusion injury. *PLoS One*. 2013;8:e62400. doi: 10.1371/journal.pone.0062400.
282. Kim KY, Stevens MV, Akter MH, Rusk SE, Huang RJ, Cohen A, Noguchi A, Springer D, Bocharov AV, Eggerman TL, Suen DF, Youle RJ, Amar M, Remaley AT, Sack MN. Parkin is a lipid-responsive regulator of fat uptake in mice and mutant human cells. *J Clin Invest*. 2011;121:3701–3712. doi: 10.1172/JCI44736.
283. Kundu M, Thompson CB. Macroautophagy versus mitochondrial autophagy: a question of fate? *Cell Death Differ*. 2005;12(suppl 2):1484–1489. doi: 10.1038/sj.cdd.4401780.
284. Dorn GW 2nd. Mitochondrial pruning by Nix and BNip3: an essential function for cardiac-expressed death factors. *J Cardiovasc Transl Res*. 2010;3:374–383. doi: 10.1007/s12265-010-9174-x.
285. Skulachev VP. Programmed death phenomena: from organelle to organism. *Ann NY Acad Sci*. 2002;959:214–237.
286. Schwarten M, Mohrlüder J, Ma P, Stoldt M, Thielmann Y, Stangler T, Hersch N, Hoffmann B, Merkel R, Willbold D. Nix directly binds to GABARAP: a possible crosstalk between apoptosis and autophagy. *Autophagy*. 2009;5:690–698.
287. Novak I, Kirkin V, McEwan DG, Zhang J, Wild P, Rozenknop A, Rogov V, Löhr F, Popovic D, Occhipinti A, Reichert AS, Terzic J, Dötsch V, Ney PA, Dikic I. Nix is a selective autophagy receptor for mitochondrial clearance. *EMBO Rep*. 2010;11:45–51. doi: 10.1038/embor.2009.256.
288. Ding WX, Ni HM, Li M, Liao Y, Chen X, Stolz DB, Dorn GW 2nd, Yin XM. Nix is critical to two distinct phases of mitophagy, reactive oxygen species-mediated autophagy induction and Parkin-ubiquitin-p62-mediated mitochondrial priming. *J Biol Chem*. 2010;285:27879–27890. doi: 10.1074/jbc.M110.119537.
289. Hanna RA, Quinsay MN, Orogo AM, Giang K, Rikka S, Gustafsson ÅB. Microtubule-associated protein 1 light chain 3 (LC3) interacts with Bnip3 protein to selectively remove endoplasmic reticulum and mitochondria via autophagy. *J Biol Chem*. 2012;287:19094–19104. doi: 10.1074/jbc.M111.322933.
290. Yussman MG, Toyokawa T, Odley A, Lynch RA, Wu G, Colbert MC, Aronow BJ, Lorenz JN, Dorn GW 2nd. Mitochondrial death protein Nix is induced in cardiac hypertrophy and triggers apoptotic cardiomyopathy. *Nat Med*. 2002;8:725–730. doi: 10.1038/nm719.
291. Diwan A, Krenz M, Syed FM, Wansapura J, Ren X, Koesters AG, Li H, Kirshenbaum LA, Hahn HS, Robbins J, Jones WK, Dorn GW. Inhibition of ischemic cardiomyocyte apoptosis through targeted ablation of Bnip3 restrains postinfarction remodeling in mice. *J Clin Invest*. 2007;117:2825–2833. doi: 10.1172/JCI32490.
292. Diwan A, Wansapura J, Syed FM, Matkovich SJ, Lorenz JN, Dorn GW 2nd. Nix-mediated apoptosis links myocardial fibrosis, cardiac remodeling, and hypertrophy decompensation. *Circulation*. 2008;117:396–404. doi: 10.1161/CIRCULATIONAHA.107.727073.
293. Chaanine AH, Gordon RE, Kohlbrener E, Benard L, Jeong D, Hajjar RJ. Potential role of BNIP3 in cardiac remodeling, myocardial stiffness, and endoplasmic reticulum: mitochondrial calcium homeostasis in diastolic and systolic heart failure. *Circ Heart Fail*. 2013;6:572–583. doi: 10.1161/CIRCHEARTFAILURE.112.000200.
294. Yuan H, Perry CN, Huang C, Iwai-Kanai E, Carreira RS, Glembotski CC, Gottlieb RA. LPS-induced autophagy is mediated by oxidative signaling in cardiomyocytes and is associated with cytoprotection. *Am J Physiol Heart Circ Physiol*. 2009;296:H470–H479. doi: 10.1152/ajpheart.01051.2008.
295. Tatsuta T, Langer T. Quality control of mitochondria: protection against neurodegeneration and ageing. *EMBO J*. 2008;27:306–314. doi: 10.1038/sj.emboj.7601972.
296. Pratt JM, Petty J, Riba-Garcia I, Robertson DH, Gaskell SJ, Oliver SG, Beynon RJ. Dynamics of protein turnover, a missing dimension in proteomics. *Mol Cell Proteomics*. 2002;1:579–591.
297. Lam MP, Wang D, Lau E, Liem DA, Kim AK, Ng DC, Liang X, Bleakley BJ, Liu C, Tabaraki JD, Cadeiras M, Wang Y, Deng MC, Ping P. Protein kinetic signatures of the remodeling heart following isoproterenol stimulation. *J Clin Invest*. 2014;124:1734–1744. doi: 10.1172/JCI73787.
298. Hsieh EJ, Shulman NJ, Dai DF, Vincow ES, Karunadharma PP, Pallanck L, Rabinovitch PS, MacCoss MJ. Topograph, a software platform for precursor enrichment corrected global protein turnover measurements. *Mol Cell Proteomics*. 2012;11:1468–1474. doi: 10.1074/mcp.O112.017699.
299. Shekar KC, Li L, Dabkowski ER, Xu W, Ribeiro RF Jr, Hecker PA, Recchia FA, Sadygov RG, Willard B, Kasumov T, Stanley WC. Cardiac mitochondrial proteome dynamics with heavy water reveals stable rate of mitochondrial protein synthesis in heart failure despite decline in mitochondrial oxidative capacity. *J Mol Cell Cardiol*. 2014;75:88–97. doi: 10.1016/j.yjmcc.2014.06.014.
300. Claydon AJ, Beynon R. Proteome dynamics: revisiting turnover with a global perspective. *Mol Cell Proteomics*. 2012;11:1551–1565. doi: 10.1074/mcp.O112.022186.
301. Busch R, Neese RA, Awada M, Hayes GM, Hellerstein MK. Measurement of cell proliferation by heavy water labeling. *Nat Protoc*. 2007;2:3045–3057. doi: 10.1038/nprot.2007.420.
302. Raman A, Schoeller DA, Subar AF, Troiano RP, Schatzkin A, Harris T, Bauer D, Bingham SA, Everhart JE, Newman AB, Tylavsky FA. Water turnover in 458 American adults 40–79 yr of age. *Am J Physiol Renal Physiol*. 2004;286:F394–F401. doi: 10.1152/ajprenal.00295.2003.
303. Messmer BT, Messmer D, Allen SL, Kolitz JE, Kudalkar P, Cesar D, Murphy EJ, Koduru P, Ferrarini M, Zupo S, Cutrona G, Damle RN, Wasil T, Rai KR, Hellerstein MK, Chiorazzi N. *In vivo* measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells. *J Clin Invest*. 2005;115:755–764. doi: 10.1172/JCI23409.
304. Zhang Y, Reckow S, Webhofer C, Boehme M, Gormanns P, Egge-Jacobsen WM, Turck CW. Proteome scale turnover analysis in live animals using stable isotope metabolic labeling. *Anal Chem*. 2011;83:1665–1672. doi: 10.1021/ac102755n.
305. Rao PK, Rodriguez GM, Smith I, Li Q. Protein dynamics in iron-starved Mycobacterium tuberculosis revealed by turnover and abundance measurement using hybrid-linear ion trap-Fourier transform mass spectrometry. *Anal Chem*. 2008;80:6860–6869. doi: 10.1021/ac800288t.

306. Pupim LB, Flakoll PJ, Ikizler TA. Nutritional supplementation acutely increases albumin fractional synthetic rate in chronic hemodialysis patients. *J Am Soc Nephrol*. 2004;15:1920–1926.
307. Vaux DL. Apoptogenic factors released from mitochondria. *Biochim Biophys Acta*. 2011;1813:546–550. doi: 10.1016/j.bbamcr.2010.08.002.
308. Chandel NS. Mitochondria as signaling organelles. *BMC Biol*. 2014;12:34. doi: 10.1186/1741-7007-12-34.
309. Nakayama H, Otsu K. Translation of hemodynamic stress to sterile inflammation in the heart. *Trends Endocrinol Metab*. 2013;24:546–553. doi: 10.1016/j.tem.2013.06.004.
310. Arnoult D, Soares F, Tattoli I, Girardin SE. Mitochondria in innate immunity. *EMBO Rep*. 2011;12:901–910. doi: 10.1038/embor.2011.157.
311. Krysko DV, Agostinis P, Krysko O, Garg AD, Bachert C, Lambrecht BN, Vandenabeele P. Emerging role of damage-associated molecular patterns derived from mitochondria in inflammation. *Trends Immunol*. 2011;32:157–164. doi: 10.1016/j.it.2011.01.005.
312. Nakahira K, Haspel JA, Rathinam VA, Lee SJ, Dolinay T, Lam HC, Englert JA, Rabinovitch M, Cernadas M, Kim HP, Fitzgerald KA, Ryter SW, Choi AM. Autophagy proteins regulate innate immune responses by inhibiting the release of mitochondrial DNA mediated by the NALP3 inflammasome. *Nat Immunol*. 2011;12:222–230. doi: 10.1038/ni.1980.
313. Bliksøen M, Mariero LH, Ohm IK, Haugen F, Yndestad A, Solheim S, Seljeflot I, Ranheim T, Andersen GØ, Aukrust P, Valen G, Vinge LE. Increased circulating mitochondrial DNA after myocardial infarction. *Int J Cardiol*. 2012;158:132–134. doi: 10.1016/j.ijcard.2012.04.047.
314. Zhang Q, Raoof M, Chen Y, Sumi Y, Sursal T, Junger W, Brohi K, Itagaki K, Hauser CJ. Circulating mitochondrial DAMPs cause inflammatory responses to injury. *Nature*. 2010;464:104–107. doi: 10.1038/nature08780.
315. Carp H. Mitochondrial N-formylmethionyl proteins as chemoattractants for neutrophils. *J Exp Med*. 1982;155:264–275.
316. Zhang Q, Itagaki K, Hauser CJ. Mitochondrial DNA is released by shock and activates neutrophils via p38 map kinase. *Shock*. 2010;34:55–59. doi: 10.1097/SHK.0b013e3181cd8c08.
317. Oka T, Hikoso S, Yamaguchi O, Taneike M, Takeda T, Tamai T, Oyabu J, Murakawa T, Nakayama H, Nishida K, Akira S, Yamamoto A, Komuro I, Otsu K. Mitochondrial DNA that escapes from autophagy causes inflammation and heart failure [published correction appears in *Nature*. 2012;490:292]. *Nature*. 2012;485:251–255. doi: 10.1038/nature10992.
318. Wallace DC. Bioenergetic origins of complexity and disease. *Cold Spring Harb Symp Quant Biol*. 2011;76:1–16. doi: 10.1101/sqb.2011.76.010462.
319. Pagliarini DJ, Calvo SE, Chang B, Sheth SA, Vafai SB, Ong SE, Walford GA, Sugiana C, Boneh A, Chen WK, Hill DE, Vidal M, Evans JG, Thorburn DR, Carr SA, Mootha VK. A mitochondrial protein compendium elucidates complex I disease biology. *Cell*. 2008;134:112–123. doi: 10.1016/j.cell.2008.06.016.
320. Wallace DC, Fan W. Energetics, epigenetics, mitochondrial genetics. *Mitochondrion*. 2010;10:12–31. doi: 10.1016/j.mito.2009.09.006.
321. Wallace DC, Fan W, Procaccio V. Mitochondrial energetics and therapeutics. *Annu Rev Pathol*. 2010;5:297–348. doi: 10.1146/annurev.pathol.4.110807.092314.
322. Wallace DC. Mitochondria and cancer. *Nat Rev Cancer*. 2012;12:685–698. doi: 10.1038/nrc3365.
323. Wallace DC. Bioenergetics in human evolution and disease: implications for the origins of biological complexity and the missing genetic variation of common diseases. *Philos Trans R Soc Lond B Biol Sci*. 2013;368:20120267. doi: 10.1098/rstb.2012.0267.
324. Koopman WJ, Willems PH, Smeitink JA. Monogenic mitochondrial disorders. *N Engl J Med*. 2012;366:1132–1141. doi: 10.1056/NEJMra1012478.
325. Wallace DC, Lott MT, Procaccio V. Mitochondrial medicine: the mitochondrial biology and genetics of metabolic and degenerative diseases, cancer, and aging. In: Rimoin DL, Peyeritz RE, Korf BR, eds. *Emery and Rimoin's Principles and Practice of Medical Genetics*. 6th ed. Philadelphia, PA: Churchill Livingstone Elsevier; 2013.
326. Gómez-Durán A, Pacheu-Grau D, López-Gallardo E, Díez-Sánchez C, Montoya J, López-Pérez MJ, Ruiz-Pesini E. Unmasking the causes of multifactorial disorders: OXPHOS differences between mitochondrial haplogroups. *Hum Mol Genet*. 2010;19:3343–3353. doi: 10.1093/hmg/ddq246.
327. Shoffner JM, Brown MD, Torroni A, Lott MT, Cabell MF, Mirra SS, Beal MF, Yang CC, Gearing M, Salvo R. Mitochondrial DNA variants observed in Alzheimer disease and Parkinson disease patients. *Genomics*. 1993;17:171–184.
328. MITOMAP: a human mitochondrial genome database [database online]. <http://www.mitomap.org>. 2016. Accessed March 31, 2016.
329. Wallace DC, Singh G, Lott MT, Hodge JA, Schurr TG, Lezza AM, Elsas LJ 2nd, Nikoskelainen EK. Mitochondrial DNA mutation associated with Leber's hereditary optic neuropathy. *Science*. 1988;242:1427–1430.
330. Sadun AA, La Morgia C, Carelli V. Leber's hereditary optic neuropathy. *Curr Treat Options Neurol*. 2011;13:109–117. doi: 10.1007/s11940-010-0100-y.
331. Wallace DC, Zheng XX, Lott MT, Shoffner JM, Hodge JA, Kelley RI, Epstein CM, Hopkins LC. Familial mitochondrial encephalomyopathy (MERRF): genetic, pathophysiological, and biochemical characterization of a mitochondrial DNA disease. *Cell*. 1988;55:601–610.
332. Shoffner JM, Lott MT, Lezza AM, Seibel P, Ballinger SW, Wallace DC. Myoclonic epilepsy and ragged-red fiber disease (MERRF) is associated with a mitochondrial DNA tRNA(Lys) mutation. *Cell*. 1990;61:931–937.
333. Heddi A, Stepien G, Benke PJ, Wallace DC. Coordinate induction of energy gene expression in tissues of mitochondrial disease patients. *J Biol Chem*. 1999;274:22968–22976.
334. Goto Y, Nonaka I, Horai S. A mutation in the tRNA(Leu)(UUR) gene associated with the MELAS subgroup of mitochondrial encephalomyopathies. *Nature*. 1990;348:651–653. doi: 10.1038/348651a0.
335. van den Ouweland JM, Lemkes HH, Ruitenbeek W, Sandkuijl LA, de Vijlder MF, Struyvenberg PA, van de Kamp JJ, Maassen JJA. Mutation in mitochondrial tRNA(Leu)(UUR) gene in a large pedigree with maternally transmitted type II diabetes mellitus and deafness. *Nat Genet*. 1992;1:368–371. doi: 10.1038/ng0892-368.
336. Wallace DC. A mitochondrial paradigm of metabolic and degenerative diseases, aging, and cancer: a dawn for evolutionary medicine. *Annu Rev Genet*. 2005;39:359–407. doi: 10.1146/annurev.genet.39.110304.095751.
337. Pons R, Andreu AL, Checcarelli N, Vilà MR, Engelstad K, Sue CM, Shungu D, Haggerty R, de Vivo DC, DiMauro S. Mitochondrial DNA abnormalities and autistic spectrum disorders. *J Pediatr*. 2004;144:81–85. doi: 10.1016/j.jpeds.2003.10.023.
338. Trifunovic A, Wredenberg A, Falkenberg M, Spelbrink JN, Rovio AT, Bruder CE, Bohlooly-Y M, Gidlöf S, Oldfors A, Wibom R, Törnell J, Jacobs HT, Larsson NG. Premature ageing in mice expressing defective mitochondrial DNA polymerase. *Nature*. 2004;429:417–423. doi: 10.1038/nature02517.
339. Zeviani M, Bresolin N, Gellera C, Bordoni A, Pannacci M, Amati P, Moggio M, Servidei S, Scarlato G, DiDonato S. Nucleus-driven multiple large-scale deletions of the human mitochondrial genome: a new autosomal dominant disease. *Am J Hum Genet*. 1990;47:904–914.
340. Coskun PE, Beal MF, Wallace DC. Alzheimer's brains harbor somatic mtDNA control-region mutations that suppress mitochondrial transcription and replication. *Proc Natl Acad Sci U S A*. 2004;101:10726–10731. doi: 10.1073/pnas.0403649101.
341. Coskun PE, Wyrembak J, Derbereva O, Melkonian G, Doran E, Lott IT, Head E, Cotman CW, Wallace DC. Systemic mitochondrial dysfunction and the etiology of Alzheimer's disease and down syndrome dementia. *J Alzheimers Dis*. 2010;20(suppl 2):S293–S310. doi: 10.3233/JAD-2010-100351.
342. Coskun P, Wyrembak J, Schriener SE, Chen HW, Marciniak C, Laferla F, Wallace DC. A mitochondrial etiology of Alzheimer and Parkinson disease. *Biochim Biophys Acta*. 2012;1820:553–564. doi: 10.1016/j.bbagen.2011.08.008.
343. Picard M, Zhang J, Hancock S, Derbeneva O, Golhar R, Golik P, O'Hearn S, Levy S, Potluri P, Lvova M, Davila A, Lin CS, Perin JC, Rappaport EF, Hakonarson H, Trounce IA, Procaccio V, Wallace DC. Progressive increase in mtDNA 3243A>G heteroplasmy causes abrupt transcriptional reprogramming. *Proc Natl Acad Sci U S A*. 2014;111:E4033–E4042. doi: 10.1073/pnas.1414028111.
344. Fuku N, Park KS, Yamada Y, Nishigaki Y, Cho YM, Matsuo H, Segawa T, Watanabe S, Kato K, Yokoi K, Nozawa Y, Lee HK, Tanaka M. Mitochondrial haplogroup N9a confers resistance against type 2 diabetes in Asians. *Am J Hum Genet*. 2007;80:407–415. doi: 10.1086/512202.
345. Nishigaki Y, Yamada Y, Fuku N, Matsuo H, Segawa T, Watanabe S, Kato K, Yokoi K, Yamaguchi S, Nozawa Y, Tanaka M. Mitochondrial haplogroup N9b is protective against myocardial infarction in Japanese males. *Hum Genet*. 2007;120:827–836. doi: 10.1007/s00439-006-0269-z.
346. Rodríguez-Iturbe B, Sepassi L, Quiroz Y, Ni Z, Wallace DC, Vaziri ND. Association of mitochondrial SOD deficiency with salt-sensitive hypertension and accelerated renal senescence [published correction appears in *J Appl Physiol*. 2007;102:1297]. *J Appl Physiol (1985)*. 2007;102:255–260. doi: 10.1152/jappphysiol.00513.2006.

347. van Oven M, Kayser M. Updated comprehensive phylogenetic tree of global human mitochondrial DNA variation. *Hum Mutat*. 2009;30:E386–E394. doi: 10.1002/humu.20921.
348. Zaragoza MV, Brandon MC, Diegoli M, Arbustini E, Wallace DC. Mitochondrial cardiomyopathies: how to identify candidate pathogenic mutations by mitochondrial DNA sequencing, MITOMASTER and phylogeny. *Eur J Hum Genet*. 2011;19:200–207. doi: 10.1038/ejhg.2010.169.
349. Brown MD, Trounce IA, Jun AS, Allen JC, Wallace DC. Functional analysis of lymphoblast and cybrid mitochondria containing the 3460, 11778, or 14484 Leber's hereditary optic neuropathy mitochondrial DNA mutation. *J Biol Chem*. 2000;275:39831–39836. doi: 10.1074/jbc.M006476200.
350. Ji F, Sharples MS, Derbeneva O, Alves LS, Qian P, Wang Y, Chalkia D, Lvova M, Xu J, Yao W, Simon M, Platt J, Xu S, Angelin A, Davila A, Huang T, Wang PH, Chuang LM, Moore LG, Qian G, Wallace DC. Mitochondrial DNA variant associated with Leber hereditary optic neuropathy and high-altitude Tibetans. *Proc Natl Acad Sci U S A*. 2012;109:7391–7396. doi: 10.1073/pnas.1202484109.
351. Fan W, Waymire KG, Narula N, Li P, Rocher C, Coskun PE, Vannan MA, Narula J, Macgregor GR, Wallace DC. A mouse model of mitochondrial disease reveals germline selection against severe mtDNA mutations. *Science*. 2008;319:958–962. doi: 10.1126/science.1147786.
352. Corral-Debrinski M, Stepien G, Shoffner JM, Lott MT, Kanter K, Wallace DC. Hypoxemia is associated with mitochondrial DNA damage and gene induction: implications for cardiac disease. *JAMA*. 1991;266:1812–1816.
353. Phoon CK, Acehan D, Schlame M, Stokes DL, Edelman-Novemsky I, Yu D, Xu Y, Viswanathan N, Ren M. Tafazzin knockdown in mice leads to a developmental cardiomyopathy with early diastolic dysfunction preceding myocardial noncompaction. *J Am Heart Assoc*. 2012;1:e000455. doi: 10.1161/JAHA.111.000455.
354. Li K, Warner CK, Hodge JA, Minoshima S, Kudoh J, Fukuyama R, Maekawa M, Shimizu Y, Shimizu N, Wallace DC. A human muscle adenine nucleotide translocator gene has four exons, is located on chromosome 4, and is differentially expressed. *J Biol Chem*. 1989;264:13998–14004.
355. Li K, Hodge JA, Wallace DC. OXBOX, a positive transcriptional element of the heart-skeletal muscle ADP/ATP translocator gene. *J Biol Chem*. 1990;265:20585–20588.
356. Palmieri L, Alberio S, Pisano I, Lodi T, Meznaric-Petrusa M, Zidar J, Santoro A, Scarcia P, Fontanesi F, Lamantea E, Ferrero I, Zeviani M. Complete loss-of-function of the heart/muscle-specific adenine nucleotide translocator is associated with mitochondrial myopathy and cardiomyopathy. *Hum Mol Genet*. 2005;14:3079–3088. doi: 10.1093/hmg/ddi341.
357. Echaniz-Laguna A, Chassagne M, Ceresuela J, Rouvet I, Padet S, Acquaviva C, Nataf S, Vinzio S, Bozon D, Mousson de Camaret B. Complete loss of expression of the ANTI gene causing cardiomyopathy and myopathy. *J Med Genet*. 2012;49:146–150. doi: 10.1136/jmedgenet-2011-100504.
358. Strauss KA, DuBiner L, Simon M, Zaragoza M, Sengupta PP, Li P, Narula N, Dreike S, Platt J, Procaccio V, Ortiz-González XR, Puffenberger EG, Kelley RI, Morton DH, Narula J, Wallace DC. Severity of cardiomyopathy associated with adenine nucleotide translocator-1 deficiency correlates with mtDNA haplogroup. *Proc Natl Acad Sci U S A*. 2013;110:3453–3458. doi: 10.1073/pnas.1300690110.
359. Graham BH, Waymire KG, Cottrell B, Trounce IA, MacGregor GR, Wallace DC. A mouse model for mitochondrial myopathy and cardiomyopathy resulting from a deficiency in the heart/muscle isoform of the adenine nucleotide translocator. *Nat Genet*. 1997;16:226–234. doi: 10.1038/ng0797-226.
360. Narula N, Zaragoza MV, Sengupta PP, Li P, Haider N, Verjans J, Waymire K, Vannan M, Wallace DC. Adenine nucleotide translocase 1 deficiency results in dilated cardiomyopathy with defects in myocardial mechanics, histopathological alterations, and activation of apoptosis. *JACC Cardiovasc Imaging*. 2011;4:1–10. doi: 10.1016/j.jcmg.2010.06.018.
361. Dörner A, Schulze K, Rauch U, Schultheiss HP. Adenine nucleotide translocator in dilated cardiomyopathy: pathophysiological alterations in expression and function. *Mol Cell Biochem*. 1997;174:261–269.
362. Dörner A, Schultheiss HP. Adenine nucleotide translocase in the focus of cardiovascular diseases. *Trends Cardiovasc Med*. 2007;17:284–290. doi: 10.1016/j.tcm.2007.10.001.
363. Anzovino A, Lane DJ, Huang ML, Richardson DR. Fixing frataxin: "ironing out" the metabolic defect in Friedreich's ataxia. *Br J Pharmacol*. 2014;171:2174–2190. doi: 10.1111/bph.12470.
364. Seifert EL, Ligeti E, Mayr JA, Sondheimer N, Hajnóczky G. The mitochondrial phosphate carrier: role in oxidative metabolism, calcium handling and mitochondrial disease. *Biochem Biophys Res Commun*. 2015;464:369–375. doi: 10.1016/j.bbrc.2015.06.031.
365. Potluri P, Davila A, Ruiz-Pesini E, Mishmar D, O'Hearn S, Hancock S, Simon M, Scheffler IE, Wallace DC, Procaccio V. A novel NDUFA1 mutation leads to a progressive mitochondrial complex I-specific neurodegenerative disease. *Mol Genet Metab*. 2009;96:189–195. doi: 10.1016/j.ymgme.2008.12.004.
366. Arbustini E, Fasani R, Morbini P, Diegoli M, Grasso M, Dal Bello B, Marangoni E, Banfi P, Banchieri N, Bellini O, Comi G, Narula J, Campana C, Gavazzi A, Danesino C, Viganò M. Coexistence of mitochondrial DNA and beta myosin heavy chain mutations in hypertrophic cardiomyopathy with late congestive heart failure [published correction appears in *Heart*. 1999;81:330]. *Heart*. 1998;80:548–558.
367. Gatta G, Capocaccia R, Coleman MP, Ries LA, Berrino F. Childhood cancer survival in Europe and the United States. *Cancer*. 2002;95:1767–1772. doi: 10.1002/cncr.10833.
368. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ. Cancer statistics, 2006. *CA Cancer J Clin*. 2006;56:106–130.
369. Krischer JP, Epstein S, Cuthbertson DD, Goorin AM, Epstein ML, Lipschultz SE. Clinical cardiotoxicity following anthracycline treatment for childhood cancer: the Pediatric Oncology Group experience. *J Clin Oncol*. 1997;15:1544–1552.
370. Todaro MC, Oretto L, Qamar R, Paterick TE, Carerj S, Khandheria BK. Cardiotoxicology: state of the heart. *Int J Cardiol*. 2013;168:680–687. doi: 10.1016/j.ijcard.2013.03.133.
371. Yeh ET, Bickford CL. Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. *J Am Coll Cardiol*. 2009;53:2231–2247. doi: 10.1016/j.jacc.2009.02.050.
372. Ewer MS, Ewer SM. Cardiotoxicity of anticancer treatments: what the cardiologist needs to know. *Nat Rev Cardiol*. 2010;7:564–575. doi: 10.1038/nrcardio.2010.121.
373. Davies KJ, Doroshov JH. Redox cycling of anthracyclines by cardiac mitochondria. I: anthracycline radical formation by NADH dehydrogenase. *J Biol Chem*. 1986;261:3060–3067.
374. Doroshov JH, Davies KJ. Redox cycling of anthracyclines by cardiac mitochondria. II: formation of superoxide anion, hydrogen peroxide, and hydroxyl radical. *J Biol Chem*. 1986;261:3068–3074.
375. Keizer HG, Pinedo HM, Schuurhuis GJ, Joenje H. Doxorubicin (adriamycin): a critical review of free radical-dependent mechanisms of cytotoxicity. *Pharmacol Ther*. 1990;47:219–231.
376. Myers CE, Gianni L, Simone CB, Klecker R, Greene R. Oxidative destruction of erythrocyte ghost membranes catalyzed by the doxorubicin-iron complex. *Biochemistry*. 1982;21:1707–1712.
377. Mordente A, Meucci E, Silvestrini A, Martorana GE, Giardina B. Anthracyclines and mitochondria. *Adv Exp Med Biol*. 2012;942:385–419. doi: 10.1007/978-94-007-2869-1\_18.
378. Zhang S, Liu X, Bawa-Khalife T, Lu LS, Lyu YL, Liu LF, Yeh ET. Identification of the molecular basis of doxorubicin-induced cardiotoxicity. *Nat Med*. 2012;18:1639–1642. doi: 10.1038/nm.2919.
379. Lebrecht D, Walker UA. Role of mtDNA lesions in anthracycline cardiotoxicity. *Cardiovasc Toxicol*. 2007;7:108–113. doi: 10.1007/s12012-007-0009-1.
380. Goormaghtigh E, Huart P, Bresseur R, Ruyschaert JM. Mechanism of inhibition of mitochondrial enzymatic complex I-III by adriamycin derivatives. *Biochim Biophys Acta*. 1986;861:83–94.
381. Pointon AV, Walker TM, Phillips KM, Luo J, Riley J, Zhang SD, Parry JD, Lyon JJ, Marczylo EL, Gant TW. Doxorubicin *in vivo* rapidly alters expression and translation of myocardial electron transport chain genes, leads to ATP loss and caspase 3 activation [published correction appears in *PLoS One*. 2014;9:e102278]. *PLoS One*. 2010;5:e12733. doi: 10.1371/journal.pone.0012733.
382. Montaigne D, Marechal X, Preau S, Baccouch R, Modine T, Fayad G, Lancel S, Nevieri R. Doxorubicin induces mitochondrial permeability transition and contractile dysfunction in the human myocardium. *Mitochondrion*. 2011;11:22–26. doi: 10.1016/j.mito.2010.06.001.
383. Zhou S, Starkov A, Froberg MK, Leino RL, Wallace KB. Cumulative and irreversible cardiac mitochondrial dysfunction induced by doxorubicin. *Cancer Res*. 2001;61:771–777.
384. Ichikawa Y, Ghanefar M, Bayeva M, Wu R, Khechaduri A, Naga Prasad SV, Mutharasan RK, Naik TJ, Ardehali H. Cardiotoxicity of doxorubicin is mediated through mitochondrial iron accumulation. *J Clin Invest*. 2014;124:617–630. doi: 10.1172/JCI72931.
385. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes [published correction

- appears in *N Engl J Med*. 2007;357:100]. *N Engl J Med*. 2007;356:2457–2471. doi: 10.1056/NEJMoa072761.
386. Schaefer AM, Taylor RW, Turnbull DM, Chinnery PF. The epidemiology of mitochondrial disorders: past, present and future. *Biochim Biophys Acta*. 2004;1659:115–120. doi: 10.1016/j.bbabo.2004.09.005.
  387. Liang C, Ahmad K, Sue CM. The broadening spectrum of mitochondrial disease: shifts in the diagnostic paradigm. *Biochim Biophys Acta*. 2014;1840:1360–1367. doi: 10.1016/j.bbagen.2013.10.040.
  388. Ellinger J, Albers P, Müller SC, von Ruecker A, Bastian PJ. Circulating mitochondrial DNA in the serum of patients with testicular germ cell cancer as a novel noninvasive diagnostic biomarker. *BJU Int*. 2009;104:48–52. doi: 10.1111/j.1464-410X.2008.08289.x.
  389. Fernandes J, Michel V, Camorlinga-Ponce M, Gomez A, Maldonado C, De Reuse H, Torres J, Touati E. Circulating mitochondrial DNA level, a noninvasive biomarker for the early detection of gastric cancer. *Cancer Epidemiol Biomarkers Prev*. 2014;23:2430–2438. doi: 10.1158/1055-9965.EPI-14-0471.
  390. Nakahira K, Kyung SY, Rogers AJ, Gazourian L, Youn S, Massaro AF, Quintana C, Osorio JC, Wang Z, Zhao Y, Lawler LA, Christie JD, Meyer NJ, Mc Causland FR, Waikar SS, Waxman AB, Chung RT, Bueno R, Rosas IO, Fredenburgh LE, Baron RM, Christiani DC, Hunninghake GM, Choi AM. Circulating mitochondrial DNA in patients in the ICU as a marker of mortality: derivation and validation. *PLoS Med*. 2013;10:e1001577. doi: 10.1371/journal.pmed.1001577.
  391. Zhong S, Ng MC, Lo YM, Chan JC, Johnson PJ. Presence of mitochondrial tRNA(Leu(UUR)) A to G 3243 mutation in DNA extracted from serum and plasma of patients with type 2 diabetes mellitus. *J Clin Pathol*. 2000;53:466–469.
  392. Schwarzenbach H, Hoon DS, Pantel K. Cell-free nucleic acids as biomarkers in cancer patients. *Nat Rev Cancer*. 2011;11:426–437. doi: 10.1038/nrc3066.
  393. Chiu RW, Chan LY, Lam NY, Tsui NB, Ng EK, Rainer TH, Lo YM. Quantitative analysis of circulating mitochondrial DNA in plasma [published correction appears in *Clin Chem*. 2004;50:461]. *Clin Chem*. 2003;49:719–726.
  394. Pfeffer G, Horvath R, Klopstock T, Mootha VK, Suomalainen A, Koene S, Hirano M, Zeviani M, Bindoff LA, Yu-Wai-Man P, Hanna M, Carelli V, McFarland R, Majamaa K, Turnbull DM, Smeitink J, Chinnery PF. New treatments for mitochondrial disease: no time to drop our standards. *Nat Rev Neurol*. 2013;9:474–481. doi: 10.1038/nrneuro.2013.129.
  395. Addona TA, Shi X, Keshishian H, Mani DR, Burgess M, Gillette MA, Clauser KR, Shen D, Lewis GD, Farrell LA, Fifer MA, Sabatine MS, Gerszten RE, Carr SA. A pipeline that integrates the discovery and verification of plasma protein biomarkers reveals candidate markers for cardiovascular disease. *Nat Biotechnol*. 2011;29:635–643. doi: 10.1038/nbt.1899.
  396. Suomalainen A, Elo JM, Pietiläinen KH, Hakonen AH, Sevastianova K, Korpela M, Isohanni P, Marjavaara SK, Tyni T, Kiuru-Enari S, Pihko H, Darin N, Öunap K, Kluijtmans LA, Paetau A, Buzkova J, Bindoff LA, Annunen-Rasila J, Uusimaa J, Rissanen A, Yki-Järvinen H, Hirano M, Tulinius M, Smeitink J, Tyynismaa H. FGF-21 as a biomarker for muscle-manifesting mitochondrial respiratory chain deficiencies: a diagnostic study. *Lancet Neurol*. 2011;10:806–818. doi: 10.1016/S1474-4422(11)70155-7.
  397. Davis RL, Liang C, Edema-Hildebrand F, Riley C, Needham M, Sue CM. Fibroblast growth factor 21 is a sensitive biomarker of mitochondrial disease. *Neurology*. 2013;81:1819–1826. doi: 10.1212/01.wnl.0000436068.43384.ef.
  398. Enns GM, Moore T, Le A, Atkuri K, Shah MK, Cusmano-Ozog K, Niemi AK, Cowan TM. Degree of glutathione deficiency and redox imbalance depend on subtype of mitochondrial disease and clinical status. *PLoS One*. 2014;9:e100001. doi: 10.1371/journal.pone.0100001.
  399. Hoppins S, Nunnari J. Cell biology: mitochondrial dynamics and apoptosis: the ER connection. *Science*. 2012;337:1052–1054. doi: 10.1126/science.1224709.
  400. Settembre C, Fraldi A, Medina DL, Ballabio A. Signals from the lysosome: a control centre for cellular clearance and energy metabolism. *Nat Rev Mol Cell Biol*. 2013;14:283–296. doi: 10.1038/nrm3565.
  401. Ngho GA, Papanicolaou KN, Walsh K. Loss of mitofusin 2 promotes endoplasmic reticulum stress. *J Biol Chem*. 2012;287:20321–20332. doi: 10.1074/jbc.M112.359174.